WO2024018205A1 - Antibodies against sars-cov-2 and uses thereof - Google Patents
Antibodies against sars-cov-2 and uses thereof Download PDFInfo
- Publication number
- WO2024018205A1 WO2024018205A1 PCT/GB2023/051898 GB2023051898W WO2024018205A1 WO 2024018205 A1 WO2024018205 A1 WO 2024018205A1 GB 2023051898 W GB2023051898 W GB 2023051898W WO 2024018205 A1 WO2024018205 A1 WO 2024018205A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- sequence
- nos
- sequence identity
- region
- Prior art date
Links
- 238000009739 binding Methods 0.000 claims abstract description 490
- 230000027455 binding Effects 0.000 claims abstract description 489
- 239000012634 fragment Substances 0.000 claims abstract description 294
- 108091007433 antigens Proteins 0.000 claims abstract description 293
- 102000036639 antigens Human genes 0.000 claims abstract description 293
- 239000000427 antigen Substances 0.000 claims abstract description 292
- 238000000034 method Methods 0.000 claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 50
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 26
- 102000005962 receptors Human genes 0.000 claims abstract description 26
- 108020003175 receptors Proteins 0.000 claims abstract description 26
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims abstract description 22
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims abstract description 17
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 236
- 210000004027 cell Anatomy 0.000 claims description 94
- 241001678559 COVID-19 virus Species 0.000 claims description 58
- 238000012360 testing method Methods 0.000 claims description 48
- 239000008194 pharmaceutical composition Substances 0.000 claims description 39
- 238000011282 treatment Methods 0.000 claims description 39
- 241000282414 Homo sapiens Species 0.000 claims description 37
- 239000013598 vector Substances 0.000 claims description 37
- 239000002245 particle Substances 0.000 claims description 30
- 229940096437 Protein S Drugs 0.000 claims description 26
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 claims description 26
- 101710198474 Spike protein Proteins 0.000 claims description 25
- 108091033319 polynucleotide Proteins 0.000 claims description 25
- 102000040430 polynucleotide Human genes 0.000 claims description 25
- 239000002157 polynucleotide Substances 0.000 claims description 25
- 239000003814 drug Substances 0.000 claims description 19
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 18
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 18
- 238000002560 therapeutic procedure Methods 0.000 claims description 17
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims description 14
- 210000000605 viral structure Anatomy 0.000 claims description 14
- 230000009977 dual effect Effects 0.000 claims description 9
- 230000000840 anti-viral effect Effects 0.000 claims description 8
- 238000002648 combination therapy Methods 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000003053 toxin Substances 0.000 claims description 7
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 5
- 210000004748 cultured cell Anatomy 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229960003957 dexamethasone Drugs 0.000 claims description 3
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 3
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 claims description 3
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical group NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 claims description 3
- 229960003989 tocilizumab Drugs 0.000 claims description 3
- 206010061818 Disease progression Diseases 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000005750 disease progression Effects 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 claims description 2
- 230000000153 supplemental effect Effects 0.000 claims description 2
- 238000009423 ventilation Methods 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 description 53
- 235000018102 proteins Nutrition 0.000 description 46
- 108090000765 processed proteins & peptides Proteins 0.000 description 36
- 239000000523 sample Substances 0.000 description 36
- 235000001014 amino acid Nutrition 0.000 description 33
- 239000000203 mixture Substances 0.000 description 32
- 150000007523 nucleic acids Chemical class 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- 102000039446 nucleic acids Human genes 0.000 description 29
- 108020004707 nucleic acids Proteins 0.000 description 29
- 102000004196 processed proteins & peptides Human genes 0.000 description 29
- 150000001413 amino acids Chemical class 0.000 description 26
- 229920001184 polypeptide Polymers 0.000 description 26
- 229940024606 amino acid Drugs 0.000 description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 25
- 238000003018 immunoassay Methods 0.000 description 24
- 230000003612 virological effect Effects 0.000 description 24
- 102000025171 antigen binding proteins Human genes 0.000 description 23
- 108091000831 antigen binding proteins Proteins 0.000 description 23
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 22
- 108060003951 Immunoglobulin Proteins 0.000 description 21
- 102000018358 immunoglobulin Human genes 0.000 description 21
- 238000003556 assay Methods 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 239000007788 liquid Substances 0.000 description 19
- 210000004072 lung Anatomy 0.000 description 19
- 238000006467 substitution reaction Methods 0.000 description 18
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 17
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- 238000005259 measurement Methods 0.000 description 16
- 230000035772 mutation Effects 0.000 description 16
- 230000036515 potency Effects 0.000 description 16
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 239000012491 analyte Substances 0.000 description 14
- 239000012636 effector Substances 0.000 description 14
- 101100454807 Caenorhabditis elegans lgg-1 gene Proteins 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000002998 immunogenetic effect Effects 0.000 description 13
- 241000711573 Coronaviridae Species 0.000 description 12
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 12
- 230000003993 interaction Effects 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 11
- 238000013207 serial dilution Methods 0.000 description 11
- 239000007790 solid phase Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 10
- 125000000539 amino acid group Chemical group 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 230000003472 neutralizing effect Effects 0.000 description 10
- 238000002823 phage display Methods 0.000 description 10
- 229940124597 therapeutic agent Drugs 0.000 description 10
- 102100031673 Corneodesmosin Human genes 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 108091027544 Subgenomic mRNA Proteins 0.000 description 9
- 239000011230 binding agent Substances 0.000 description 9
- 230000037396 body weight Effects 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 125000005647 linker group Chemical group 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000007492 two-way ANOVA Methods 0.000 description 9
- 101100454808 Caenorhabditis elegans lgg-2 gene Proteins 0.000 description 8
- 101100217502 Caenorhabditis elegans lgg-3 gene Proteins 0.000 description 8
- 101710139375 Corneodesmosin Proteins 0.000 description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 239000013068 control sample Substances 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000010494 dissociation reaction Methods 0.000 description 8
- 230000005593 dissociations Effects 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000003780 insertion Methods 0.000 description 8
- 230000037431 insertion Effects 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 230000000869 mutational effect Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 241000588724 Escherichia coli Species 0.000 description 7
- 102000044437 S1 domains Human genes 0.000 description 7
- 238000013459 approach Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 241000699800 Cricetinae Species 0.000 description 6
- 108090000288 Glycoproteins Proteins 0.000 description 6
- 102000003886 Glycoproteins Human genes 0.000 description 6
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 6
- 101710167605 Spike glycoprotein Proteins 0.000 description 6
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 6
- 239000000470 constituent Substances 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000013507 mapping Methods 0.000 description 6
- 230000002265 prevention Effects 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 108010087819 Fc receptors Proteins 0.000 description 5
- 102000009109 Fc receptors Human genes 0.000 description 5
- 101710114810 Glycoprotein Proteins 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 238000011887 Necropsy Methods 0.000 description 5
- 101001028244 Onchocerca volvulus Fatty-acid and retinol-binding protein 1 Proteins 0.000 description 5
- 241000235648 Pichia Species 0.000 description 5
- 108091005774 SARS-CoV-2 proteins Proteins 0.000 description 5
- 238000007792 addition Methods 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 239000000975 dye Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000012146 running buffer Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- 239000004471 Glycine Substances 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000036142 Viral infection Diseases 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000012575 bio-layer interferometry Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000011088 calibration curve Methods 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 229920000126 latex Polymers 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 230000009385 viral infection Effects 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000014150 Interferons Human genes 0.000 description 3
- 108010050904 Interferons Proteins 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 241001112090 Pseudovirus Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 238000009175 antibody therapy Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000562 conjugate Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- -1 e. g. an elixir Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 238000007912 intraperitoneal administration Methods 0.000 description 3
- 239000004816 latex Substances 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 2
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 2
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 2
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 2
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 241000235058 Komagataella pastoris Species 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000713666 Lentivirus Species 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 241001489174 Ogataea minuta Species 0.000 description 2
- 102000015636 Oligopeptides Human genes 0.000 description 2
- 108010038807 Oligopeptides Proteins 0.000 description 2
- 241001068263 Replication competent viruses Species 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000004520 agglutination Effects 0.000 description 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
- 210000002588 alveolar type II cell Anatomy 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000611 antibody drug conjugate Substances 0.000 description 2
- 229940049595 antibody-drug conjugate Drugs 0.000 description 2
- 235000009582 asparagine Nutrition 0.000 description 2
- 229960001230 asparagine Drugs 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000013060 biological fluid Substances 0.000 description 2
- 230000008827 biological function Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000000424 bronchial epithelial cell Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005889 cellular cytotoxicity Effects 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000003467 diminishing effect Effects 0.000 description 2
- 238000013504 emergency use authorization Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 229940051184 imdevimab Drugs 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 229940127121 immunoconjugate Drugs 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 238000007433 macroscopic evaluation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000000941 radioactive substance Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102220080600 rs797046116 Human genes 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 238000009736 wetting Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JDXCOXKBIGBZSK-PSNKNOTQSA-N (2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,5S,8S,11S,14S,22S)-22-acetamido-11-benzyl-8-(3-carbamimidamidopropyl)-5-(2-carboxyethyl)-3,6,9,12,16,23-hexaoxo-2-propan-2-yl-1,4,7,10,13,17-hexazacyclotricosane-14-carbonyl]-methylamino]-3-carboxypropanoyl]amino]-3,3-dimethylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-(1H-pyrrolo[2,3-b]pyridin-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carbonyl]amino]-2-cyclohexylacetyl]amino]-6-[3-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[[(4S)-4-carboxy-4-(hexadecanoylamino)butanoyl]amino]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoylamino]hexanoic acid Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]1CCCN1C(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](Cc1c[nH]c2ncccc12)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)N(C)C(=O)[C@@H]1CC(=O)NCCCC[C@H](NC(C)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc2ccccc2)C(=O)N1)C(C)(C)C)C1CCCCC1)C(O)=O)C(O)=O JDXCOXKBIGBZSK-PSNKNOTQSA-N 0.000 description 1
- HMLGSIZOMSVISS-ONJSNURVSA-N (7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 description 1
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- KXMZDGSRSGHMMK-VWLOTQADSA-N 1-(6,7-dihydro-5h-benzo[2,3]cyclohepta[2,4-d]pyridazin-3-yl)-3-n-[(7s)-7-pyrrolidin-1-yl-6,7,8,9-tetrahydro-5h-benzo[7]annulen-3-yl]-1,2,4-triazole-3,5-diamine Chemical compound N1([C@H]2CCC3=CC=C(C=C3CC2)NC=2N=C(N(N=2)C=2N=NC=3C4=CC=CC=C4CCCC=3C=2)N)CCCC1 KXMZDGSRSGHMMK-VWLOTQADSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 description 1
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 description 1
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 description 1
- FJEJHJINOKKDCW-INIZCTEOSA-N 3-[5-(azetidine-1-carbonyl)pyrazin-2-yl]oxy-5-[(2s)-1-methoxypropan-2-yl]oxy-n-(5-methylpyrazin-2-yl)benzamide Chemical compound C=1C(C(=O)NC=2N=CC(C)=NC=2)=CC(O[C@@H](C)COC)=CC=1OC(N=C1)=CN=C1C(=O)N1CCC1 FJEJHJINOKKDCW-INIZCTEOSA-N 0.000 description 1
- MCSXGCZMEPXKIW-UHFFFAOYSA-N 3-hydroxy-4-[(4-methyl-2-nitrophenyl)diazenyl]-N-(3-nitrophenyl)naphthalene-2-carboxamide Chemical compound Cc1ccc(N=Nc2c(O)c(cc3ccccc23)C(=O)Nc2cccc(c2)[N+]([O-])=O)c(c1)[N+]([O-])=O MCSXGCZMEPXKIW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 229940127110 AZD1656 Drugs 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 239000012114 Alexa Fluor 647 Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000008873 Angiotensin II receptor Human genes 0.000 description 1
- 108050000824 Angiotensin II receptor Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 102000019260 B-Cell Antigen Receptors Human genes 0.000 description 1
- 108010012919 B-Cell Antigen Receptors Proteins 0.000 description 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000151861 Barnettozyma salicaria Species 0.000 description 1
- 101100476210 Caenorhabditis elegans rnt-1 gene Proteins 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 241000288673 Chiroptera Species 0.000 description 1
- 241001674013 Chrysosporium lucknowense Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 238000007702 DNA assembly Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000223218 Fusarium Species 0.000 description 1
- 241001149959 Fusarium sp. Species 0.000 description 1
- 241000567178 Fusarium venenatum Species 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 229940121672 Glycosylation inhibitor Drugs 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101000913074 Homo sapiens High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101000917826 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-a Proteins 0.000 description 1
- 101000917824 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor II-b Proteins 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108700021006 Interleukin-1 receptor antagonist Proteins 0.000 description 1
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 241001138401 Kluyveromyces lactis Species 0.000 description 1
- 241000170280 Kluyveromyces sp. Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000002144 L01XE18 - Ruxolitinib Substances 0.000 description 1
- 102100029204 Low affinity immunoglobulin gamma Fc region receptor II-a Human genes 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 241001292005 Nidovirales Species 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000320412 Ogataea angusta Species 0.000 description 1
- 241001452677 Ogataea methanolica Species 0.000 description 1
- 241000489470 Ogataea trehalophila Species 0.000 description 1
- 241000826199 Ogataea wickerhamii Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000530350 Phaffomyces opuntiae Species 0.000 description 1
- 241000529953 Phaffomyces thermotolerans Species 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 108010004729 Phycoerythrin Proteins 0.000 description 1
- 241000195887 Physcomitrella patens Species 0.000 description 1
- 241000235062 Pichia membranifaciens Species 0.000 description 1
- 241000235061 Pichia sp. Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 108700036684 S1 domains Proteins 0.000 description 1
- 241000235088 Saccharomyces sp. Species 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010042566 Superinfection Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 241000255993 Trichoplusia ni Species 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 229940118555 Viral entry inhibitor Drugs 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 108010031318 Vitronectin Proteins 0.000 description 1
- 241000370136 Wickerhamomyces pijperi Species 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 description 1
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- KWJDHELCGJFUHW-SFTDATJTSA-N [4-[(2s)-2-[[(2s)-2-(methoxycarbonylamino)-3-phenylpropanoyl]amino]-2-(2-thiophen-2-yl-1,3-thiazol-4-yl)ethyl]phenyl]sulfamic acid Chemical compound C([C@H](NC(=O)OC)C(=O)N[C@@H](CC=1C=CC(NS(O)(=O)=O)=CC=1)C=1N=C(SC=1)C=1SC=CC=1)C1=CC=CC=C1 KWJDHELCGJFUHW-SFTDATJTSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 229950009821 acalabrutinib Drugs 0.000 description 1
- WDENQIQQYWYTPO-IBGZPJMESA-N acalabrutinib Chemical compound CC#CC(=O)N1CCC[C@H]1C1=NC(C=2C=CC(=CC=2)C(=O)NC=2N=CC=CC=2)=C2N1C=CN=C2N WDENQIQQYWYTPO-IBGZPJMESA-N 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960002964 adalimumab Drugs 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960004238 anakinra Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 229950000586 aviptadil Drugs 0.000 description 1
- 108010006060 aviptadil Proteins 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229940052143 bamlanivimab Drugs 0.000 description 1
- 229950000971 baricitinib Drugs 0.000 description 1
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 229950009568 bemcentinib Drugs 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 150000001639 boron compounds Chemical class 0.000 description 1
- 229940010847 brensocatib Drugs 0.000 description 1
- AEXFXNFMSAAELR-RXVVDRJESA-N brensocatib Chemical compound C(#N)[C@H](CC1=CC=C(C=C1)C=1C=CC2=C(N(C(O2)=O)C)C1)NC(=O)[C@H]1OCCCNC1 AEXFXNFMSAAELR-RXVVDRJESA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960001838 canakinumab Drugs 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940051183 casirivimab Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006757 chemical reactions by type Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229940051181 cilgavimab Drugs 0.000 description 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 description 1
- 229960003009 clopidogrel Drugs 0.000 description 1
- 230000004186 co-expression Effects 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000001268 conjugating effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 229940051243 etesevimab Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 1
- 229950008454 favipiravir Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000002868 homogeneous time resolved fluorescence Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 229940098197 human immunoglobulin g Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960004171 hydroxychloroquine Drugs 0.000 description 1
- XXSMGPRMXLTPCZ-UHFFFAOYSA-N hydroxychloroquine Chemical compound ClC1=CC=C2C(NC(C)CCCN(CCO)CC)=CC=NC2=C1 XXSMGPRMXLTPCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003317 immunochromatography Methods 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 229960000598 infliximab Drugs 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 description 1
- XMBWDFGMSWQBCA-YPZZEJLDSA-N iodane Chemical compound [125IH] XMBWDFGMSWQBCA-YPZZEJLDSA-N 0.000 description 1
- 229940044173 iodine-125 Drugs 0.000 description 1
- 239000003621 irrigation water Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000012004 kinetic exclusion assay Methods 0.000 description 1
- 239000000990 laser dye Substances 0.000 description 1
- 229950007439 lenzilumab Drugs 0.000 description 1
- 229940121292 leronlimab Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940113983 lopinavir / ritonavir Drugs 0.000 description 1
- 230000001050 lubricating effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 239000002923 metal particle Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229950007708 namilumab Drugs 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 108010068617 neonatal Fc receptor Proteins 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 229960001920 niclosamide Drugs 0.000 description 1
- 229960003753 nitric oxide Drugs 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001160 nonlethal Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 229950007074 opaganib Drugs 0.000 description 1
- VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
- 229960003752 oseltamivir Drugs 0.000 description 1
- 229940121480 otilimab Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000000906 photoactive agent Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940071643 prefilled syringe Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 231100000654 protein toxin Toxicity 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000003653 radioligand binding assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 229950007085 ravulizumab Drugs 0.000 description 1
- 229940070114 razuprotafib Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229950007943 risankizumab Drugs 0.000 description 1
- 229960000215 ruxolitinib Drugs 0.000 description 1
- HFNKQEVNSGCOJV-OAHLLOKOSA-N ruxolitinib Chemical compound C1([C@@H](CC#N)N2N=CC(=C2)C=2C=3C=CNC=3N=CN=2)CCCC1 HFNKQEVNSGCOJV-OAHLLOKOSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229950006348 sarilumab Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000010865 sewage Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- MPLHNVLQVRSVEE-UHFFFAOYSA-N texas red Chemical compound [O-]S(=O)(=O)C1=CC(S(Cl)(=O)=O)=CC=C1C(C1=CC=2CCCN3CCCC(C=23)=C1O1)=C2C1=C(CCC1)C3=[N+]1CCCC3=C2 MPLHNVLQVRSVEE-UHFFFAOYSA-N 0.000 description 1
- 229940124598 therapeutic candidate Drugs 0.000 description 1
- 229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
- 238000002849 thermal shift Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 description 1
- 229940051871 tixagevimab Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229950011232 tradipitant Drugs 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- KCFYEAOKVJSACF-UHFFFAOYSA-N umifenovir Chemical compound CN1C2=CC(Br)=C(O)C(CN(C)C)=C2C(C(=O)OCC)=C1CSC1=CC=CC=C1 KCFYEAOKVJSACF-UHFFFAOYSA-N 0.000 description 1
- 229960004626 umifenovir Drugs 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007501 viral attachment Effects 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 230000007482 viral spreading Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000012855 volatile organic compound Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 229940121352 zilucoplan Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Definitions
- the present invention relates to monoclonal antibodies (mAbs) targeted against the receptorbinding domain (RBD) of the spike (S) glycoprotein of coronavirus SARS-CoV-2.
- mAbs monoclonal antibodies targeted against the receptorbinding domain (RBD) of the spike (S) glycoprotein of coronavirus SARS-CoV-2.
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- COVID-19 coronavirus disease
- Monoclonal antibodies have been advocated as a potential alternative to provide protection to individuals that cannot be vaccinated.
- the majority of commonly identified antibodies neutralize coronaviruses by binding to the receptor binding motif (RBM) in the Spike (S) protein domain 1 (S1) (also termed receptor-binding domain (RBD)). They are therefore most effective when delivered at the early stages of the disease and function by blocking the interaction between the S protein and the receptor ACE2.
- RBM receptor binding motif
- S1 Spike protein domain 1
- RBD receptor-binding domain
- EUA Emergency-Use Authorization
- FDA Food and Drug Administration
- soluble ACE2 An alternative therapeutic strategy for the treatment of COVID-19 is the administration of soluble ACE2.
- This approach offers a variant-proof treatment, working to abrogate viral entry through a decoy binding of the ACE2 receptor, diverting the SARS-CoV-2 virus away from the endogenous receptor (73).
- a further advantage to the soluble ACE2 approach is that novel S1 mutations that increase the affinity of the viral protein to the receptor will also increase affinity to the decoy receptor. Soluble ACE2 alone has been evaluated as a treatment for COVID-19 (14); however this has limitations due to the low circulating half-life and affinity of the receptor in the monovalent form.
- ACE2 Improvements to ACE2 have been made by fusing the molecule to the Fc portion of an antibody to both enhance the half-life through Fc neonatal receptor binding and increase the apparent affinity though avidity effects (16, 17). Additional engineering of ACE2 molecules has improved potency further by incorporating a self-assembling, tetramerization domain from p53 protein (17). While this approach has led to potencies comparable to approved mAb therapies (78), the large molecular weight and complexities in the production of such molecules may prove a challenge to its widespread adoption as a therapeutic.
- mAb-based binding molecules in particular biparatopic binding molecules, as therapeutic candidates that are resistant to the prevalent variants of concern.
- Each candidate is objectively superior to the parental mAb clones from which they were derived, in terms of virus neutralising ability and binding kinetics.
- the invention relates to isolated antibodies and antigen-binding fragments thereof that bind the SARS-CoV-2 Spike protein RBD region.
- the invention relates to biparatopic binding molecules that bind non-overlapping epitopes within RBD.
- the inventors have demonstrated that the biparatopic binding molecules have increased overall affinity for the Spike protein relative to the constituent antibodies and are superior in terms of virus neutralising ability and binding kinetics.
- the combination of two non-competing antibodies or antigen-binding fragments thereof in a biparatopic format provides an at least additive, in one embodiment synergistic effect with regard to neutralisation potency.
- the biparatopic binding molecule may have greater resilience to viral mutational drift.
- the invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein wherein said isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and
- the isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of
- the antibody or antigen-binding fragment thereof comprises a human heavy chain constant region.
- the antibody or antigen-binding fragment thereof comprises a light chain constant region.
- the antibody or antigen-binding fragment thereof comprises a Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain FV (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, or single domain antibody.
- the antibody or antigen-binding fragment thereof neutralizes SARS-CoV-2.
- the antibody or antigen-binding fragment thereof is linked to a second antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein.
- RBD receptor binding domain
- S SARS-CoV-2 Spike
- the antibody or antigen-binding fragment thereof binds to a first epitope and the second antibody or antigen-binding fragment binds to a second epitope.
- the first and second antibody are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
- DVD dual variable domain
- scFv4-Fc or IgG-scFv format.
- the invention also relates to a polynucleotide encoding an antibody or antibody fragment as described herein.
- the invention also relates to a vector comprising a polynucleotide as described herein.
- the invention also relates to a host cell comprising a polynucleotide or a vector as described herein.
- the invention also relates to a method of making the antibody or antigen-binding fragment as described herein comprising (a) culturing a cell as described herein; and (b) isolating the antibody or antigen-binding fragment thereof or the protein from the cultured cell.
- the invention also relates to a binding molecule comprising a) a first antibody or antibody binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antibody fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV-2.
- the first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 1 1 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2
- the first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and
- the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR
- the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable
- the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36,
- the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- the binding molecule the first and second isolated antibody or antigen-binding fragment thereof are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
- DVD dual variable domain
- the invention also relates to a pharmaceutical composition comprising one or more isolated antibody or antigen-binding fragment thereof or a binding molecule as described herein.
- the invention also relates to an isolated antibody or antigen-binding fragment thereof as described herein, a binding molecule as described herein or a pharmaceutical composition as described herein for use as a medicament, in particular in the treatment of a SARS-CoV-2 infection.
- FIG. 1 Flow cytometry staining of cells expressing Wuhan trimeric Spike protein. Antibody clones obtained from phage display were utilised for cell staining (A). Identification of neutralising antibodies. Binding clones showing 2-fold binding over background (in A) were evaluated for neutralisation of lentivral vectors pseudotyped with spike protein (Wuhan) at a fixed concentration of 50 pg/mL (B). Clones demonstrating a greaterthan 85% neutralisation (black dotted line) were selected for further evaluation
- FIG. 1 Surface plasmon resonance sensograms for phage display derived clones against SARS-CoV-2 S1 domain (Wuhan). Curved fitted with a Langmuir 1 :1 binding model. Analyte was titrated over a 2-fold serial dilution, with a starting concentration of 250 nM, with double reference subtraction.
- Figure 4 Kinetic affinity of the interactions of control antibodies REGn10933, REGN10987 and LY-COV555 to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
- Figure 5. Neutralisation of SARS-CoV-2 pseudotyped vectors. Antibodies were tested against lentiviral vector pseudotyped with Spike protein (Wuhan). REGN10933, REGN10987 and LY- CoV555 antibodies were utilised as positive controls.
- Figure 7 Concentration of half maximal neutralisation observed for different antibody constructs. 2-way ANOVA of variant neutralisation compared to Wuhan for each test compound. ** p ⁇ 0.01 , *** p ⁇ 0.001 , **** p ⁇ 0.0001 .
- Figure 8 Flow cytometry staining of cells expressing Wuhan trimeric Spike protein.
- Antibody clones obtained from phage display were utilised for cell staining (A). Identification of neutralising antibodies. Binding clones showing 2-fold binding over background (in A) were evaluated for neutralisation of lentivral vectors pseudotyped with spike protein (Wuhan) at a fixed concentration of 50 pg/mL (B). Clones demonstrating a greaterthan 85% neutralisation (black dotted line) were selected for further evaluation.
- Figure 9 Surface plasmon resonance sensograms for phage display derived clones against SARS-CoV-2 S1 domain (Wuhan). Curved fitted with a Langmuir 1 :1 binding model. Analyte was titrated over a 2-fold serial dilution, with a starting concentration of 250 nM, with double reference subtraction.
- FIG. 10 Neutralisation of SARS-CoV-2 pseudotyped vectors. Antibodies were tested against lentiviral vector pseudotyped with Spike protein (Wuhan). REGN10933, REGN10987 and LY- CoV555 antibodies were utilised as positive controls.
- Figure 1 Kinetic affinity of the interactions of control antibodies REGnl 0933, REGN10987 and LY-COV555 to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
- FIG. 13 A) Representative setup of epitope binning data.
- Ligand Antibody (REGN10933) was coated on the surface of a sensor chip and then exposed to S1 protein or buffer for (negative control). Following injection of S1 protein the chip was exposed to buffer (red), REGN10933 (competing) and REGN10987 (non-competing).
- FIG. 14 Schematic representation of designed biparatopic antibody formats. D12C1 (blue) and D13C1 (yellow) binding domains were incorporated into DVD, IgG-scFv and scFv4-Fc formats.
- Figure 15. Neutralisation of SARS-CoV-2 spike (Wuhan), alpha, beta, gamma, and delta variant pseudotyed vectors with D12C1 , D13C1 , DVD, IgG-scFv and scFv-4 biparatopic antibodies.
- REGN10933/REGN10987 cocktail and LY-CoV555 antibodies were tested against each variant as a control and are shown compared to each antibody format.
- Figure 17 Kinetic affinity of the scFv4-Fc biparatopic antibodies to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
- FIG. 1 Neutralisation of SARS-CoV-2 spike (Wuhan), beta and delta variant pseudotyed vectors with 84-152, 152-84, 84-222 and 222-84 scFv4-Fc biparatocpic antibodies.
- REGN10933/REGN10987 cocktail was tested against each variant as a control.
- Figure 20 Activity wheel measurement (rotations/day).
- Figure 21 Macroscopic evaluation showing macroscopic lung score and relative lung weight.
- Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein.
- the nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Suitable assays to measure the properties of the molecules disclosed herein are also described in the examples.
- Coronaviruses are enveloped positive-stranded RNA viruses that belong to the family Coronaviridae and the order Nidovirales. Coronaviruses frequently infect people around the globe. There are a large number of coronaviruses, most of which circulate among peridomestic animals including pigs, camels, bats and cats. Of the seven coronaviruses identified in human so far, Coronaviruses 229E, NL63 were classified as Group 1 antigenic viruses, OC43 and HKU1 were classified as Group 2 antigenic viruses. They typically infect upper respiratory tract in human, and can bring about acute respiratory syndrome and can be fatal. Coronaviruses may be zoonotic in origin.
- SARS-CoV, MERS-CoV and 2019 SARS CoV-2 have human transmission and infective capability and have caused major public health concern worldwide over a short period within the century.
- the expansion of genetic diversity among coronaviruses and their consequent ability to cause disease in human beings is mainly achieved through infecting peridomestic animals, which serve as intermediate hosts, nurturing recombination and mutation events.
- the spike glycoprotein (S glycoprotein) which attaches the virion to the host cell membrane, is postulated to play a dominant role in host range restriction.
- MERS-CoV exploits dipeptidyl peptidase 4 (DPP4), a transmembrane glycoprotein, to infect type 2 pneumocytes and unciliated bronchial epithelial cells.
- DPP4 dipeptidyl peptidase 4
- the inventors have identified and isolated neutralizing antibodies which can be used to treat an infection with SARS-CoV-2, detect SARS-CoV-2 or monitor the progression of COVID-19 disease.
- the monoclonal antibodies specifically bind to the SARS-CoV-2 Spike protein RBD region.
- the binding reaction may be shown by standard methods, for example with reference to a negative control test using an antibody of unrelated specificity.
- the amino acid sequence of the RBD region of the Spike protein of SARS-CoV-2 (the target antigen) is provided below:
- SARS-CoV-2 (RBD) SEQ ID NO: 1 :
- Antibodies and antibody fragments as described herein bind an antigen comprising SEQ ID NO: 1 or variants thereof.
- a variant of SEQ ID NO:1 has at least 80%, 90% or 95% sequence identity to SEQ ID NO:1.
- Omicron includes Pango lineage B.1 .1 .529 and descendent Pango lineages BA.1 , BA.1.1 , BA.2 and BA.3.
- the antibodies and antigen-binding fragments thereof of the present invention can be used to detect and neutralize any other SARS-CoV-2 variants existent at the time of filing or with any future variants.
- the coronavirus S protein which includes the RBD region may be the S protein of any of these variants.
- antigen(s) and “epitope(s)” are well established in the art and refer to the portion of a protein or polypeptide which is specifically recognized by a component of the immune system, e.g. an antibody or a T-cell I B-cell antigen receptor.
- the term “antigen(s)” encompasses antigenic epitopes, e.g. fragments of antigens which are recognized by, and bind to, immune components.
- Epitopes can be recognized by antibodies in solution, e.g. free from other molecules.
- Epitopes can also be recognized by T-cell antigen receptors when the epitope is associated with a class I or class II major histocompatibility complex molecule.
- epitopes or “antigenic determinant” refers to a site on the surface of an antigen to which an immunoglobulin, antibody or antigen-binding fragment thereof specifically binds. Generally, an antigen has several or many different epitopes and reacts with many different antibodies. The term “specifically” includes linear epitopes and conformational epitopes.
- Epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or non-contiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope). Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents.
- An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14 or 15 amino acids in a unique spatial conformation.
- epitope mapping Methods for determining what epitopes are bound by a given antibody or antigen-binding fragment thereof (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides from are tested for reactivity with a given antibody or antigen-binding fragment thereof.
- Competition assays can also be used to determine if a test antibody binds to the same epitope as a reference antibody. Suitable competition assays are mentioned elsewhere herein and also shown in the examples.
- the epitope to which an antibody or antigen-binding fragment thereof binds can be determined by, e.g, NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g, site-directed mutagenesis mapping).
- antibody refers to an immunoglobulin protein that is capable of binding an antigen, i.e. SARS-CoV-2.
- antibody as used herein broadly refers to any polypeptide comprising complementarity determining regions (CDRs) that confer specific binding affinity of the polypeptide for an antigen.
- CDRs complementarity determining regions
- the term antibody as used herein encompasses polyclonal and monoclonal antibody preparations.
- the antibody or antigen-binding fragment thereof described herein "which binds” or is “capable of binding” the antigen of interest, binds the antigen with sufficient affinity such that the antibody or antigen-binding fragment thereof is useful as a therapeutic or diagnostic agent in targeting SARS-CoV-2 as described herein.
- the term “specific” may refer to the situation in which the antibody molecule will not show any significant binding to molecules other than its specific binding partner.
- polypeptide(s) and “protein(s)” are used interchangeably throughout the application and denote at least two covalently attached amino acids, thus may signify proteins, polypeptides, oligopeptides, peptides, and fragments thereof.
- the protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures.
- amino acid(s) or “peptide residue(s)”, as used herein denote both naturally occurring and synthetic amino acids.
- the immunoglobulin proteins of the present invention may be synthesized using any in vivo or in vitro protein synthesis technique known in the art.
- antibody As antibodies can be modified in a number of ways, the term “antigen-binding protein” or “antibody” should be construed as covering antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain,
- each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as HCVR, VH or VH) and a heavy chain constant region.
- the heavy chain constant region is comprised of three domains, CH1 , CH2 and CH3.
- Each light chain is comprised of a light chain variable region or domain (abbreviated herein as LCVR, VL or VL) and a light chain constant region.
- the light chain constant region is comprised of one domain, CL.
- Antibodies may include the kappa (K) and lambda (A) light chains and the alpha (IgA), gamma (lgG1 , lgG2, lgG3, lgG4), delta (IgD), epsilon (IgE) and mu (IgM) heavy chains, or their equivalents in other species.
- Full-length immunoglobulin “light chains” (usually of about 25 kDa or 214 amino acids long) consist of a variable region of approximately 110 amino acids at the NH2-terminus and a kappa or lambda constant region at the COOH-terminus.
- Fully-length immunoglobulin “heavy chains” (usually of about 50 kDa or 446 amino acids long), likewise consist of a variable region (of about 116 amino acids) and one of the aforementioned heavy chain constant regions, e.g. gamma (of about 330 amino acids).
- Light or heavy chain variable regions are generally composed of a “framework” region (FR) interrupted by three hypervariable regions, also called CDRs.
- the extent of the framework region and CDRs have been precisely defined. The sequences of the framework regions of different light and heavy chains are relatively conserved within a species.
- the framework region of an antibody i.e. the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs.
- the CDRs are primarily responsible for binding to an epitope of an antigen.
- CDR set refers to a group of three CDRs that occur in a single variable region capable of binding the antigen. The exact boundaries of these CDRs can be defined differently according to different systems known in the art.
- Heavy chain CDRs are designated HCDR1 , HCDR2 and HCDR3.
- Light chain CDRs are designated LCDR1 , LCDR2 and LCDR3.
- the antibody is comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule.
- Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass.
- the antibody is of the IgG type.
- CDRs Different definitions of the CDRs are commonly in use. The method described by Kabat is the most commonly used and CDRs are based on sequence variability (Kabat et al., (1971) Ann. NY Acad. Sci. 190:382-391 and Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91- 3242). Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)).
- the Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1 - 113 of the heavy chain).
- Another system is the ImMunoGeneTics (IMGT) numbering scheme (Lefranc et al., Dev. Comp. Immunol., 29, 185-203 (2005)).
- IMGT ImMunoGeneTics
- a CDR is a loop region of a variable domain, delimited according to the IMGT unique numbering for V domain.
- CDR1-IMGT loop BC
- CDR2-IMGT loop C'C
- CDR3-IMGT loop FG
- IMGT system as described above is used herein, unless otherwise stated.
- IMGT numbering IMGT definitions
- IMGT labelling are used interchangeably herein, antigenbinding
- antibody is not only inclusive of antibodies generated by methods comprising immunisation, but also includes any polypeptide, e.g., a recombinantly expressed polypeptide, which is made to encompass at least one CDR capable of specifically binding to an epitope on an antigen of interest. Hence, the term applies to such molecules regardless whether they are produced in vitro, in cell culture, or in vivo. Methods of producing polyclonal and monoclonal antibodies are known in the art and described more fully below.
- antibody as used herein is meant to specifically include antibody fragments I antigenbinding fragments thereof unless stated otherwise.
- the antibody fragment I antigen-binding fragments may be selected from any fragment capable of binding the antigen or antigenic fragment of interest.
- Exemplary antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain Fv (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, antibody mimetic protein, single domain antibody, e.g. a VH.
- the antibody fragment I antigen-binding fragment may comprise or consist of any of these fragments.
- Antigen-binding fragments derived from an antibody, including single-chain antibodies may comprise the variable region(s) alone or in combination with the entire, or parts of the, following: a heavy chain constant domain, or a portion thereof, e.g. a CH1 , CH2, CH3, transmembrane, and/or cytoplasmic domain, on the heavy chain, and a light chain constant domain, e.g. a Ckappa or Clambda domain, or portion thereof on the light chain. Also included in the present disclosure are any combinations of variable region(s) and CH1 , CH2, CH3, Ckappa, Clambda, transmembrane and cytoplasmic domains.
- Fv fragments ( ⁇ 25kDa) consist of the two variable domains, VH and VL.
- VH and VL domain are non-covalently associated via hydrophobic interaction and tend to dissociate.
- stable fragments can be engineered by linking the domains with a hydrophilic flexible linker to create a single chain Fv (scFv).
- VH and VL domains respectively are capable of binding to an antigen. They are generally referred to as a “single domain antibody” or “immunoglobulin single variable domain”.
- a single domain antibody ( ⁇ 12 to 15 kDa) has thus either the VH or VL domain.
- Antigen-binding single VH domains have also been identified from, for example, a library of murine VH genes amplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al., 1989, Nature 341 : 544-546). Ward et al.
- dAbs for single domain antibodies
- dAb generally refers to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen.
- VH, VHH or VL immunoglobulin variable domain
- human single domain antibodies are preferred over camelid derived VHH, primarily because they are not as likely to provoke an immune response when administered to a patient.
- the antibody or antigen-binding fragment thereof may be chimeric, human or humanised.
- a “chimeric antibody” is a recombinant protein that contains the variable domains including the CDRs of an antibody derived from one species, for example a murine antibody, while the constant domains of the antibody molecule are derived from those of a different species, for example a human antibody.
- Methods to humanise antibodies include CDR grafting based on framework regions homology and antibody resurfacing. Human or humanised antibodies or antigen-binding fragments are most desirable for use in antibody therapies, as such molecules would elicit little or no immune response in the human subject.
- Amino acid sequences of the antibodies of the invention are set out below.
- the invention relates to antigen-binding molecules, antibodies or antigen-binding fragments thereof comprising or consisting of the full-length antibody sequence or an antigen-binding fragment thereof, e.g. single chain Fvs or single domains of any one of the antibodies listed in table 2. Also within the scope of the invention are sequence variants as explained below.
- the invention thus relates to an isolated antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said antibody or antigen-binding fragment thereof comprises or consists of any of the sequences listed below in table 2.
- the isolated antibody or antigen-binding fragment thereof comprises or consists of
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively
- a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively;
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively;
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively
- a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively;
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 130, 131 and 132, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 130, 131 and 132, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 134, 135 and 136, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 134, 135 and 136, respectively;
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 138, 139 and 140, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 138, 139 and 140, respectively
- a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143 and 144, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 142, 143 and 144, respectively or
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 146, 147 and 148, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 146, 147 and 148, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 150, 151 and 152, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 150, 151 and 152, respectively.
- the present disclosure also includes antibodies comprising one, two, or three heavy chain CDRs of at least 80%, 90% or 95% sequence identity to HCDR1 , HCDR2, and/or HCDR3 as mentioned above. Furthermore, the present invention encompasses antibodies having one, two, or three light chain CDRs of at least 80%, 90% or 95% sequence identity to LCDR1 , LCDR2, and/or LCDR3 as mentioned above. All CDRs may either be derived from the same antibody or be independently selected from the different antibodies described herein.
- VH and VL CDRs are separated by framework regions (FR1 , 2, 3, and 4). FR sequences are also provided above. Amino acid and nucleic acid sequences for FRs are exemplified by the FRs of the antibodies disclosed herein. Antibodies containing FRs with amino acid sequences that are different from the framework regions disclosed herein and encoded by different nucleic acid sequences than those exemplified herein, are expected to exhibit similar or identical immunological binding properties and are viewed as derivatives or variants of the present invention. Conservative amino acid substitutions may also be contemplated for any amino acid residue of CDRs, framework regions, and/or linker regions as further explained below.
- the isolated antibody or antigen-binding fragment comprises or consists of ) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO:
- the antibody is a fragment or single-chain immunoglobulin, comprising or consisting of the variable region(s) alone as described above or combined with the entire, or parts of the, following: a heavy chain constant domain, or portion thereof, e.g., a CH1 , CH2 or CH3 transmembrane, and/or cytoplasmic domain, on the heavy chain, and a light chain constant domain, e.g., a Ckappa or Clambda domain, or portion thereof, on the light chain.
- a heavy chain constant domain e.g., a CH1 , CH2 or CH3 transmembrane, and/or cytoplasmic domain, on the heavy chain
- a light chain constant domain e.g., a Ckappa or Clambda domain, or portion thereof, on the light chain.
- the antibody is a full length antibody and comprises human constant regions and human light chain regions.
- Sequence identity as defined in the aspects and embodiments herein, in particular with regard to sequences of Table 2 relating to CDR or variable domain sequences (amino acid or polynucleotide sequences) can be at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, for example at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity.
- sequence variants with these percentage identities of the antibodies as shown in Table 2 are all within the scope of the invention.
- sequence “homology” or “identity” generally refers to the percentage of amino acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity.
- percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences.
- N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known.
- the percent identity between two amino acid sequences can be determined using well known mathematical algorithms.
- GAP Garnier GCG package, Accelerys Inc, San Diego USA.
- GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximising the number of matches and minimising the number of gaps. Generally, default parameters are used, with a gap creation penalty equalling 12 and a gap extension penalty equalling 4.
- Use of GAP may be preferred but other algorithms may be used, e.g. BLAST (which uses the method of Altschul et al. (1990) J. Mol. Biol. 215: 405-410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85: 2444-2448), or the Smith- Waterman algorithm (Smith and Waterman (1981) J. Mol Biol.
- an isolated antibody or antigen-binding fragment thereof that is a variant of any of the above antibodies or antigen-binding fragments and having one or more amino acid substitutions, deletions, insertions or other modifications, and which retains a biological function of the single domain antibody, that is binding to the target antigen and, thus, variant antibody or antigen-binding fragment thereof can be sequence engineered.
- Modifications may include one or more substitution, deletion or insertion of one or more codons encoding the single domain antibody or polypeptide that results in a change in the amino acid sequence as compared with the native sequence of the antibody or antigen-binding fragment thereof.
- Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements.
- Substitutions, insertions, additions or deletions may optionally be in the range of about 1 to 25 or 1 to 50, for example 1 to 5, 1 to 10, 1 to 15, 1 to 20 amino acids, for example 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids.
- the substitution e.g. 1 , 2, 3, 4 or 5 amino acid substitutions
- insertion, addition or deletion is in HCDR1 , HCDR2 and or HCDR3.
- the substitutions, insertion, addition or deletion is in LCDR1 , LCDR2 and or LCDR3.
- the substitution, insertion, addition or deletion is in a heavy chain framework region or a light chain framework region.
- the variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
- the modification is a conservative sequence modification.
- conservative sequence modifications is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
- amino acids with basic side chains e.g., lysine, arginine, histidine
- acidic side chains e.g., aspartic acid, glutamic acid
- uncharged polar side chains e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
- nonpolar side chains e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
- beta-branched side chains e.g., threonine, valine, isoleucine
- aromatic side chains e.g., tyrosine, phenylalanine, tryptophan, histidine
- one or more amino acid residues within the CDR regions of a single domain antibody of the invention can be replaced with other amino acid residues from the same side chain family and the altered antibody can be tested for retained function (i.e. antigen binding) using the functional assays described herein.
- amino acid changes can typically be made without altering the biological activity, function, or other desired property of the polypeptide, such as its affinity or its specificity for antigen.
- single amino acid substitutions in nonessential regions of a polypeptide do not substantially alter biological activity.
- substitutions of amino acids that are similar in structure or function are less likely to disrupt the polypeptides' biological activity.
- Abbreviations for the amino acid residues that comprise polypeptides and peptides described herein, and conservative substitutions for these amino acid residues are shown in Table 3 below.
- Binding affinity generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or antigen-binding fragment thereof) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g, antibody or antigen -binding fragment thereof and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD).
- Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (KD), and equilibrium association constant (KA).
- KD equilibrium dissociation constant
- KA equilibrium association constant
- Kon refers to the association rate constant of, e.g, an antibody or antigen-binding fragment thereof to an antigen
- koff refers to the dissociation of, e.g, an antibody or antigenbinding fragment thereof from an antigen.
- the affinity can be determined by techniques known to one of ordinary skill in the art, such as surface plasmon resonance (SPR) or KinExA.
- an antibody or antigen-binding fragment thereof of the invention has an affinity KD of ⁇ 250nM, ⁇ 200nM, ⁇ 1 OOnM, ⁇ 50nM, ⁇ 1 OnM or ⁇ 1 nM for the target antigen.
- an antibody or antigen-binding fragment thereof ofthe invention has an EC50 value of ⁇ 5pM, ⁇ 1 pM, ⁇ 900nM, ⁇ 800nM, ⁇ 700nM, ⁇ 600nM, ⁇ 500nM, ⁇ 400nM, ⁇ 300nM, ⁇ 200nM, ⁇ 100nM, ⁇ 50nM, ⁇ 10nM, ⁇ 5nM, ⁇ 1 nM, ⁇ 0.5nM, or ⁇ 0.1 nM.
- the EC50 value may be 0.5nM to 0.98 pM.
- the EC50 is the concentration of a drug that gives half-maximal response. Suitable methods for determining neutralising EC50 values are described in the examples
- the antibody may comprise a CH2 domain.
- the CH2 domain is for example located at the N- terminus of the CH3 domain, as in the case in a human IgG molecule.
- the CH2 domain of the antibody is in one embodiment the CH2 domain of human lgG1 , lgG2, lgG3, or lgG4, e.g the CH2 domain of human lgG1 .
- the sequences of human IgG domains are known in the art.
- the antibody may comprise an immunoglobulin hinge region, or part thereof, at the N-terminus of the CH2 domain.
- the immunoglobulin hinge region allows the two CH2-CH3 domain sequences to associate and form a dimer.
- the hinge region, or part thereof is a human lgG1 , lgG2, lgG3 or lgG4 hinge region, or part thereof.
- the hinge region, or part thereof is an lgG1 hinge region, or part thereof.
- the sequence of the CH3 domain is not particularly limited.
- the CH3 domain is a human immunoglobulin G domain, such as a human lgG1 , lgG2, lgG3, or lgG4 CH3 domain, e.g. a human lgG1 CH3 domain.
- An antibody of the invention may comprise a human lgG1 , lgG2, lgG3, or lgG4 constant region.
- the sequences of human lgG1 , lgG2, lgG3, or lgG4 CH3 domains are known in the art.
- An antibody of the invention may comprise a non-human IgG constant region, e.g., a rabbit lgG1 constant region.
- An antibody of the invention may comprise a human IgG Fc with effector function.
- Fc receptors are key immune regulatory receptors connecting the antibody mediated (humoral) immune response to cellular effector functions. Receptors for all classes of immunoglobulins have been identified, including FcyR (IgG), FcsRI (IgE), FcaRI (IgA), FcpR (IgM) and FcbR (IgD). There are three classes of receptors for human IgG found on leukocytes: CD64 (FcyRI), CD32 (FcyRlla, FcyRllb and FcyRllc) and CD16 (FcyRllla and FcyRlllb). FcyRI is classed as a high affinity receptor (nanomolar range KD) while FcyRI I and FcyRIII are low to intermediate affinity (micromolar range KD).
- ADCC antibody dependent cellular cytotoxicity
- FcvRs on the surface of effector cells Natural killer cells, macrophages, monocytes and eosinophils
- a signalling pathway is triggered which results in the secretion of various substances, such as lytic enzymes, perforin, granzymes and tumour necrosis factor, which mediate in the destruction of the target cell.
- the level of ADCC effector function various for IgG subtypes.
- ADCC effector function is high for human lgG1 and lgG3, and low for lgG2 and lgG4. See below for IgG subtype variation in effector functions, ranked in decreasing potency.
- FcyRs bind to IgG asymmetrically across the hinge and upper CH2 region. Knowledge of the binding site has resulted in engineering efforts to modulate IgG effector functions
- Antibodies of the invention may have an Fcwith effector function, with enhanced effector function or with reduced effector function.
- the potency of antibodies can be increased by enhancement of the ability to mediate cellular cytotoxicity functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP).
- ADCC antibody-dependent cell-mediated cytotoxicity
- ADCP antibody-dependent cell-mediated phagocytosis
- a number of mutations within the Fc domain have been identified that either directly or indirectly enhance binding of Fc receptors and significantly enhance cellular cytotoxicity: the mutations S239D/A330L/I332E (“3M”), F243L or G236A.
- enhancement of effector function can be achieved by modifying the glycosylation of the Fc domain, FcyRs interact with the carbohydrates on the CH2 domain and the glycan composition has a substantial effect on effector function activity.
- Afucosylated (non- fucosylated) antibodies exhibit greatly enhanced ADCC activity through increased binding to FcyRllla.
- ADCC and CDC may be desirable for some therapeutic antibodies, however, in some embodiments, an antibody that does not activate effector functions is preferred.
- an antibody that does not activate effector functions is preferred.
- lgG4 antibodies are the preferred IgG subclass for receptor blocking without cell depletion.
- lgG4 molecules can exchange half molecules in a dynamic process termed Fab-arm exchange. This phenomenon can occur between therapeutic antibodies and endogenous lgG4.
- the S228P mutation has been shown to prevent this recombination process allowing the design of lgG4 antibodies with a reduced propensity for Fab-arm exchange.
- the CH2 domain of an antibody or fragment of the invention may comprise one or more mutations to decrease or abrogate binding of the CH2 domain to one or more FcyR receptors, such as FcyRI, FcyRlla, FcyRllb, FcyRIII and/or to complement.
- CH2 domains of human IgG domains normally bind to Fey receptors and complement, decreased binding to FcyR receptors is expected to decrease antibody-dependent cell-mediated cytotoxicity (ADCC) and decreased binding to complement is expected to decrease the complement-dependent cytotoxicity (CDC) activity of the antibody molecule.
- ADCC antibody-dependent cell-mediated cytotoxicity
- CDC complement-dependent cytotoxicity
- An antibody molecule of the invention may comprise an Fc with modifications K322A/L234A/L235A or L234F/L235E/P331 S (“TM”), which almost completely abolish FcyR and C1q binding.
- An antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) ("LALA mutation").
- complement activation and ADCC can be decreased by mutation of Pro329 (position according to EU numbering), e.g., to either P329A or P329G.
- the antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) and an alanine (LALA- PA) or glycine (LALA-PG) at EU position 329 (position 114 by IMGT numbering).
- an antibody molecule of the invention may comprise an alanine, glutamine or glycine at EU position 297 (position 84.4 by IMGT numbering).
- Modification of glycosylation on asparagine 297 of the Fc domain which is known to be required for optimal FcR interaction may confer a loss of binding to FcRs; a loss of binding to FcRs has been observed in N297 point mutations.
- An antibody molecule of the invention may comprise an Fc with an N297A, N297G or N297Q mutation.
- An antibody molecule of the invention with an aglycosyl Fc domain may be obtained by enzymatic deglycosylation, by recombinant expression in the presence of a glycosylation inhibitor or following the expression of Fc domains in bacteria.
- IgG naturally persists for a prolonged period in the serum due to FcRn-mediated recycling, giving it a typical half-life of approximately 21 days.
- Half-life can be extended by engineering the pH- dependant interaction of the Fc domain with FcRn to increase affinity at pH 6.0 while retaining minimal binding at pH 7.4.
- the T250Q/M428L variant conferred an approximately 2-fold increase in IgG half-life (assessed in rhesus monkeys), while the M252Y/S254T/T256E variant ("YTE”), gave an approximately 4-fold increase in IgG half-life (assessed in cynomolgus monkeys). Extending half-life may allow the possibility of decreasing administration frequency, while maintaining or improving efficacy.
- Immunoglobulins are known to have a modular architecture comprising discrete domains, which can be combined in a multitude of different ways to create multispecific, e.g. bispecific, trispecific, or tetraspecific antibody formats.
- Exemplary multispecific antibody formats are described in Spiess et ai, (2015) Mol Immunol 67: 95-106 and Kontermann (2012) Mabs 4(2): 182-97, for example.
- the antibodies or antigen-binding fragments thereof of the invention may be employed in such multispecific formats.
- the antibodies or antigen-binding fragments thereof of the invention may be employed in biparatopic format thus binding to two different epitopes.
- the invention thus provides an isolated binding molecule comprising or consisting of a) a first antibody or antigen-binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antigen-binding fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV- 2.
- the first and second epitope are not identical. In one embodiment, the first and second epitope are overlapping epitopes. In another embodiment, the first and second epitope are not overlapping epitopes. In one embodiment, the biparatopic binding molecule is capable of simultaneously engaging two non-overlapping epitopes within the RBD.
- the first and/or second isolated antibody or antigen-binding fragment thereof may be selected from Table 2.
- said first and/or second isolated antibody or antigenbinding fragment thereof comprises
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively
- a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively;
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 114, 115 and 116, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 14, 115 and 116, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 118, 119 and 120, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 18, 119 and 120, respectively;
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 122, 123 and 124, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 122, 123 and 124, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 126, 127 and 128, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 126, 127 and 128, respectively;
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 130, 131 and 132, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 130, 131 and 132, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 134, 135 and 136, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 134, 135 and 136, respectively;
- HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 138, 139 and 140, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 138, 139 and 140, respectively
- a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143 and 144, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 142, 143 and 144, respectively or
- a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 146, 147 and 148, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 146, 147 and 148, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 150, 151 and 152, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 150, 151 and 152, respectively.
- Combinations where one of 1) to 19) is a first antibody and combined with one a second antibody of 1) to 19) are specifically envisaged.
- said first and/or second isolated antibody or antigen-binding fragment thereof comprises 1) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
- said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the
- said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
- said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable
- said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36,
- said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- first and second isolated antibody or antigen-binding fragment thereof can be combined in a biparatopic format in different ways.
- the binding molecule may comprise more than one fragment of the first antibody and more than one fragment of the second antibody.
- dual variable domain (DVD) or DVD-IgG is one type of bispecific antibody format, which is generated from two parental mAbs by stacking the two variable heavy domains of both parental antibodies onto the heavy chain and the variable light domains of both parental antibodies onto the light chain, forming an IgG-like molecule with a double VH/VL domain.
- the DVD-IgG retains the antigen-binding specificity, affinity, and biologic activities from its both parental antibodies, therefore, all of its four variable domains are functional (see Wu et al, 2007).
- the invention also relates to a DVD, scFv4-Fc and IgG-scFv comprising a first and a second isolated antigen-binding fragment as described above.
- DVD-lg can be manufactured by fusing the VH domain of antibody A to the heavy chain of antibody B, and the VL domain of antibody A to the light chain of antibody B, via a peptide linker.
- scFv4-Fc can be manufactured by substituting the original VH and VL domains of an IgG with one scFv for each chain. The resulting antibody would comprise one scFv4 (binding domain A) on the heavy CH1-CH2-CH3 chain, and one scFv4 (binding domain B) on the light chain.
- the biparatopic binding molecule may have an increased overall affinity for the Spike protein relative to the constituent antibodies.
- the combination of two competing antibodies may provide an additive or synergistic effect with regard to affinity and/or neutralisation potency.
- Neutralisation potency can be defined as the capacity to block viral mediated infection on target cells.
- Neutralisation potency assays can be selected from Pseudovirus infectivity assay with reporter marker gene (Ferrari et al ASM Journals Journal of Virology Vol. 95, No. 19); ACE2- Spike/S1/RBD competition ELISA assays; TCID50 replication competent virus titration assay; Replication competent virus plaque reduction neutralisation assay.
- Increase in potency compared the individual constituents may be improved at least 5, 20 or 20 fold.
- the biparatopic binding molecule may have greater resilience to viral mutational drift.
- first and second are used to differentiate between the two antibodies or antigenbinding fragments thereof used in the binding molecules of the invention, but are not understood to designate their orientation in the multivalent molecule with respect to the C and N terminus of the protein.
- said antibody or antigen-binding fragment thereof is located N-terminally and said second antibody or antigen-binding fragment thereof is located C-terminally.
- said first single antibody or antigen-binding fragment thereof is located C-terminally and said second antibody or antigen-binding fragment thereof is located N-terminally.
- a biparatopic construct is one selected from the table below having the sequence shown.
- Data for biparatopic molecule is shown in the examples, e.g. tables 9 and 10.
- the molecules as shown in Tables 9 and 10 are specifically part of the invention.
- the invention also relates to the use of an antibody or antigen-binding fragment as disclosed herein in a biparatopic binding molecule.
- the present invention further provides an isolated nucleic acid encoding an antibody, antigenbinding fragment thereof or binding molecule of the present invention.
- nucleic acid(s) or polynucleotide as used herein, denotes either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. Nucleic acid(s) may be naturally occurring or synthetically made, and as such, may denote analogues of naturally occurring polynucleotides in which one or more nucleotides are artificially modified.
- a polynucleotide encoding an isolated antibody or antigenbinding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said polynucleotide encodes a heavy chain variable region polypeptide that comprises HCDR1 , HCDR2, and HCDR3 sequences as shown in Table 2 or sequences with at least 80%, 90% or 95% sequence identity thereto, and a light chain variable region that encodes a light chain variable region polypeptide that comprises LCDR1 , LCDR2 and LCDR3 sequences as shown in Table 2 or sequences with at least 80%, 90% or 95% sequence identity thereto.
- polynucleotide encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said polynucleotide encodes a VH polypeptide as shown in Table 2 or a polypeptide with at least 80%, 90% or 95% sequence identity thereto and a VL polypeptide as shown in Table 2 or a polypeptide with at least 80%, 90% or 95% sequence identity thereto.
- Nucleic acids according to the invention can be selected from the following table
- nucleic acids as shown in Table 3 can be combined.
- the invention also provides kits of nucleic acids where more than two nucleic acids are needed to generate the molecule (this includes full-length antibodies).
- the invention also provides nucleic acid constructs that contain two or more nucleic acids (for light and heavy chain respectively), separated by a nucleic acid encoding a sequence that allows co-expression of both nucleic acids, for example an internal ribosome entry site (IRES) or 2A selfcleaving peptide.
- a nucleic acid encoding a sequence that allows co-expression of both nucleic acids, for example an internal ribosome entry site (IRES) or 2A selfcleaving peptide.
- IRS internal ribosome entry site
- the invention relates to a nucleic acid construct comprising at least one nucleic acid as defined herein.
- the construct may be in the form of a plasmid, vector, transcription or expression cassette.
- the invention also relates to an isolated recombinant host cell comprising one or more nucleic acid construct as described above.
- the host cell may be a bacterial, viral, plant, mammalian or other suitable host cell.
- Such host cells are well known in the art and many are available from the American Type Culture Collection (ATCC). These host cells include, inter alia, Chinese hamster ovary (CHO) cells, such as ExpiCHO cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, HEK- 293 cells and a number of other cell lines.
- CHO Chinese hamster ovary
- NSO Chinese hamster ovary
- SP2 cells such as ExpiCHO cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, HEK- 293 cells and a number of other cell lines.
- Mammalian host cells include human, mouse, rat, dog, monkey
- yeast and filamentous fungus cells including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp., Kluyveromyces lactis, Candida alb
- the antibodies or antigen-binding fragments thereof of the invention are coupled or conjugated to at least one therapeutic moiety, such as a drug, an enzyme or a toxin, thus forming an immunuconjugate.
- the therapeutic moiety is a toxin, for example a cytotoxic radionuclide, chemical toxin or protein toxin.
- conjugation and conjugated refer to chemical linkages, either covalent or non-covalent, which proximally associates one molecule of interest with a second molecule of interest.
- immunoconjugate refers to an antigen-binding protein, e.g., an antibody or antigen-binding fragment, which is chemically or biologically linked to a radioactive agent, a cytokine, an interferon, a target or reporter moiety, an enzyme, a peptide or protein or a therapeutic agent.
- the antigen-binding protein may be linked to the radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, peptide or therapeutic agent at any location along the molecule so long as it is able to bind its target.
- immunoconjugates include antibody-drug conjugates and antibody-toxin fusion proteins.
- the second moity is a label, for example a fluorescent molecule, 0- galactosidase, luciferase molecules, chemical dyes, fluorophores or a radioisotope.
- the antibodies or antigen-binding fragments thereof of the invention are modified to increase half-life, for example by a chemical modification, especially by PEGylation, or by incorporation in a liposome, or using a serum albumin protein or an antibody or antibody fragment that binds human serum albumin. Increased half-life can also be conferred by conjugating the molecule to an antibody fragment.
- half-life refers to the time taken for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, in vivo, for example due to degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms.
- Half-life may be increased by at least 1 .5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, greater than the half-life of the corresponding antibodies of the invention.
- increased half-life may be more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the antibody of the invention.
- the in vivo half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art.
- Half-life can for example be expressed using parameters such as the t1 /2-alpha t1/2-beta and the area under the curve (AUC).
- linker for example a polypeptide linker.
- Other linkers are known in the art, for example cysteine linkers for antibody drug conjugates.
- Antigen-binding protein e.g. antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof of the invention
- the invention also relates to an antigen-binding protein e.g. an antibody or antigen-binding fragment that competes with an antibody or antigen-binding fragment of the invention.
- the term “competes” as used herein, refers to an antigen-binding protein e.g., antibody or antigen-binding fragment thereof) that binds to the target antigen (e.g., SARS-CoV-2) and inhibits or blocks the binding of another antigen-binding protein (e.g., antibody or antigen-binding fragment thereof) to the antigen.
- the term also includes competition between two antigen-binding proteins e.g., antibodies, in both orientations, i.e., a first antibody that binds and blocks binding of second antibody and vice versa.
- the first antigen-binding protein (e.g., antibody) and second antigen-binding protein (e.g., antibody) may bind to the same epitope.
- the first and second antigen-binding proteins (e.g., antibodies) may bind to different, but, for example, overlapping epitopes, wherein binding of one inhibits or blocks the binding of the second antibody, e.g., via steric hindrance.
- competition between antigen-binding proteins may be measured by methods known in the art, for example, by a real-time, label-free bio-layer interferometry assay.
- competition between a first and second anti- SARS-CoV-2 antigenbinding protein is determined by measuring the ability of an immobilized first anti- SARS-CoV-2 antigen-binding protein (e.g., antibody) (not initially complexed with SARS-CoV-2 protein) to bind to soluble SARS-CoV-2 protein complexed with a second anti- SARS-CoV-2 antigen-binding protein (e.g., antibody).
- first anti- SARS-CoV-2 antigen-binding protein e.g., antibody
- the degree of competition can be expressed as a percentage of the reduction in binding.
- Such competition can be measured using a real time, label-free bio-layer interferometry assay, e.g., on an Octet RED384 biosensor (Pall ForteBio Corp.), ELISA (enzyme-linked immunosorbent assays) or SPR (surface plasmon resonance), HTRF; flow cytometry; fluorescent microvolume assay technology (FMAT) assay, Mirrorball, high content imaging based fluorescent immunoassays, radioligand binding assays, bio-layer interferometry (BLI), surface plasmon resonance (SPR) and thermal shift assays.
- FMAT fluorescent microvolume assay technology
- An antibody that binds to the same epitope as a reference antibody refers to an antibody that blocks binding of the reference antibody to its binding partner (e.g., an antigen or “target”) in a competition assay by 50% or more, and I or conversely, the reference antibody blocks binding of the antibody to its binding partner in a competition assay by 50% or more.
- binding partner e.g., an antigen or “target”
- the reference antibody blocks binding of the antibody to its binding partner in a competition assay by 50% or more.
- Such antibodies are said to compete for binding to an epitope of interest.
- the present disclosure includes an antibody or antigen-binding fragment thereof or binding molecule as described in previous aspects of the invention may be produced in/by murine, mammal or other animal models, by using hybridoma technology or other methods known in the art.
- nucleic acids encoding the antibody or antigen-binding fragment thereof or binding molecule as described in previous aspects of the invention may be inserted into a plasmid and expressed in a suitable expression system.
- the present invention includes methods for expressing an antibody or antigen-binding fragment thereof or immunoglobulin chain thereof in a host cell (e.g., bacterial host cell such as E.
- a bacterial host cell such as an E. coli, includes a polynucleotide encoding the T7 RNA polymerase gene operably linked to a lac promoter and expression of the polymerase and the chain is induced by incubation of the host cell with IPTG (isopropyl-beta-D-thiogalactopyranoside).
- Transformation can be by any known method for introducing polynucleotides into a host cell.
- Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene- mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, biolistic injection and direct microinjection of the DNA into nuclei.
- nucleic acid molecules may be introduced into mammalian cells by viral vectors. Methods of transforming cells are well known in the art.
- the present invention also includes recombinant methods for making an antibody or antigen-binding fragment thereof or binding molecule of the present invention comprising (i) introducing one or more polynucleotides (e.g., including the nucleotide sequence disclosed herein) encoding light and/or heavy immunoglobulin domains of the antigen-binding protein, for example, wherein the polynucleotide is in a vector; and/or integrated into a host cell chromosome and/or is operably linked to a promoter; (ii) culturing the host cell (e.g., E.
- the polynucleotide under condition favorable to expression of the polynucleotide and, (iii) optionally, isolating the antigen-binding protein, (e.g., antibody orfragment) or chain from the host cell and/or medium in which the host cell is grown.
- antigen-binding protein e.g., antibody orfragment
- an antigen-binding protein e.g., antibody or antigen-binding fragment
- coexpression of the chains in a single host cell leads to association of the chains, e.g., in the cell or on the cell surface or outside the cell if such chains are secreted, so as to form the antigen-binding protein (e.g., antibody or antigen-binding fragment).
- the methods include those wherein only a heavy immunoglobulin chain or only a light immunoglobulin chain (e.g., any of those discussed herein including mature fragments and/or variable domains thereof) is expressed.
- Such chains are useful, for example, as intermediates in the expression of an antibody or antigen-binding fragment that includes such a chain.
- Eukaryotic and prokaryotic host cells including mammalian cells, may be used as hosts for expression of an anti-TMPRSS2 antigen-binding protein. Such host cells are mentioned elsewhere herein,
- the disease is a viral infection, i.e. SARS-CoV-2 infection.
- Methods of treatment are also envisaged.
- a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or a binding molecule as described herein and optionally a pharmaceutically acceptable carrier or excipient.
- the pharmaceutical composition may comprise one or more antibody or antigen-binding fragment thereof as shown in Table 2 and described herein. All combinations of these antibodies or fragments are envisaged.
- the pharmaceutical composition may comprise only one antibody or antigen-binding fragment thereof as shown in Table 2 and described herein.
- the pharmaceutical composition may comprise two or more antibodies or antigen-binding fragments thereof as shown in Table 2 and described herein.
- the pharmaceutical composition may comprise two or more binding molecules as described herein.
- the antibody or antigen-binding fragment thereof or binding molecule as described herein or the pharmaceutical composition of the invention can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitreal, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.
- Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical or subcutaneous administration.
- the pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form.
- carrier refers to a diluent, adjuvant or excipient, with which an antibody or antigen-binding fragment thereof or binding molecule of the present invention is administered.
- Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like.
- the carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like.
- auxiliary, stabilizing, thickening, lubricating and coloring agents can be used.
- the antibody or antigen-binding fragment thereof or binding molecule of the present invention or compositions and pharmaceutically acceptable carriers are sterile.
- Water is a preferred carrier when the antibody or antigen-binding fragment thereof or binding molecule of the present invention are administered intravenously.
- Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions.
- Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
- the present compositions if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
- the pharmaceutical composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension.
- the liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or sub-cutaneously.
- composition When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
- the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
- a solid composition typically contains one or more inert diluents.
- binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
- a liquid carrier such as polyethylene glycol
- the composition can be in the form of a liquid, e. g. an elixir, syrup, solution, emulsion or suspension.
- the liquid can be useful for oral administration or for delivery by injection.
- a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
- a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
- compositions can take the form of one or more dosage units.
- the composition can be desirable to administer the composition locally to the area in need of treatment, or by injection, intravenous injection or infusion.
- the composition is part of a device which includes an injector pen.
- the composition may be provided as a pre-filled syringe or other self-administration device.
- the term “effective amount” means an amount of antibody or antigen-binding fragment thereof of the invention, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to achieve the desired therapeutic or prophylactic effect under the conditions of administration.
- the term “effective amount” of a composition, as used herein, is intended to denote a non-lethal but sufficient amount of the composition to provide the desired effect.
- the effective amount is the one which eliminates or diminishes the symptoms associated with the disorder, e.g. so as to provide control over SARS-Cov-2 infection by eliminating viral particles.
- An effective amount may be determined by one of ordinary skill in the art, using routine experimentation.
- in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges.
- the precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
- the amount is at least about 0.01 % of a the antibody or antigen-binding fragment thereof of the present invention by weight of the composition.
- this amount can be varied to range from about 0.1 % to about 80% by weight of the composition.
- Preferred oral compositions can comprise from about 4% to about 50% of the single domain antibody of the present invention by weight of the composition.
- compositions of the present invention can be prepared so that a parenteral dosage unit contains from about 0.01 % to about 2% by weight of the single domain antibody of the present invention.
- the composition can comprise from about typically about 0.1 mg/kg to about 250 mg/kg of the subject’s body weight, forexample, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, for example about 1 mg/kg to about 10 mg/kg of the animal's body weight.
- the composition is administered at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg.
- the dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks.
- the antibody or antigen-binding fragment thereof or binding molecule of the present invention can be administered at an initial dose, followed by one or more secondary doses.
- the initial dose may be followed by administration of a second or a plurality of subsequent doses of antibody or antigen-binding fragment thereof in an amount that can be approximately the same or less than that of the initial dose, wherein the subsequent doses are separated by at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.
- the invention provides methods of treating SARS-CoV-2-mediated diseases or disorders in a mammal, e.g., a human patient or subject, comprising administering an effective amount of an antibody or antigen-binding fragment thereof or binding molecule of the present invention to a mammal in need thereof.
- the invention furthermore relates to a method for the prevention and/or treatment of SARS-CoV-2 infection said method comprising administering, to a subject in need thereof, a pharmaceutically active amount of an antibody or antigen-binding fragment thereof or binding molecule of the invention or pharmaceutical composition of the invention.
- treat means inhibiting or relieving a disease or disorder.
- treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease.
- the terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms.
- the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.
- a subject refers to an animal which is the object of treatment, observation, or experiment.
- a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, murine, bovine, equine, canine, ovine, or feline.
- the subject may have a viral infection, e.g., a SARS-CoV-2 infection, or be predisposed to developing an infection.
- Subjects predisposed to developing an infection, or subjects who may be at elevated risk for contracting an infection include subjects with compromised immune systems because of autoimmune disease, subjects receiving immunosuppressive therapy (for example, following organ transplant), subjects afflicted with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), subjects with forms of anemia that deplete or destroy white blood cells, subjects receiving radiation or chemotherapy, or subjects afflicted with an inflammatory disorder. Additionally, subjects of old age (e.g., 65 years of age or older) are at increased risk.
- the invention also relates to an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region, or pharmaceutical composition of the invention for use in the treatment or prevention of a disease.
- the invention relates to an antibody or antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention for use in the treatment or prevention of a SARS-CoV-2 infection.
- the invention relates to an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention for use in the manufacture of a medicament for the treatment or prevention of a SARS-CoV-2 infection.
- the invention in another aspect, relates to an immunotherapy comprising an antibody or antigenbinding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention.
- This may include the step of administering the antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition to a subject in need thereof.
- the invention in another aspect, relates to a method of treating or preventing prevention of a SARS-CoV-2 infection comprising administering an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or administering a pharmaceutical composition of the invention.
- immunotherapy refers to the treatment of a disease (e.g. of a viral infection) by modulating, directing or supplementing the immune response to an antigen associated with, or produced during, the disease (e.g. an antigen of the infectious agent).
- immunotherapy refers to blocking or diminishing the infection and/or intercellular spreading of the virus in any given subject by administering one or more of the monoclonal antibodies of the invention.
- the SARS-CoV-2 infection may be caused by a variant, for example as shown in Table 1 .
- the variant is omicron.
- the antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention may be administered as the sole active ingredient or in combination with one or more other therapeutic agent.
- a therapeutic agent is a compound or molecule which is useful in the treatment of a disease. Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, pro-apoptotic agents, anti- angiogenic agents, boron compounds, photoactive agents or dyes and radioisotopes.
- An antibody molecule includes a full antibody or fragment thereof as mentioned elsewhere herein, e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment (scFv) or a single domain antibody, for example a VH domain, or antibody mimetic protein.
- the antibody or antigen-binding fragment thereof or binding molecule may be administered alone or in combination, e.g. one of the antibodies or antibody fragments listed in Table 2 may be administered followed by administration of one, two or three other antibodies or antibody fragments listed in Table 2.
- the invention also relates to a combination therapy comprising at least two of the antibodies or antigen-binding fragment thereof listed in Table 2.
- one or more antibody or antigen-binding fragment thereof or binding molecule or pharmaceutical composition as described herein is used in combination with an existing therapy ortherapeutic agent, for example an anti-viral compound, an antibody therapy that targets SARS-CoV-2, a vaccine, an immunomodulator or an anti-inflammatory.
- the invention also relates to a combination therapy comprising administration of one or more antibody, or antigen-binding fragment thereof, binding molecule or pharmaceutical composition described herein and an anti-viral therapy.
- the combination therapy may comprise one of more of antibodies or antigenbinding fragments thereof listed in Table 2. In one embodiment, the combination therapy may comprise one antibody or antigen-binding fragment thereof listed in Table 2. In another embodiment, the combination therapy may comprise two or more antibodies or antigen-binding fragments thereof listed in Table 2.
- a further anti-viral therapy may be administered concurrently or sequentially with one or more of antibody or antigen-binding fragment thereof listed in Table 2.
- a number of therapies that treat and prevent COVID-19 are known or being developed and the antibody or antibody fragment of the invention and any of these therapies may be used in conjunction with the antibodies of the invention.
- these therapies include: i) Antivirals, e.g. Remdesivir, Chloroquine/hydroxychloroquine, Lopinavir/ritonavir combination, Favipiravir, Umifenovir, Ribavirin, EIDD-2801 , Niclosamide and Oseltamivir; ii) Immune modulators, e.g.
- Colchicine Angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, Statins, Aspirin, Clopidogrel, Anticoagulants, Bemcentinib, Omeprazole, Famotidine, Zilucoplan, Ascorbic acid/vitamin C, Aviptadil, Opaganib, Tradipitant, AZD1656, Nitric oxide and Razuprotafib or iv) Antibodies that neutralise SARS-CoV-2, e.g. asirivimab and imdevimab. bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, tixagevimab plus cilgavimab: or combinations thereof.
- a viral entry inhibitor or a viral attachment inhibitor is administered.
- administration of the antibody, antigen-binding fragment thereof, binding molecule pharmaceutical composition of the invention with the therapeutic agent; e.g. anti-viral therapy is concurrent or sequential.
- the antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention is administered prior or subsequent to administration of the therapeutic agent, e.g. at least an hour, five hours, 12 hours, a day, a week, a month, for example several months (e. g. up to three months), prior or subsequent to administration of composition of the present invention.
- the invention provides a kit for the treatment or prevention of Covid-19 and/or for detecting SARS-CoV-2 for diagnosis, prognosis or monitoring disease comprising an antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention; e.g. one or more antibody or antigen-binding fragment thereof listed in Table 2.
- a kit may contain other components, packaging, instructions, or material to aid in the detection of SARS-CoV-2 protein.
- the kit may include a labeled antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention and one or more compounds for detecting the label.
- the invention in another aspect provides an antibody, antigen-binding fragment thereof, binding molecule or a pharmaceutical composition of the invention packaged in lyophilized form or packaged in an aqueous medium.
- an antibody, antigen-binding fragment thereof, , e.g. as shown in Table 2, or binding molecule of the invention is used for non-therapeutic purposes, such as diagnostic tests and assays, for example immunoassays for the detection or quantification of SARS-Cov-2 virus.
- the immunoassays per se are well-known and any of the well-known immunoassays may be employed. That is, classifying the known immunoassays according to the reaction type, known immunoassays include sandwich immunoassays, competition immunoassays, agglutination immunoassays, Western blot and the like.
- known immunoassays include fluorescence immunoassays, enzyme immunoassays, radio immunoassays, biotin immunoassays and the like. Any of these immunoassays may be employed. Further, diagnosis may be attained by immunohistostaining. In cases where a labeled antibody antigen-binding fragment thereof or binding molecule is used in the immunoassay, the methods per se for labeling an antibody are well-known, and any of the well-known methods may be employed.
- the antibody, antigen-binding fragment thereof or binding molecule of the present invention is immobilized on a solid phase as a first antibody, first antigen-binding fragment thereof or first binding molecule.
- the first antibody first antigenbinding fragment thereof or first binding molecule is then reacted with a sample, and after washing the solid phase, the resultant is then reacted with a second antibody which reacts with the enzyme of the present invention by antigen-antibody reaction. After washing the solid phase, the second antibody bound to the solid phase is measured.
- the second antibody bound to the solid phase is measured.
- the above-mentioned measurement is conducted for a plurality of standard samples each containing a known concentration of the enzyme, and the relationship between the concentrations of the enzyme in the standard samples and the measured amounts of the label is plotted to prepare a calibration curve.
- the enzyme in a test sample may be quantified by applying the measured amount to the calibration curve.
- detecting is used herein in the broadest sense to include both qualitative and quantitative measurements of a target molecule. Detecting includes identifying the mere presence of the target molecule in a sample as well as determining whether the target molecule is present in the sample at detectable levels. Detecting may be direct or indirect.
- the above-mentioned first antibody and the above-mentioned second antibody may be exchanged.
- the antibody according to the present invention or an antigen-binding fragment thereof is immobilized on particles such as latex particles, and the particles are reacted with a sample, followed by measurement of the absorbance.
- the above-mentioned measurement is conducted for a plurality of standard samples each containing a known concentration of the enzyme, and the relationship between the concentrations of the enzyme in the standard samples and the measured absorbance is plotted to prepare a calibration curve.
- the enzyme in a test sample may be determined by applying the measured absorbance to the calibration curve.
- a method for detecting the presence of SARS-Cov-2 particles or SARS- Cov-2 viral components in a test subject comprising contacting a test sample with an isolated antibody, antigen-binding fragment thereof or binding molecule of the invention.
- the method may further comprise i) determining the degree of binding of the antibody, antigenbinding fragment thereof or binding molecule to the test sample (ii) contacting a control sample with an isolated antibody, antigen-binding fragment thereof or binding molecule according to any of claims 1 to x and determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (iii, wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered positive for the presence of SARS-Cov-2.
- the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating a healthy value.
- the method may further comprise the step of obtaining a test sample from a subject.
- the test sample may be a healthy subject or a diseased subject, e.g. a subject showing symptoms of CoVID-19 disease.
- the control sample is from a subject that does not have CoVID-19 disease, i.e. a healthy subject.
- patients may be tested before receiving any treatment.
- patients may be tested following treatment, after a certain period or periodically, to monitor their response to therapy.
- the method also includes the additional step of treating the patient with a COVID-19 therapy.
- a method for monitoring the progression of COVID -19 disease in a test subject that suffers from infection comprising contacting a test sample with an isolated antibody, antigen-binding fragment thereof or binding molecule of the invention and detecting the presence of SARS-CoV-2 particles or SARS-CoV-2 viral components in a test subject.
- the method may further comprise i) determining the degree of binding of the antibody, antigenbinding fragment thereof or binding molecule to the test sample (ii) contacting a control sample with an isolated antibod , antigen-binding fragment thereof or binding molecule as described herein determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (ii), wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered to indicate progression of disease.
- the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating a certain stage of disease.
- the method may further comprise the step of obtaining a test sample from a subject.
- the test sample is from a subject which has previously been diagnosed as having COVID-19.
- patients may be at an early stage of COVID-19 disease, exhibiting few and mild symptoms.
- patients may be at a more advanced stage of COVID-19 disease, exhibiting more severe symptoms.
- patients may be tested before receiving any treatment.
- patients may be tested following treatment, after a certain period or periodically, to monitor their response to therapy.
- the method also includes the additional step of treating the patient with a COVID-19 therapy.
- the control sample may be a sample from the same subject taken at an earlier timepoint.
- Samples used in the methods above may be used include, but are not limited to, nasal I nasopharyngeal swabs I washes I aspirates, nasal mucosal fluid, oral I oropharyngeal swabs I washes I aspirates, biological fluids such as serum, saliva plasma, whole I peripheral I capillary blood, sputum and cough secretions, isolated / separated cells / cell populations, cultured cells of any origin and cell extracts, as well as tissue material such as fresh / frozen biopsies and formalin- fixed I paraffin-embedded biopsies.
- the invention also relates to a method for detecting the presence of SARS- Cov-2 particles or SARS-Cov-2 viral components on solids and in fluids of any type including, but not limited to, surfaces and objects in medical I hospital environments, schools, recreational facilities and households, hotels, drinking I washing I irrigation water supplies, and sewage reservoirs.
- the method comprises contacting a test solid or fluid sample with an isolated antibody or antigen-binding fragment of the invention and detecting the presence of SARS-Cov-2 particles or SARS-Cov-2 viral components in test solid or fluid sample.
- the test sample is not from a subject.
- the method may further comprise i) determining the degree of binding of the antibody or antibody fragment to the test sample (ii) contacting a control sample with an isolated antibody or antigenbinding fragment thereof as described herein determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (ii), wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered to indicate progression of disease.
- the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating test sample free of SARS-Cov-2 particles or SARS-Cov-2 viral components.
- Suitable detectable labels which may be conjugated to antigen-binding proteins are known in the art and include radioisotopes such as iodine-125, iodine-131 , yttrium- 90, indium-1 11 and technetium-99; fluorochromes, such as fluorescein, rhodamine, phycoerythrin, Texas Red and cyanine dye derivatives for example, Cy7, Alexa750 and Alexa Fluor 647; chromogenic dyes, such as diaminobenzidine; latex beads; enzyme labels such as horseradish peroxidase; phospho or laser dyes with spectrally isolated absorption or emission characteristics; electro-chemiluminescent labels, such as SULFO-TAG which may be detected via stimulation with electricity in an appropriate chemical environment; and chemical moieties, such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g. labelled avidin or streptavidin.
- the high sensitivity exhibited by the antibody, antigen-binding fragment thereof or binding molecule of the invention is particularly advantageous in facilitating detection of virus even in low viral titer biological fluids such as might be self-sampled by a consumer relatively non-invasively, e.g., by swabbing mucosal fluids such as nasal fluids or saliva.
- the antibody, antigen-binding fragment thereof or binding molecule according to the present invention as at least one of the solid phase antibody, antigen-binding fragment thereof or binding molecule and labeled antibody, antigen-binding fragment thereof or binding molecule, a reagent for measuring SARS-Cov-2 virus may be produced.
- the solid phase on which the above-described antibody, antigen-binding fragment thereof or binding molecule is immobilized various solid phases used in conventional immunoassays may be used.
- solid phases examples include various solid phases such as ELISA plates, latices, gelatin particles, magnetic particles, polystyrenes and glasses, insoluble carriers such as beads and matrices through which liquid can be transported and the like.
- the labeled antibody, antigenbinding fragment thereof or binding molecule may be produced by labeling an antibody, antigenbinding fragment thereof or binding molecule with an enzyme, colloidal metal particle, colored latex particle, luminescent substance, fluorescent substance, radioactive substance or the like.
- reagents such as these solid phase antibodies, antigen-binding fragment thereof or binding molecule and/or labeled antibodies, antigen-binding fragment thereof or binding molecule, reagents used in enzyme immunoassays, radioimmunoassays, fluoroimmunoassays or the like may be produced.
- These measurement reagents are the reagents for measuring an antigen of interest present in the test sample by sandwich immunoassay or competitive binding immunoassay.
- the immunoassay device of the present invention for measuring SARS-Cov-2 virus utilizes the principle of immunochromatography.
- the device comprises a detection zone having the monoclonal antibody of the present invention immobilized on a matrix through which liquid can be transported, and a labeled reagent zone having a labeled anti- SARS-Cov-2 virus monoclonal antibody of the present invention spotted movably on the above-described matrix.
- the invention relates to a solid support comprising an isolated antibody, antigen-binding fragment thereof or binding molecule according to the invention.
- the solid support may be selected from a polystyrene plate, polystyrene beads, nitrocellulose test strip, a nanoparticle or microfluidic chip.
- the invention relates to a lateral flow immunoassay for detecting SARS-Cov-2 particles or SARS-Cov-2 viral components in a sample, comprising:
- a mobile phase comprising a detection antibody conjugated or otherwise associated with a detectible signal, said detection antibody being capable of binding SARS-Cov-2 particles or SARS-Cov-2 viral components to form a binary complex;
- a stationary phase comprising a substrate comprising immunochromatographic material having immobilized thereon a capture antibody or fragment as described herein, said capture antibody being capable of binding said SARS-Cov-2 of the binary complex to form a ternary complex, whereby a detectible signal generated by said ternary complex is indicative of the presence of SARS-Cov-2 in the sample.
- lateral flow refers to capillary flow through a material in a horizontal direction, but will be understood to apply to the flow of a liquid from a point of application of the liquid to another lateral position even if, for example, the device is vertical or on an incline. Lateral flow depends upon properties of the liquid/substrate interaction (surface wetting orwicking action) and does not require application of outside forces, e.g., vacuum or pressure applications by the user.
- the mobile phase typically comprises the sample, liquid diluents and a detection antibody-signal conjugate
- the immobile phase typically comprises the capture antibody immobilized at the test and control lines, both detection and capture antibodies being specific for the analyte.
- the liquid biological sample is absorbed onto the sample pad, and the sample progresses by capillary action into the conjugate pad, where it rehydrates detection antibody particles labelled with a detectable moiety such as a colored label, allowing for the mixing of these particles with the absorbed liquid sample.
- the labelled antibody interacts with the specific analyte contained in the sample, thereby initiating the intermolecular interactions which are dependent on the affinity and avidity of the reagents.
- the binary complex of the labelled antibody and its specific analyte migrate along the strip toward the capture antibody immobilized in the reaction zone (typically in a line transverse, for example perpendicular, to the sample flow to form a "test line” across the strip), which recognizes and captures the complex, where it becomes immobilized and produces a distinct signal, for example, in the form of a colored line.
- This technique may be used to obtain quantitative or semi- quantitative results.
- solutions or suspensions of labelled antibody and biological sample are combined under conditions to form a binary complex of the labelled antibody with the analyte, prior to application to a test strip.
- the chromatographic strip is "dipped into” or otherwise contacts the liquid, so that the complex of labelled antibody and target analyte is drawn across the strip as described above, toward the capture antibody at the test line.
- the invention relates to the use of the antibodies, antigen-binding fragment thereof or binding molecule according to the invention as detection agents for SARS-Cov-2 particles or SARS-Cov-2 viral components or therapeutic agents.
- the invention relates to the following aspects
- An isolated antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein wherein said isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 9
- the isolated antibody or antigen-binding fragment thereof according to aspect 1 comprising i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL
- the antigen-binding fragment comprises a Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain FV (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, or single domain antibody,.
- the antibody or antigen-binding fragment thereof according to any preceding aspect which is linked to a second antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein.
- RBD receptor binding domain
- S SARS-CoV-2 Spike
- a vector comprising a polynucleotide according to aspect 16.
- a host cell comprising a polynucleotide according to aspect 16 or a vector according to aspect 17.
- a method of making the antibody or antigen-binding fragment according to any one of aspects 1 to 16 comprising (a) culturing a cell according to aspect 18; and (b) isolating the antibody or antigen-binding fragment thereof or the protein from the cultured cell.
- a binding molecule comprising a) a first antibody or antibody binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antibody fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV-2.
- the binding molecule according to aspect 20 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that
- the binding molecule according to aspect 20 or 21 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%
- binding molecule according to any of aspects 20 to 23 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
- binding molecule according to any of aspects 20 to 22 or 27 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
- binding molecule according to any of aspects 20 to 28 wherein the first and second isolated antibody or antigen-binding fragment thereof are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
- DVD dual variable domain
- a combination therapy comprising at least two antibodies or antigen-binding fragments according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 .
- a pharmaceutical composition comprising one or more isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15 or a binding molecule according to any of aspects 20 to 29.
- a method of treatment of a patient suffering from a SARS-CoV-2 infection comprising administering an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 to said patient.
- a method for diagnosing a SARS-CoV-2 infection comprising detecting SARS-CoV-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigenbinding fragment thereof according to aspects 1 to 15.
- a method for monitoring disease progression comprising detecting SARS-Cov-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigen-binding fragment thereof according to aspects 1 to 15.
- a method for detecting the presence of SARS-CoV-2 particles or SARS-CoV-2 viral components in a test subject comprising contacting a test sample with an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15.
- a kit comprising an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 and optionally instructions for use.
- Immune phage-display libraries were generated from cDNA derived from PBMCs of two convalescent donors and RNA from 5x10 6 cells extracted then purified using the I llustra RNAspin Mini kit (GE healthcare, 25-055-71), according to manufacturer’s instructions. cDNA was then amplified from the extracted RNA using oligo dT and the Superscript IV First-Strand Synthesis System (Thermo Fisher) with RiboLock RNase inhibitor (Thermo Fisher), in accordance with manufacturer’s instructions. Heavy chain VDJ and light chain VJ region amplification was performed by PCR on each donor cDNA separately, using KOD Xtreme Hot Start DNA Polymerase Kit (Sigma-Aldrich) to manufacturer’s instructions.
- the generated phage display libraries were electroporated in E.coli and subsequently used for the biopanning process. A library size of 10 8 was determined for both libraries used. Phage particles were obtained by superinfection with helper phage (M13K07, New England Biolabs, N0315). The libraries were initially selected against the full-length Spike protein (Aero biosystems, SPN-C52H9) and a further round of biopanning was carried out against the RBD only domain (Aero biosystems, SPD-C52H3). Briefly, immunotubes were coated at 4°C overnight using the SARS-CoV2 antigens at 5 and 2 pg/ml, respectively, in sterile PBS (Lonza, BE17-513F).
- variable regions of the identified chains were formatted into full length IgG antibodies, then expressed, purified, and subjected to biophysical and flow cytometry analysis.
- Antibody clones were assayed for binding against SupT1 cells expressing Spike protein (Wuhan).
- a total of 24 unique Spike binding clones were identified via phage display approach (Fig. 1A).
- the neutralisation capacity of clones capable of binding to Spike protein was evaluated against an engineered replication-deficient lentiviral vector pseudotyped with the Wuhan Spike glycoprotein (76).
- Spike-binding clones were each mixed in a 1 :1 ratio with 1x10 5 IU/ml of pseudotyped lentivirus (PsV), at a fixed concentration of 50 pg/ml.
- PsV pseudotyped lentivirus
- Clones D12C1 , D12C3 and D13C1 were analysed via surface plasmon resonance (SPR) for binding kinetics to SARS-CoV-2 S1 domain ( Figure 2). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K instrument (Cytiva). HBS-P + buffer was used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml.
- SPR surface plasmon resonance
- Flow cell 1 was unmodified and used for reference subtraction.
- a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift.
- Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case.
- Clones D12C1 and D13C1 were screened via SPR for binding kinetics to SARS-CoV-2 S1 domain of variants Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and omicron (Figure 3).
- control antibodies LY-CoV555, REGN10933 and REGN10987 were tested on the same variants ( Figure 4). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K or Biacore T200 instrument (Cytiva). HBS-P + buffer was used as running buffer in all experimental conditions.
- Recombinant S1 at 250 nM with 2-fold serial dilutions was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml.
- Flow cell 1 was unmodified and used for reference subtraction.
- a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift.
- Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case.
- the D12C1 , D12C2, D12C3, D13C1 , D13C27, D13C32 and D13C37 neutralising antibodies were tested in a more stringent neutralisation assay by titrating against 1x10 6 lU/ml PsV (described above) and compared to the control antibodies REGN10933, REGN10987 and Ly-CoV555 (Figure 5).
- Clones identified through phage display demonstrated varying levels of neutralisation with four antibodies showing ECso values ranging from 6.5 nM to 0.98 pM and three failing to show appreciable activity.
- Clones D12C1 and D13C1 were tested in neutralization assays against SARS-CoV-2 pseudotyped lentiviral vectors carrying the spike protein of Wuhan, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants.
- Antibodies were tested at a range of concentrations with 4-fold serial dilutions. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x10 5 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h.
- Antibody-virus mixtures were added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X- 20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control.
- a 1 :1 antibody cocktail of REGN10933 and REGN10987, and the clone LY- CoV555 were used as controls (Figure 6). Clone D13C1 showed sustained neutralisation capacity over all variants tested.
- Activated and memory B cells that bound S1-tetramer were FACS-purified from PBMCs and partitioned into single B cell V(D)J libraries using the 10x genomics platform.
- the libraries were sequenced, and the native IgA and IgG heavy and light chains identified and paired for each cell using the 10x barcodes.
- the variable regions of the identified chains from each approach were formatted into full length IgG antibodies, then expressed, purified, and subjected to biophysical and flow cytometry analysis.
- Antibody clones were assayed for binding against SupT 1 cells expressing Spike protein (Wuhan) (Fig. 8A). A total of 213 unique Spike binding clones were identified, of which 131 demonstrated appreciable binding to the spike protein.
- the neutralisation capacity of clones capable of binding to Spike protein were evaluated against an engineered replication-deficient lentiviral vector pseudotyped with the Wuhan Spike glycoprotein.
- Spike-binding clones were each mixed in a 1 :1 ratio with 1x10 5 lU/ml of pseudotyped lentivirus, at a fixed concentration of 50 pg/ml.
- a total of 24 antibodies demonstrated over 85% neutralisation capacity (Fig. 8B).
- Antibody-virus mixtures were added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. Clones demonstrated varying levels of neutralisation with four antibodies showing ECso values ranging from 0.7 nM to 212 nM.
- Clones S4A_84 (84), S4B_56 (56), S4B_152 (152) and S4B_222 (222) were screened via SPR for binding kinetics to SARS-CoV-2 S1 domain of variants Wuhan, alpha (B.1 .1 .7), beta (B.1 .351), gamma (P.1), delta (B.1.617.2) and omicron ( Figure 11 , Table 3). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K instrument (Cytiva). HBS-P + buffer was used as running buffer in all experimental conditions.
- Recombinant S1 at 250 nM with 2-fold serial dilutions was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml.
- Flow cell 1 was unmodified and used for reference subtraction.
- a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift.
- Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case. Antibodies tested showed high affinity interactions against the spike variants tested. Clones 84 and 56 showed impaired binding to omicron variant.
- Clones 84, 56, 152 and 222 were tested at a range of concentrations with 4-fold serial dilutions. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x10 5 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. SARS-CoV-2 spike variants tested were Wuhan, Beta (1.351) and Delta (B.1.617.2) as these were the ones shoving more challenging conditions among the available Variants of concern. Antibody-virus mixtures were added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h.
- Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control.
- a 1 :1 antibody cocktail of REGN10933 and REGN10987 was used as control ( Figure 12).
- Clone D13C1 showed sustained neutralisation capacity over all variants tested. All clones showed consistent neutralisation against Wuhan, Beta and delta variants.
- the binding epitope for these binders has already been precisely determined based on their solved co-crystal structures (PDB 6XDG and 7L3N) and would therefore serve as reference for mapping our own candidates. Simultaneous binding of two antibodies to S1 would indicate targeting non-overlapping regions of the S1 protein and would therefore fall into separate bins; while two antibodies binding to the same or overlapping epitopes would show limited secondary binding events and would be grouped into the same bin (Fig. 13A). Mapping the data highlighted a number of antibodies with unique binding epitopes (Fig. 13B).
- Antibodies were selected based on ability to co-operatively binding to S1 , as well as showing competition with ACE2-Fc.
- To LY-CoV555 was assigned the Bin 1 , to REGN10933 the Bin 2, to REGN10987 the Bin 3 and to ACE2-Fc the Bin 4.
- Bin 1 and Bin 3 are overlapping or in close proximity epitopes and clones LY-CoV555 and REGN10987 do compete with each other.
- ACE2- Fc bin (bin 4) comprises all 3 bins. Clones D12C3, D13C1 and S4B_177 bound to a distinct epitope not occupied by LY-CoV-555 (Bin 1), REGN10933 (Bin 2) or REGN10987 (Bin 3).
- Clones S4A_16, S4A_54, S4A_60 and S4A_79 also mapped to a distinct epitope but lied outside of the ACE2 epitope.
- Clone D12C1 mapped in the Bin 1 and Bin 3.
- Clones S4A_84 and S4B_56 mapped in Bin 3.
- Clones S4B_156, S4B_222 and S4B_276 mapped in Bin 1 and Bin 2.
- Clones D13C27, D13C32, D13C37, S4A_18, S4B_39, S4B109B and S4B_142 mapped on a broad epitope encompassing Bin 1 , 2, 3 and 4 ( Figure 13B).
- Two antibody clones, D12C1 and D13C1 were clones in the dual variable domain (DVD) architecture (Fig. 14).
- Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x10 5 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h.
- Antibody-virus mixtures were added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X- 20 cell analyser and infectivity of all fractions was determined as a percentage of viral titres in the PBS only control. As a control, the REGN10933/10987 cocktail and LY-CoV555 were evaluated against the same variants.
- the D12C1 and D13C1 antibodies were able to neutralise SARS-CoV- 2 (Wuhan), with a dose-response curve demonstrating an EC50 of 4.7 and 7 nM, respectively.
- a reduction in neutralisation was observed for D12C1 against the beta and delta variants, indicating susceptibility to the current mutational landscape.
- a similar effect was observed with the REGN10933/10987 antibody cocktail.
- D13C1 proved to be resistant to mutational drift in spike (Fig. 15B).
- the DVD consistently showed better EC50 values across the variants, with a 61- and 21 -fold improvement over D12C1 for the beta and gamma variants, respectively, while maintaining neutralisation capacity against the delta variant.
- IgG-scFv and scFv4-Fc two additional biparatopic antibody architectures: IgG-scFv and scFv4-Fc (Fig. 14).
- the IgG-scFv, and scFv4-Fc constructs showed significantly improved EC50 values, compared to the DVD molecule, ranging between 0.9-5.1 and 0.5-2.7 nM against the Wuhan, alpha, beta and delta variants, respectively.
- the scFv4-Fc construct showed the highest overall neutralisation, comparable to the REGN10933/10987 cocktail, against the Wuhan, alpha and gamma variants.
- Binding affinities of the biparatopic constructs were further evaluated to recombinant S1 protein domains of the different variants. Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555), using a Biacore 8K instrument (Cytiva). HBS-P + bufferwas used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction.
- the binding kinetics data indicates that the DVD biparatopic antibody construct was capable of consistently increasing the overall affinity to the Spike protein relative to the constituent antibodies, with a 4.4-fold increase for the delta variant compared to the parental D12C1 antibody, to 6.7 nM (Fig. 16, Table 7).
- the IgG-scFv and the scFv4-Fc formats also showed greatly improved affinities for the SARS- CoV-2 S1 variants compared to the parental D12C1 and D13C1 IgG antibody formats, with up to 6.3-fold affinity increase for the IgG-scFv format and up to 9.7-fold improvement for the scFv4-Fc format (Table 9).
- all biparatopic formats (DVD, IgG-scFv and scFv4-Fc) showed a greatly improved affinity profile for the omicron variant.
- ScFv4-Fc biparatopic format of combinations of clone 84 and 152 (84-152 and 152-84 orientations) or 84 and 222 (84-222 and 222-84 orientations) also showed a greatly improved affinities towards Wuhan, alpha, beta gamma and delta S1 variants, with affinity improvements in excess of 10-fold and in the pM range ( Figure 17, Table 10).
- Biparatopic formats also showed nM affinities for the Omicron variant, despite the loss of binding for the parental clone 84, highlighting the resistance to mutational escape (Figure 17 and Table 10).
- Neutralisation efficiency of scFv4-Fc 84-152, 152-84, 84-222 and 222-84 against SARS-CoV-2 Wuhan, beta and delta pseudotyped lentiviral vectors was performed as described above. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x10 5 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibody-virus mixtures were added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h.
- Viral titres were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control.
- a 1 :1 antibody cocktail of REGN10933 and REGN10987 was used as control ( Figure 18). All biparatopic antibodies showed efficient neutralisation of pseudotyped viral infection with consistent performance across all variants tested. Of note, the scFv4-Fc biparatopic antibodies showed > 5-fold improvement in EC50 compared to the REGN cocktail for the beta variant.
- Clones D12C1 , D13C1 , 84, 56, 152, 222 IgG antibodies, D12C1/D13C1 biparatopic antibody (DVD, IgG-Fc and scFv4-Fc) and scFv4-Fc antibodies 84-152, 152-84, 84-222 and 222-84 are tested at a range of concentrations with 4-fold serial dilutions in a SARS-CoV-2 pseudotyped lentiviral vector neutralisation assay against Wuhan and Omicron variants.
- Each antibody dilution is mixed 1 :1 with lentiviral vectors normalised to 1x10 5 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h.
- Antibodyvirus mixtures are added to 3x10 4 HEK-293T (ACE2 + , TMPRSS2 + ) in 48-well plates and incubated for 72 h.
- Viral titres are then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions is determined as a percentage of viral titres in the PBS only control.
- a 1 :1 antibody cocktail of REGN10933 and REGN10987 and the Ly-CoV555 antibody are used as control.
- the total area of consolidated lung tissue was evaluated (dorsal and ventral perspective) with a photograph of the lungs and drawing during necropsy by a veterinary pathologist or trained veterinarian. A second evaluation was performed after the necropsy with the drawing and photos. The score represents mean of both evaluations.
- the whole left side (one lobe) was evaluated and the percentage of affected lung tissue of the left lobe was graded (objective 2.5x or 5x in duplicate):
- Swabs collected at DPI -4 were all negative for viral RNA.
- sgRNA levels were significantly lower for D12/D13 scFv4-Fc group compared to PBS at DPI 9 and for D12C1/D13C1 antibody cocktail DP1 10 (two-way ANOVA with Dunnett’s post-test versus PBS group, * P ⁇ 0.05, ** P ⁇ 0.01).
- CDRs are according to IMGT. CDRs are underlined
- LCDR3 SEQ ID NO: 32 QVWDSSSDHPV
- VH SEQ ID NO: 69 QITLKESGPTLVKPTQTLTLACTVSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDQRYSPS
- LCDR1 SEQ ID NO: 70 QNIGDY
- VH SEQ ID NO: 77 QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCVNWIRQPPGKALEWLARIDWDDAKYYST
- LCDR3 SEQ ID NO: 96 GTWDNSLSAGV
- LCDR1 SEQ ID NO: 102 QDINHY
- HCDR2 SEQ ID NO: 35 ISGNGGAI HCDR3 SEQ ID NO: 36 AKGYYYDDGGYSGREDAFDI
- LCDR1 SEQ ID NO: 38 QGISNF
- HCDR1 SEQ ID NO: 106 GITVSSNY HCDR2 SEQ ID NO: 107 IYSGGST
- LCDR1 SEQ ID NO: 110 QSVSSSS
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention relates to antibodies or antigen-binding fragments thereof that specifically bind to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein. The invention further relates to methods for treating or preventing SARS-CoV-2 infection and related medical uses of the antibodies or antigen-binding fragments thereof.
Description
P44004W01
Antibodies Against SARS-CoV-2 and Uses Thereof
Field of the invention
The present invention relates to monoclonal antibodies (mAbs) targeted against the receptorbinding domain (RBD) of the spike (S) glycoprotein of coronavirus SARS-CoV-2.
Introduction
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the end of 2019 (7) has led to a major coronavirus disease (COVID-19) pandemic outbreak. As of September 2021 , there has been a total of> 220 million confirmed cases and > 4.7 million deaths associated with SARS-CoV-2, worldwide (https://covid19.who.int/). In the past year, highly effective vaccines have been rapidly developed and approved that reduce the severity of SARS- CoV-2 infection and subsequent hospitalisation (2-4). Despite these achievements, the availability of treatments for patients infected with the virus has lagged. Further, several patients might not benefit from available vaccines. Individuals with non-functioning immune systems, suffering from immune deficiency or those taking immune-suppressing drugs may account for as much as 5% of the population for whom the available vaccines will not provide protection against the virus.
Monoclonal antibodies (mAb) have been touted as a potential alternative to provide protection to individuals that cannot be vaccinated. The majority of commonly identified antibodies neutralize coronaviruses by binding to the receptor binding motif (RBM) in the Spike (S) protein domain 1 (S1) (also termed receptor-binding domain (RBD)). They are therefore most effective when delivered at the early stages of the disease and function by blocking the interaction between the S protein and the receptor ACE2. Over 20 mAbs are currently under clinical evaluation (5). The antibodies LY-CoV555 and LY-CoV016 developed by Eli Lilly and Company, and the antibody cocktail REGN-COV2 (REGN10933 plus REGN10987) developed by Regeneron, were granted Emergency-Use Authorization (EUA) by the Food and Drug Administration (FDA). Despite the enormous endeavour applied to the generation of therapeutic antibodies to treat or prevent Covid- 19, many barriers have prevented their widespread use. These include logistical challenges in administration and the emergence of new variants of concern that have already demonstrated resistance to some of these molecules.
Several SARS-CoV-2 variants have been described for which there is evidence of increased transmissibility, severity or immunity. The B.1.1.7 (WHO designation: alpha) (6) B.1.351 (beta) (7) , B.1.1 .28.1 (P.1 , gamma) (8) and B.1.617.2 (delta) (9) variants carry mutations in the RBM (K417N/T, E484K/Q, N501 Y and/or L452R), which could facilitate viral escape from mAb binding (70, 77). Furthermore, detailed mapping of the mutations that escape approved antibody therapies REGN-COV2 and LY-CoV555 demonstrated that single point mutations such as the
E406W substitution was capable of diminishing the neutralisation capacity of these therapeutics (72), further highlighting the risk of viral evolution and escape due to selective pressure as a result of antibody treatment.
An alternative therapeutic strategy for the treatment of COVID-19 is the administration of soluble ACE2. This approach offers a variant-proof treatment, working to abrogate viral entry through a decoy binding of the ACE2 receptor, diverting the SARS-CoV-2 virus away from the endogenous receptor (73). A further advantage to the soluble ACE2 approach is that novel S1 mutations that increase the affinity of the viral protein to the receptor will also increase affinity to the decoy receptor. Soluble ACE2 alone has been evaluated as a treatment for COVID-19 (14); however this has limitations due to the low circulating half-life and affinity of the receptor in the monovalent form. Improvements to ACE2 have been made by fusing the molecule to the Fc portion of an antibody to both enhance the half-life through Fc neonatal receptor binding and increase the apparent affinity though avidity effects (16, 17). Additional engineering of ACE2 molecules has improved potency further by incorporating a self-assembling, tetramerization domain from p53 protein (17). While this approach has led to potencies comparable to approved mAb therapies (78), the large molecular weight and complexities in the production of such molecules may prove a challenge to its widespread adoption as a therapeutic.
Here, we have engineered mAb-based binding molecules, in particular biparatopic binding molecules, as therapeutic candidates that are resistant to the prevalent variants of concern. Each candidate is objectively superior to the parental mAb clones from which they were derived, in terms of virus neutralising ability and binding kinetics. We also recently reported the preclinical efficacy of an ACE2-Fc fusion molecule and showed the resistance of the molecule to viral mutational drift (76). We have further built upon the biparatopic engineering strategies used, to produce antibody-like ACE2-fusion molecules with the highest reported viral neutralisation potency while maintaining mAb-like biophysical properties.
Summary of the invention
The invention relates to isolated antibodies and antigen-binding fragments thereof that bind the SARS-CoV-2 Spike protein RBD region. In particular, the invention relates to biparatopic binding molecules that bind non-overlapping epitopes within RBD. The inventors have demonstrated that the biparatopic binding molecules have increased overall affinity for the Spike protein relative to the constituent antibodies and are superior in terms of virus neutralising ability and binding kinetics. Thus, the combination of two non-competing antibodies or antigen-binding fragments thereof in a biparatopic format provides an at least additive, in one embodiment synergistic effect with regard to neutralisation potency. Moreover, the biparatopic binding molecule may have greater resilience to viral mutational drift. In particular, the inventors have demonstrated neutralisation of the prevalent omicron variant as well as other variants of the virus.
In one aspect, the invention relates to an isolated antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein wherein said isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising
the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
In one embodiment, the isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or
viii) a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, the antibody or antigen-binding fragment thereof comprises a human heavy chain constant region.
In one embodiment, the antibody or antigen-binding fragment thereof comprises a light chain constant region.
In one embodiment, the antibody or antigen-binding fragment thereof comprises a Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain FV (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, or single domain antibody.
In one embodiment, the antibody or antigen-binding fragment thereof neutralizes SARS-CoV-2.
In one embodiment, the antibody or antigen-binding fragment thereof is linked to a second antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein.
In one embodiment, the antibody or antigen-binding fragment thereof binds to a first epitope and the second antibody or antigen-binding fragment binds to a second epitope.
In one embodiment, the first and second antibody are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
The invention also relates to a polynucleotide encoding an antibody or antibody fragment as described herein.
The invention also relates to a vector comprising a polynucleotide as described herein.
The invention also relates to a host cell comprising a polynucleotide or a vector as described herein.
The invention also relates to a method of making the antibody or antigen-binding fragment as described herein comprising (a) culturing a cell as described herein; and (b) isolating the antibody or antigen-binding fragment thereof or the protein from the cultured cell.
The invention also relates to a binding molecule comprising a) a first antibody or antibody binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antibody fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV-2.
In one embodiment, the first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively;
ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 1 1 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively,
and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
In one embodiment, the first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or a VH region of SEQ ID NO: 61 thereto or viii) or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least
80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively.
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively.
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3
comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively
In one embodiment, the first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, the binding molecule the first and second isolated antibody or antigen-binding fragment thereof are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format. The invention also relates to a pharmaceutical composition comprising one or more isolated antibody or antigen-binding fragment thereof or a binding molecule as described herein.
The invention also relates to an isolated antibody or antigen-binding fragment thereof as described herein, a binding molecule as described herein or a pharmaceutical composition as described herein for use as a medicament, in particular in the treatment of a SARS-CoV-2 infection.
Figures
The invention is further described in the following non-limiting figures.
Figure 1. Flow cytometry staining of cells expressing Wuhan trimeric Spike protein. Antibody clones obtained from phage display were utilised for cell staining (A). Identification of neutralising antibodies. Binding clones showing 2-fold binding over background (in A) were evaluated for neutralisation of lentivral vectors pseudotyped with spike protein (Wuhan) at a fixed concentration of 50 pg/mL (B). Clones demonstrating a greaterthan 85% neutralisation (black dotted line) were selected for further evaluation
Figure 2. Surface plasmon resonance sensograms for phage display derived clones against SARS-CoV-2 S1 domain (Wuhan). Curved fitted with a Langmuir 1 :1 binding model. Analyte was titrated over a 2-fold serial dilution, with a starting concentration of 250 nM, with double reference subtraction.
Figure 3. Kinetic affinity of the interactions to Wuhan, alpha (B.1.1.7), beta (B.1 .351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
Figure 4. Kinetic affinity of the interactions of control antibodies REGn10933, REGN10987 and LY-COV555 to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
Figure 5. Neutralisation of SARS-CoV-2 pseudotyped vectors. Antibodies were tested against lentiviral vector pseudotyped with Spike protein (Wuhan). REGN10933, REGN10987 and LY- CoV555 antibodies were utilised as positive controls.
Figure 6. Neutralisation of SARS-CoV-2 spike (Wuhan), alpha, beta, gamma and delta variant pseudotyed vectors with D12C1 and D13C1 antibodies. REGN10933/REGN10987 cocktail and LY-CoV555 antibodies were tested against each variant as a control.
Figure 7. Concentration of half maximal neutralisation observed for different antibody constructs. 2-way ANOVA of variant neutralisation compared to Wuhan for each test compound. ** p<0.01 , *** p<0.001 , **** p<0.0001 .
Figure 8. Flow cytometry staining of cells expressing Wuhan trimeric Spike protein. Antibody clones obtained from phage display were utilised for cell staining (A). Identification of neutralising antibodies. Binding clones showing 2-fold binding over background (in A) were evaluated for neutralisation of lentivral vectors pseudotyped with spike protein (Wuhan) at a fixed concentration of 50 pg/mL (B). Clones demonstrating a greaterthan 85% neutralisation (black dotted line) were selected for further evaluation.
Figure 9. Surface plasmon resonance sensograms for phage display derived clones against SARS-CoV-2 S1 domain (Wuhan). Curved fitted with a Langmuir 1 :1 binding model. Analyte was titrated over a 2-fold serial dilution, with a starting concentration of 250 nM, with double reference subtraction.
Figure 10. Neutralisation of SARS-CoV-2 pseudotyped vectors. Antibodies were tested against lentiviral vector pseudotyped with Spike protein (Wuhan). REGN10933, REGN10987 and LY- CoV555 antibodies were utilised as positive controls.
Figure 1 1 . Kinetic affinity of the interactions of control antibodies REGnl 0933, REGN10987 and LY-COV555 to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
Figure 12. Neutralisation of SARS-CoV-2 spike (Wuhan), beta and delta variant pseudotyed vectors with 84, 56, 152 and 222 antibody clones. REGN10933/REGN10987 cocktail was tested against each variant as a control.
Figure 13. A) Representative setup of epitope binning data. Ligand: Antibody (REGN10933) was coated on the surface of a sensor chip and then exposed to S1 protein or buffer for (negative control). Following injection of S1 protein the chip was exposed to buffer (red), REGN10933 (competing) and REGN10987 (non-competing). B) Heat map demonstrating binding of various identified binding clones.
Figure 14. Schematic representation of designed biparatopic antibody formats. D12C1 (blue) and D13C1 (yellow) binding domains were incorporated into DVD, IgG-scFv and scFv4-Fc formats.
Figure 15. Neutralisation of SARS-CoV-2 spike (Wuhan), alpha, beta, gamma, and delta variant pseudotyed vectors with D12C1 , D13C1 , DVD, IgG-scFv and scFv-4 biparatopic antibodies. REGN10933/REGN10987 cocktail and LY-CoV555 antibodies were tested against each variant as a control and are shown compared to each antibody format. A) pronounced decrease of neutralisation capacity against the p variant was observed for D12C1 , D13C1 , LY-CoV555 and REGN10933/10987. Representative profile of two independent experiments with two technical replicates. B) Concentration of half maximal neutralisation observed for different antibody constructs (from A). No significant loss of neutralisation efficiency was observed for the biparatopic DVD, IgG-scFv and scFv4-Fc constructs against alpha, beta and gamma variants. Partial potency loss with the delta variant. The scFv4-Fc construct demonstrated the highest potency neutralisation with half maximal neutralisation EC50 values between 0.5-2.7 nM observed across the variants. Empty bars were limited to 1 pM. 2-way ANOVA of variant neutralisation compared to Wuhan for each test compound. * p<0.05, ** p<0.01 , *** p<0.001 , **** p<0.0001. 2-way ANOVA of test compound neutralisation potency across variants, compared to REGN10933/REGN10987. #### p<0.0001 . ns not significant.
Figure 16. Kinetic affinity of the biparatopic antibodies to Wuhan, alpha (B.1 .1 .7), beta (B.1 .351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
Figure 17. Kinetic affinity of the scFv4-Fc biparatopic antibodies to Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and Omicron SARS-CoV-2 S1 variants.
Figure 18. Neutralisation of SARS-CoV-2 spike (Wuhan), beta and delta variant pseudotyed vectors with 84-152, 152-84, 84-222 and 222-84 scFv4-Fc biparatocpic antibodies. REGN10933/REGN10987 cocktail was tested against each variant as a control.
Figure 19. Body weight measurements.
Figure 20. Activity wheel measurement (rotations/day).
Figure 21 . Macroscopic evaluation showing macroscopic lung score and relative lung weight.
Figure 22. Extent lung histopathology
Figure 23. PCR swabs
Figure 24. PCR tissues
Detailed description
The embodiments of the invention will now be further described. In the following passages, different embodiments are described. Each aspect so defined may be combined with any other aspect or aspects unless clearly indicated to the contrary.
Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, pathology, oncology, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly
used in the art. The methods and techniques of the present disclosure are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Green and Sambrook et al., Molecular Cloning: A Laboratory Manual, 4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012); Therapeutic Monoclonal Antibodies: From Bench to Clinic, Zhiqiang An (Editor), Wiley, (2009); and Antibody Engineering, 2nd Ed., Vols 1 and 2, Ontermann and Dubel, eds., Springer-Verlag, Heidelberg (2010).
Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients. Suitable assays to measure the properties of the molecules disclosed herein are also described in the examples.
Coronaviruses are enveloped positive-stranded RNA viruses that belong to the family Coronaviridae and the order Nidovirales. Coronaviruses frequently infect people around the globe. There are a large number of coronaviruses, most of which circulate among peridomestic animals including pigs, camels, bats and cats. Of the seven coronaviruses identified in human so far, Coronaviruses 229E, NL63 were classified as Group 1 antigenic viruses, OC43 and HKU1 were classified as Group 2 antigenic viruses. They typically infect upper respiratory tract in human, and can bring about acute respiratory syndrome and can be fatal. Coronaviruses may be zoonotic in origin. The SARS-CoV, MERS-CoV and 2019 SARS CoV-2 have human transmission and infective capability and have caused major public health concern worldwide over a short period within the century. The expansion of genetic diversity among coronaviruses and their consequent ability to cause disease in human beings is mainly achieved through infecting peridomestic animals, which serve as intermediate hosts, nurturing recombination and mutation events. The spike glycoprotein (S glycoprotein), which attaches the virion to the host cell membrane, is postulated to play a dominant role in host range restriction. While SARS-CoV and 2019 SARS CoV-2 infect type 2 pneumocytes and ciliated bronchial epithelial cells utilizing angiotensin converting enzyme 2 (ACE2) as a receptor, MERS-CoV exploits dipeptidyl peptidase 4 (DPP4), a transmembrane glycoprotein, to infect type 2 pneumocytes and unciliated bronchial epithelial cells.
The inventors have identified and isolated neutralizing antibodies which can be used to treat an infection with SARS-CoV-2, detect SARS-CoV-2 or monitor the progression of COVID-19 disease. The monoclonal antibodies specifically bind to the SARS-CoV-2 Spike protein RBD
region. The binding reaction may be shown by standard methods, for example with reference to a negative control test using an antibody of unrelated specificity.
The amino acid sequence of the RBD region of the Spike protein of SARS-CoV-2 (the target antigen) is provided below:
SARS-CoV-2 (RBD) SEQ ID NO: 1 :
RVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFK
CYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNS
NNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQ
PTNGVGYQPYRVWLSFELLHAPATVCGPKKSTNLVKNKCVNF
Antibodies and antibody fragments as described herein bind an antigen comprising SEQ ID NO: 1 or variants thereof. A variant of SEQ ID NO:1 has at least 80%, 90% or 95% sequence identity to SEQ ID NO:1.
Several variants carrying mutations in S-protein, including in its receptor-binding domain (RBD), have emerged. The established nomenclature systems for naming and tracking SARS-CoV-2 genetic lineages are GISAID, Nextstrain and Pango. The WHO classifies variants into variants of concern (VOCs), variants of interest (VOIs), variants under monitoring (VUMs) and formerly monitored variants. Variants that fall under the first three definitions are shown in table 1 :
Table 1 . Note that Omicron includes Pango lineage B.1 .1 .529 and descendent Pango lineages BA.1 , BA.1.1 , BA.2 and BA.3.
A skilled person will understand that the antibodies and antigen-binding fragments thereof of the present invention can be used to detect and neutralize any other SARS-CoV-2 variants existent
at the time of filing or with any future variants. Thus, the coronavirus S protein which includes the RBD region may be the S protein of any of these variants.
The terms “antigen(s)” and “epitope(s)” are well established in the art and refer to the portion of a protein or polypeptide which is specifically recognized by a component of the immune system, e.g. an antibody or a T-cell I B-cell antigen receptor. As used herein, the term “antigen(s)” encompasses antigenic epitopes, e.g. fragments of antigens which are recognized by, and bind to, immune components. Epitopes can be recognized by antibodies in solution, e.g. free from other molecules. Epitopes can also be recognized by T-cell antigen receptors when the epitope is associated with a class I or class II major histocompatibility complex molecule.
The term “epitope” or “antigenic determinant” refers to a site on the surface of an antigen to which an immunoglobulin, antibody or antigen-binding fragment thereof specifically binds. Generally, an antigen has several or many different epitopes and reacts with many different antibodies. The term “specifically” includes linear epitopes and conformational epitopes.
Epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or non-contiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope). Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. An epitope typically includes at least 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14 or 15 amino acids in a unique spatial conformation. Methods for determining what epitopes are bound by a given antibody or antigen-binding fragment thereof (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides from are tested for reactivity with a given antibody or antigen-binding fragment thereof. Competition assays can also be used to determine if a test antibody binds to the same epitope as a reference antibody. Suitable competition assays are mentioned elsewhere herein and also shown in the examples. In some aspects, the epitope to which an antibody or antigen-binding fragment thereof binds can be determined by, e.g, NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g, site-directed mutagenesis mapping).
The term "antibody" as used herein refers to an immunoglobulin protein that is capable of binding an antigen, i.e. SARS-CoV-2. In particular, the term "antibody" as used herein broadly refers to any polypeptide comprising complementarity determining regions (CDRs) that confer specific binding affinity of the polypeptide for an antigen. The term antibody as used herein encompasses polyclonal and monoclonal antibody preparations.
The antibody or antigen-binding fragment thereof described herein, "which binds" or is “capable of binding” the antigen of interest, binds the antigen with sufficient affinity such that the antibody
or antigen-binding fragment thereof is useful as a therapeutic or diagnostic agent in targeting SARS-CoV-2 as described herein. The term "specific" may refer to the situation in which the antibody molecule will not show any significant binding to molecules other than its specific binding partner.
The terms “polypeptide(s)” and “protein(s)” are used interchangeably throughout the application and denote at least two covalently attached amino acids, thus may signify proteins, polypeptides, oligopeptides, peptides, and fragments thereof. The protein may be made up of naturally occurring amino acids and peptide bonds, or synthetic peptidomimetic structures. Hence, “amino acid(s)” or “peptide residue(s)”, as used herein, denote both naturally occurring and synthetic amino acids. In some cases, the immunoglobulin proteins of the present invention may be synthesized using any in vivo or in vitro protein synthesis technique known in the art.
As antibodies can be modified in a number of ways, the term “antigen-binding protein” or "antibody" should be construed as covering antibody fragments, derivatives, functional equivalents and homologues of antibodies, including any polypeptide comprising an immunoglobulin binding domain,
In a full-length antibody, each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as HCVR, VH or VH) and a heavy chain constant region. The heavy chain constant region is comprised of three domains, CH1 , CH2 and CH3. Each light chain is comprised of a light chain variable region or domain (abbreviated herein as LCVR, VL or VL) and a light chain constant region. The light chain constant region is comprised of one domain, CL.
Antibodies may include the kappa (K) and lambda (A) light chains and the alpha (IgA), gamma (lgG1 , lgG2, lgG3, lgG4), delta (IgD), epsilon (IgE) and mu (IgM) heavy chains, or their equivalents in other species. Full-length immunoglobulin “light chains” (usually of about 25 kDa or 214 amino acids long) consist of a variable region of approximately 110 amino acids at the NH2-terminus and a kappa or lambda constant region at the COOH-terminus. Full-length immunoglobulin “heavy chains” (usually of about 50 kDa or 446 amino acids long), likewise consist of a variable region (of about 116 amino acids) and one of the aforementioned heavy chain constant regions, e.g. gamma (of about 330 amino acids).
Light or heavy chain variable regions are generally composed of a “framework” region (FR) interrupted by three hypervariable regions, also called CDRs. The extent of the framework region and CDRs have been precisely defined. The sequences of the framework regions of different light and heavy chains are relatively conserved within a species. The framework region of an antibody, i.e. the combined framework regions of the constituent light and heavy chains, serves to position and align the CDRs. The CDRs are primarily responsible for binding to an epitope of an antigen. There are three CDRs in each of the variable regions of the heavy chain and the light chain, which are designated CDR1 , CDR2 and CDR3, for each of the variable regions. The term "CDR set" refers to a group of three CDRs that occur in a single variable region capable of binding the
antigen. The exact boundaries of these CDRs can be defined differently according to different systems known in the art.
Heavy chain CDRs are designated HCDR1 , HCDR2 and HCDR3. Light chain CDRs are designated LCDR1 , LCDR2 and LCDR3.
In one embodiment, the antibody is comprised of four polypeptide chains, two heavy (H) chains and two light (L) chains, or any functional fragment, mutant, variant, or derivation thereof, which retains the essential epitope binding features of an Ig molecule.
Immunoglobulin molecules can be of any type (e.g., IgG, IgE, IgM, IgD, IgA and IgY), class (e.g., lgG1 , lgG2, lgG3, lgG4, lgA1 and lgA2) or subclass. In one embodiment, the antibody is of the IgG type.
Different definitions of the CDRs are commonly in use. The method described by Kabat is the most commonly used and CDRs are based on sequence variability (Kabat et al., (1971) Ann. NY Acad. Sci. 190:382-391 and Kabat, et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91- 3242). Chothia refers instead to the location of the structural loops (Chothia and Lesk, J. Mol. Biol. 196:901-917 (1987)). The Kabat numbering system is generally used when referring to a residue in the variable domain (approximately residues 1-107 of the light chain and residues 1 - 113 of the heavy chain). Another system is the ImMunoGeneTics (IMGT) numbering scheme (Lefranc et al., Dev. Comp. Immunol., 29, 185-203 (2005)). According to the IMGT numbering scheme, a CDR is a loop region of a variable domain, delimited according to the IMGT unique numbering for V domain. There are three CDR-IMGT in a variable domain: CDR1-IMGT (loop BC), CDR2-IMGT (loop C'C"), and CDR3-IMGT (loop FG).
The IMGT system as described above is used herein, unless otherwise stated. The terms "IMGT numbering", "IMGT definitions" and "IMGT labelling" are used interchangeably herein, antigenbinding
The term "antibody" is not only inclusive of antibodies generated by methods comprising immunisation, but also includes any polypeptide, e.g., a recombinantly expressed polypeptide, which is made to encompass at least one CDR capable of specifically binding to an epitope on an antigen of interest. Hence, the term applies to such molecules regardless whether they are produced in vitro, in cell culture, or in vivo. Methods of producing polyclonal and monoclonal antibodies are known in the art and described more fully below.
It is possible to take monoclonal and other antibodies and use techniques of recombinant DNA technology to produce other antibodies or chimeric molecules which generally retain the specificity of the original antibody. Such techniques may involve introducing the CDRs into a different immunoglobulin framework, or grafting variable regions onto a different immunoglobulin constant regions. Alternatively, a hybridoma or other cell producing an antibody molecule may be
subject to genetic mutation or other changes, which may or may not alter the binding specificity of antibodies produced.
The term antibody as used herein is meant to specifically include antibody fragments I antigenbinding fragments thereof unless stated otherwise. The antibody fragment I antigen-binding fragments may be selected from any fragment capable of binding the antigen or antigenic fragment of interest. Exemplary antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain Fv (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, antibody mimetic protein, single domain antibody, e.g. a VH. Thus, the antibody fragment I antigen-binding fragment may comprise or consist of any of these fragments.
Antigen-binding fragments derived from an antibody, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entire, or parts of the, following: a heavy chain constant domain, or a portion thereof, e.g. a CH1 , CH2, CH3, transmembrane, and/or cytoplasmic domain, on the heavy chain, and a light chain constant domain, e.g. a Ckappa or Clambda domain, or portion thereof on the light chain. Also included in the present disclosure are any combinations of variable region(s) and CH1 , CH2, CH3, Ckappa, Clambda, transmembrane and cytoplasmic domains.
Fv fragments (~25kDa) consist of the two variable domains, VH and VL. Naturally, VH and VL domain are non-covalently associated via hydrophobic interaction and tend to dissociate. However, stable fragments can be engineered by linking the domains with a hydrophilic flexible linker to create a single chain Fv (scFv).
The smallest antigen-binding fragment is the single variable fragment, namely the variable heavy (VH) or variable light (VL) chain domain. VH and VL domains respectively are capable of binding to an antigen. They are generally referred to as a “single domain antibody” or “immunoglobulin single variable domain”. A single domain antibody (~12 to 15 kDa) has thus either the VH or VL domain. Antigen-binding single VH domains have also been identified from, for example, a library of murine VH genes amplified from genomic DNA from the spleens of immunized mice and expressed in E. coli (Ward et al., 1989, Nature 341 : 544-546). Ward et al. named the isolated single VH domains "dAbs," for "domain antibodies." The term "dAb" or “sdAb” (for single domain antibody) generally refers to a single immunoglobulin variable domain (VH, VHH or VL) polypeptide that specifically binds antigen. For use in therapy, human single domain antibodies are preferred over camelid derived VHH, primarily because they are not as likely to provoke an immune response when administered to a patient.
The antibody or antigen-binding fragment thereof may be chimeric, human or humanised. A “chimeric antibody” is a recombinant protein that contains the variable domains including the CDRs of an antibody derived from one species, for example a murine antibody, while the constant domains of the antibody molecule are derived from those of a different species, for example a
human antibody. Methods to humanise antibodies include CDR grafting based on framework regions homology and antibody resurfacing. Human or humanised antibodies or antigen-binding fragments are most desirable for use in antibody therapies, as such molecules would elicit little or no immune response in the human subject.
Sequences of the monoclonal antibodies
Amino acid sequences of the antibodies of the invention are set out below. The invention relates to antigen-binding molecules, antibodies or antigen-binding fragments thereof comprising or consisting of the full-length antibody sequence or an antigen-binding fragment thereof, e.g. single chain Fvs or single domains of any one of the antibodies listed in table 2. Also within the scope of the invention are sequence variants as explained below.
In a first aspect, the invention thus relates to an isolated antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said antibody or antigen-binding fragment thereof comprises or consists of any of the sequences listed below in table 2.
Table 2 Sequences of antibodies of the invention. All antibodies listed below are within the scope of the invention. Further, HCs listed below are within the scope of the invention. Further, LCs listed below are within the scope of the invention. Further, HCs having a CDR1 , 2 and 3 as listed below are within the scope of the invention. Further, LCs having a CDR1 , 2 and 3as listed below are within the scope of the invention.
Thus, in one embodiment, the isolated antibody or antigen-binding fragment thereof comprises or consists of
1) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively;
2) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively;
3) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively;
4) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least
80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 66, 67 and 68, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 66, 67 and 68, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 70, 71 and 72, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 70, 71 and 72 respectively; 0) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 74, 75 and 76, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 74, 75 and 76, respectively, and a
light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 78, 79 and 80, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 78, 79 and 80 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 82, 83 and 84, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 82, 83, and 84, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 87 and 88, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 86, 87 and 88 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 90, 91 and 92, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 90, 91 and 92, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 94, 95 and 96, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 94, 95 and 96 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 98, 99 and 100, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 98, 99 and 100, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 102, 103 and 104, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 102, 103 and 104, respectively;) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 106, 107 and 108, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 106, 107 and 108, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 110, 11 1 and 112, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 10, 111 and 112, respectively;) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 114, 115 and 116, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 14, 115 and 116, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 118, 119 and 120, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 18, 119 and 120, respectively;) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 122, 123 and 124, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 122, 123 and 124, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the
amino acid sequences of SEQ ID NOs: 126, 127 and 128, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 126, 127 and 128, respectively;
17) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 130, 131 and 132, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 130, 131 and 132, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 134, 135 and 136, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 134, 135 and 136, respectively;
18) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 138, 139 and 140, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 138, 139 and 140, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143 and 144, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 142, 143 and 144, respectively or
19) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 146, 147 and 148, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 146, 147 and 148, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 150, 151 and 152, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 150, 151 and 152, respectively.
The present disclosure also includes antibodies comprising one, two, or three heavy chain CDRs of at least 80%, 90% or 95% sequence identity to HCDR1 , HCDR2, and/or HCDR3 as mentioned above. Furthermore, the present invention encompasses antibodies having one, two, or three light chain CDRs of at least 80%, 90% or 95% sequence identity to LCDR1 , LCDR2, and/or LCDR3 as mentioned above. All CDRs may either be derived from the same antibody or be independently selected from the different antibodies described herein.
The VH and VL CDRs are separated by framework regions (FR1 , 2, 3, and 4). FR sequences are also provided above. Amino acid and nucleic acid sequences for FRs are exemplified by the FRs of the antibodies disclosed herein. Antibodies containing FRs with amino acid sequences that are different from the framework regions disclosed herein and encoded by different nucleic acid sequences than those exemplified herein, are expected to exhibit similar or identical immunological binding properties and are viewed as derivatives or variants of the present invention. Conservative amino acid substitutions may also be contemplated for any amino acid residue of CDRs, framework regions, and/or linker regions as further explained below.
In one embodiment, the isolated antibody or antigen-binding fragment comprises or consists of
) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ) a VH region of SEQ ID NO: 69 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 73 or a sequence with at least 80%, 90% or 95% sequence identity thereto; 0) a VH region of SEQ ID NO: 77 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 81 or a sequence with at least 80%, 90% or 95% sequence identity thereto; 1) a VH region of SEQ ID NO: 85 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 89 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
12) a VH region of SEQ ID NO: 93 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 97 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
13) a VH region of SEQ ID NO: 101 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 105 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
14) a VH region of SEQ ID NO: 109 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 113 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
15) a VH region of SEQ ID NO: 117 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 121 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
16) a VH region of SEQ ID NO: 125 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 129 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
17) a VH region of SEQ ID NO: 133 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 137 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
18) a VH region of SEQ ID NO: 141 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 145 or a sequence with at least 80%, 90% or 95% sequence identity thereto or
19) a VH region of SEQ ID NO: 149 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 153 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
According to another embodiment, the antibody is a fragment or single-chain immunoglobulin, comprising or consisting of the variable region(s) alone as described above or combined with the entire, or parts of the, following: a heavy chain constant domain, or portion thereof, e.g., a CH1 , CH2 or CH3 transmembrane, and/or cytoplasmic domain, on the heavy chain, and a light chain constant domain, e.g., a Ckappa or Clambda domain, or portion thereof, on the light chain. any combination of variable region(s) and CH1 , CH2, CH3, Ckappa, Clambda, transmembrane and/or cytoplasmic domains, one or more of which may be in cyclized form.
In one embodiment, the antibody is a full length antibody and comprises human constant regions and human light chain regions.
Sequence identity as defined in the aspects and embodiments herein, in particular with regard to sequences of Table 2 relating to CDR or variable domain sequences (amino acid or polynucleotide sequences), can be at least 80%, 81 %, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%, for example at least 90%, 91 %, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity. Thus, sequence variants with these percentage identities of the antibodies as shown in Table 2 are all within the scope of the invention.
As used herein, the terms sequence "homology" or “identity” generally refers to the percentage of amino acid residues in a sequence that are identical with the residues of the reference polypeptide with which it is compared, after aligning the sequences and in some embodiments after introducing gaps, if necessary, to achieve the maximum percent homology, and not considering any conservative substitutions as part of the sequence identity. Thus, the percent homology between two amino acid sequences is equivalent to the percent identity between the two sequences. Neither N- or C-terminal extensions, tags or insertions shall be construed as reducing identity or homology. Methods and computer programs for the alignment are well known. The percent identity between two amino acid sequences can be determined using well known mathematical algorithms.
Sequence identity is commonly defined with reference to the algorithm GAP (Wisconsin GCG package, Accelerys Inc, San Diego USA). GAP uses the Needleman and Wunsch algorithm to align two complete sequences, maximising the number of matches and minimising the number of gaps. Generally, default parameters are used, with a gap creation penalty equalling 12 and a gap extension penalty equalling 4. Use of GAP may be preferred but other algorithms may be used, e.g. BLAST (which uses the method of Altschul et al. (1990) J. Mol. Biol. 215: 405-410), FASTA (which uses the method of Pearson and Lipman (1988) PNAS USA 85: 2444-2448), or the Smith- Waterman algorithm (Smith and Waterman (1981) J. Mol Biol. 147: 195-197), or the TBLASTN program, of Altschul et al. (1990) supra, generally employing default parameters. In particular, the psi-Blast algorithm (Altschul et al (1997) Nucl. Acids Res. 25 3389-3402) may be used. Sequence identity may be defined using the Bioedit, ClustalW algorithm. Alignments were performed using Snapgene and based on MUSCLE (Multiple Sequence Comparison by Log-Expectation) algorithms (Edgar (2004a) Nucleic Acids Res 32: 1792-7; Edgar (2004b) BMC Bioinformatics 5:113.).
In some embodiments, there is provided an isolated antibody or antigen-binding fragment thereof that is a variant of any of the above antibodies or antigen-binding fragments and having one or more amino acid substitutions, deletions, insertions or other modifications, and which retains a biological function of the single domain antibody, that is binding to the target antigen and, thus, variant antibody or antigen-binding fragment thereof can be sequence engineered. Modifications may include one or more substitution, deletion or insertion of one or more codons encoding the
single domain antibody or polypeptide that results in a change in the amino acid sequence as compared with the native sequence of the antibody or antigen-binding fragment thereof.
Amino acid substitutions can be the result of replacing one amino acid with another amino acid having similar structural and/or chemical properties, such as the replacement of a leucine with a serine, i.e., conservative amino acid replacements. Substitutions, insertions, additions or deletions may optionally be in the range of about 1 to 25 or 1 to 50, for example 1 to 5, 1 to 10, 1 to 15, 1 to 20 amino acids, for example 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acids. In one embodiment, the substitution (e.g. 1 , 2, 3, 4 or 5 amino acid substitutions), insertion, addition or deletion is in HCDR1 , HCDR2 and or HCDR3. In one embodiment, the substitutions, insertion, addition or deletion is in LCDR1 , LCDR2 and or LCDR3. In one embodiment, the substitution, insertion, addition or deletion is in a heavy chain framework region or a light chain framework region.
The variation allowed may be determined by systematically making insertions, deletions or substitutions of amino acids in the sequence and testing the resulting variants for activity exhibited by the full-length or mature native sequence.
In one embodiment, the modification is a conservative sequence modification. As used herein, the term "conservative sequence modifications" is intended to refer to amino acid modifications that do not significantly affect or alter the binding characteristics of the antibody containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions and deletions. Modifications can be introduced into an antibody of the invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions are ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CDR regions of a single domain antibody of the invention can be replaced with other amino acid residues from the same side chain family and the altered antibody can be tested for retained function (i.e. antigen binding) using the functional assays described herein.
Thus, these amino acid changes can typically be made without altering the biological activity, function, or other desired property of the polypeptide, such as its affinity or its specificity for antigen. In general, single amino acid substitutions in nonessential regions of a polypeptide do not substantially alter biological activity. Furthermore, substitutions of amino acids that are similar
in structure or function are less likely to disrupt the polypeptides' biological activity. Abbreviations for the amino acid residues that comprise polypeptides and peptides described herein, and conservative substitutions for these amino acid residues are shown in Table 3 below.
A skilled person will know that there are different ways to identify, obtain and optimise the antigenbinding molecules as described herein, including in vitro and in vivo expression libraries. This is
further described in the examples. Optimisation techniques known in the art, such as display (e.g., ribosome and/or phage display) and I or mutagenesis (e.g., error-prone mutagenesis) can be used. The invention therefore also comprises sequence optimised variants of the antibodies described herein.
“Binding affinity” generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody or antigen-binding fragment thereof) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1 :1 interaction between members of a binding pair (e.g, antibody or antigen -binding fragment thereof and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (KD).
Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (KD), and equilibrium association constant (KA). The KD is calculated from the quotient of koff/kon, whereas KA is calculated from the quotient of kon/koff. Kon refers to the association rate constant of, e.g, an antibody or antigen-binding fragment thereof to an antigen, and koff refers to the dissociation of, e.g, an antibody or antigenbinding fragment thereof from an antigen. The affinity can be determined by techniques known to one of ordinary skill in the art, such as surface plasmon resonance (SPR) or KinExA.
In some embodiments, an antibody or antigen-binding fragment thereof of the invention has an affinity KD of <250nM, <200nM, <1 OOnM, <50nM,<1 OnM or <1 nM for the target antigen. In some embodiments, an antibody or antigen-binding fragment thereof ofthe invention has an EC50 value of <5pM, <1 pM, <900nM, <800nM, <700nM, <600nM, <500nM, <400nM, <300nM, <200nM, <100nM, <50nM, <10nM, <5nM, <1 nM, <0.5nM, or <0.1 nM. The EC50 value may be 0.5nM to 0.98 pM. The EC50 is the concentration of a drug that gives half-maximal response. Suitable methods for determining neutralising EC50 values are described in the examples
The antibody may comprise a CH2 domain. The CH2 domain is for example located at the N- terminus of the CH3 domain, as in the case in a human IgG molecule. The CH2 domain of the antibody is in one embodiment the CH2 domain of human lgG1 , lgG2, lgG3, or lgG4, e.g the CH2 domain of human lgG1 . The sequences of human IgG domains are known in the art.
The antibody may comprise an immunoglobulin hinge region, or part thereof, at the N-terminus of the CH2 domain. The immunoglobulin hinge region allows the two CH2-CH3 domain sequences to associate and form a dimer. In one embodiment, the hinge region, or part thereof, is a human lgG1 , lgG2, lgG3 or lgG4 hinge region, or part thereof. For example, the hinge region, or part thereof, is an lgG1 hinge region, or part thereof.
The sequence of the CH3 domain is not particularly limited. In one embodiment, the CH3 domain is a human immunoglobulin G domain, such as a human lgG1 , lgG2, lgG3, or lgG4 CH3 domain, e.g. a human lgG1 CH3 domain.
An antibody of the invention may comprise a human lgG1 , lgG2, lgG3, or lgG4 constant region. The sequences of human lgG1 , lgG2, lgG3, or lgG4 CH3 domains are known in the art. An antibody of the invention may comprise a non-human IgG constant region, e.g., a rabbit lgG1 constant region.
An antibody of the invention may comprise a human IgG Fc with effector function.
Fc receptors (FcRs) are key immune regulatory receptors connecting the antibody mediated (humoral) immune response to cellular effector functions. Receptors for all classes of immunoglobulins have been identified, including FcyR (IgG), FcsRI (IgE), FcaRI (IgA), FcpR (IgM) and FcbR (IgD). There are three classes of receptors for human IgG found on leukocytes: CD64 (FcyRI), CD32 (FcyRlla, FcyRllb and FcyRllc) and CD16 (FcyRllla and FcyRlllb). FcyRI is classed as a high affinity receptor (nanomolar range KD) while FcyRI I and FcyRIII are low to intermediate affinity (micromolar range KD).
In antibody dependent cellular cytotoxicity (ADCC), FcvRs on the surface of effector cells (natural killer cells, macrophages, monocytes and eosinophils) bind to the Fc region of an IgG which itself is bound to a target cell. Upon binding a signalling pathway is triggered which results in the secretion of various substances, such as lytic enzymes, perforin, granzymes and tumour necrosis factor, which mediate in the destruction of the target cell. The level of ADCC effector function various for IgG subtypes. Although this is dependent on the allotype and specific FcvR in simple terms ADCC effector function is high for human lgG1 and lgG3, and low for lgG2 and lgG4. See below for IgG subtype variation in effector functions, ranked in decreasing potency.
FcyRs bind to IgG asymmetrically across the hinge and upper CH2 region. Knowledge of the binding site has resulted in engineering efforts to modulate IgG effector functions
Antibodies of the invention may have an Fcwith effector function, with enhanced effector function or with reduced effector function.
The potency of antibodies can be increased by enhancement of the ability to mediate cellular cytotoxicity functions, such as antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cell-mediated phagocytosis (ADCP). A number of mutations within the Fc domain have been identified that either directly or indirectly enhance binding of Fc receptors and significantly enhance cellular cytotoxicity: the mutations S239D/A330L/I332E (“3M”), F243L or G236A. Alternatively enhancement of effector function can be achieved by modifying the glycosylation of the Fc domain, FcyRs interact with the carbohydrates on the CH2 domain and the glycan composition has a substantial effect on effector function activity. Afucosylated (non- fucosylated) antibodies, exhibit greatly enhanced ADCC activity through increased binding to FcyRllla.
Activation of ADCC and CDC may be desirable for some therapeutic antibodies, however, in some embodiments, an antibody that does not activate effector functions is preferred. Due to their lack
of effector functions, lgG4 antibodies are the preferred IgG subclass for receptor blocking without cell depletion. However, lgG4 molecules can exchange half molecules in a dynamic process termed Fab-arm exchange. This phenomenon can occur between therapeutic antibodies and endogenous lgG4. The S228P mutation has been shown to prevent this recombination process allowing the design of lgG4 antibodies with a reduced propensity for Fab-arm exchange. Fc engineering approaches have been used to determine the key interaction sites for the lgG1 Fc domain with FcyR receptors and C1 q and then mutate these positions to reduce or abolish binding. Through alanine scanning the binding site of C1 q to a region covering the hinge and upper CH2 of the Fc domain was identified. The CH2 domain of an antibody or fragment of the invention may comprise one or more mutations to decrease or abrogate binding of the CH2 domain to one or more FcyR receptors, such as FcyRI, FcyRlla, FcyRllb, FcyRIII and/or to complement. CH2 domains of human IgG domains normally bind to Fey receptors and complement, decreased binding to FcyR receptors is expected to decrease antibody-dependent cell-mediated cytotoxicity (ADCC) and decreased binding to complement is expected to decrease the complement-dependent cytotoxicity (CDC) activity of the antibody molecule.
Mutations to decrease or abrogate binding of the CH2 domain to one or more FcyR receptors and/or complement are known in the art. An antibody molecule of the invention may comprise an Fc with modifications K322A/L234A/L235A or L234F/L235E/P331 S (“TM”), which almost completely abolish FcyR and C1q binding. An antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) ("LALA mutation"). Furthermore, complement activation and ADCC can be decreased by mutation of Pro329 (position according to EU numbering), e.g., to either P329A or P329G. The antibody molecule of the invention may comprise a CH2 domain, wherein the CH2 domain comprises alanine residues at EU positions 234 and 235 (positions 1.3 and 1.2 by IMGT numbering) and an alanine (LALA- PA) or glycine (LALA-PG) at EU position 329 (position 114 by IMGT numbering). Additionally or alternatively, an antibody molecule of the invention may comprise an alanine, glutamine or glycine at EU position 297 (position 84.4 by IMGT numbering).
Modification of glycosylation on asparagine 297 of the Fc domain, which is known to be required for optimal FcR interaction may confer a loss of binding to FcRs; a loss of binding to FcRs has been observed in N297 point mutations. An antibody molecule of the invention may comprise an Fc with an N297A, N297G or N297Q mutation. An antibody molecule of the invention with an aglycosyl Fc domain may be obtained by enzymatic deglycosylation, by recombinant expression in the presence of a glycosylation inhibitor or following the expression of Fc domains in bacteria.
IgG naturally persists for a prolonged period in the serum due to FcRn-mediated recycling, giving it a typical half-life of approximately 21 days. Half-life can be extended by engineering the pH- dependant interaction of the Fc domain with FcRn to increase affinity at pH 6.0 while retaining minimal binding at pH 7.4. The T250Q/M428L variant, conferred an approximately 2-fold increase
in IgG half-life (assessed in rhesus monkeys), while the M252Y/S254T/T256E variant ("YTE”), gave an approximately 4-fold increase in IgG half-life (assessed in cynomolgus monkeys). Extending half-life may allow the possibility of decreasing administration frequency, while maintaining or improving efficacy.
Biparatopic molecules
Immunoglobulins are known to have a modular architecture comprising discrete domains, which can be combined in a multitude of different ways to create multispecific, e.g. bispecific, trispecific, or tetraspecific antibody formats. Exemplary multispecific antibody formats are described in Spiess et ai, (2015) Mol Immunol 67: 95-106 and Kontermann (2012) Mabs 4(2): 182-97, for example. The antibodies or antigen-binding fragments thereof of the invention may be employed in such multispecific formats.
In particular, the antibodies or antigen-binding fragments thereof of the invention may be employed in biparatopic format thus binding to two different epitopes. In one aspect, the invention thus provides an isolated binding molecule comprising or consisting of a) a first antibody or antigen-binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antigen-binding fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV- 2.
The first and second epitope are not identical. In one embodiment, the first and second epitope are overlapping epitopes. In another embodiment, the first and second epitope are not overlapping epitopes. In one embodiment, the biparatopic binding molecule is capable of simultaneously engaging two non-overlapping epitopes within the RBD.
The first and/or second isolated antibody or antigen-binding fragment thereof may be selected from Table 2. Thus, in one embodiment, said first and/or second isolated antibody or antigenbinding fragment thereof comprises
1) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively;
2) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the
amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the
amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively; ) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 66, 67 and 68, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 66, 67 and 68, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 70, 71 and 72, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 70, 71 and 72 respectively; 0) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 74, 75 and 76, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 74, 75 and 76, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 78, 79 and 80, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 78, 79 and 80 respectively; 1) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 82, 83 and 84, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 82, 83, and 84, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 86, 87 and 88, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 86, 87 and 88 respectively; 2) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 90, 91 and 92, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 90, 91 and 92, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 94, 95 and 96, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 94, 95 and 96 respectively; 3) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 98, 99 and 100, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 98, 99 and 100, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 102, 103 and 104, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 102, 103 and 104, respectively;4) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 106, 107 and 109, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 106, 107 and 109, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the
amino acid sequences of SEQ ID NOs: 110, 11 1 and 112, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 10, 111 and 112, respectively;
15) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 114, 115 and 116, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 14, 115 and 116, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 118, 119 and 120, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 1 18, 119 and 120, respectively;
16) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 122, 123 and 124, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 122, 123 and 124, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 126, 127 and 128, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 126, 127 and 128, respectively;
17) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 130, 131 and 132, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 130, 131 and 132, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 134, 135 and 136, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 134, 135 and 136, respectively;
18) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 138, 139 and 140, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 138, 139 and 140, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 142, 143 and 144, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 142, 143 and 144, respectively or
19) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 146, 147 and 148, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 146, 147 and 148, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 150, 151 and 152, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 150, 151 and 152, respectively.
Combinations where one of 1) to 19) is a first antibody and combined with one a second antibody of 1) to 19) are specifically envisaged.
In one embodiment, said first and/or second isolated antibody or antigen-binding fragment thereof comprises
1) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
2) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
3) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
4) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
5) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
6) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
7) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
8) a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
9) a VH region of SEQ ID NO: 69 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 73 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
10) a VH region of SEQ ID NO: 77 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 81 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
11) a VH region of SEQ ID NO: 85 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 89 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
12) a VH region of SEQ ID NO: 93 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 97 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
13) a VH region of SEQ ID NO: 101 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 105 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
14) a VH region of SEQ ID NO: 109 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 113 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
15) a VH region of SEQ ID NO: 117 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 121 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
16) a VH region of SEQ ID NO: 125 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 129 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
17) a VH region of SEQ ID NO: 133 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 137 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
18) a VH region of SEQ ID NO: 141 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 145 or a sequence with at least 80%, 90% or 95% sequence identity thereto or
19) a VH region of SEQ ID NO: 149 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 153 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
Combinations where one of 1) to 19) is a first antibody and combined with one a second antibody of 1) to 19) are specifically envisaged. Combinations of antibodies listed in table 2 in a bisvalent/biparatopic construct are also within the scope of the invention. In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to
SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively.
In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively.
In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID
NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively.
In one embodiment, said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
Constructs listed in table 4 are within the scope of the invention.
A skilled person would understand that the first and second isolated antibody or antigen-binding fragment thereof can be combined in a biparatopic format in different ways. For example, a peptide linker, such as peptide linker comprising glycine and serine residues ((G4S)n with n= 1 to 20), can be used.
Depending the format employed, the binding molecule may comprise more than one fragment of the first antibody and more than one fragment of the second antibody.
For example, dual variable domain (DVD) or DVD-IgG is one type of bispecific antibody format, which is generated from two parental mAbs by stacking the two variable heavy domains of both parental antibodies onto the heavy chain and the variable light domains of both parental antibodies onto the light chain, forming an IgG-like molecule with a double VH/VL domain. The DVD-IgG retains the antigen-binding specificity, affinity, and biologic activities from its both parental antibodies, therefore, all of its four variable domains are functional (see Wu et al, 2007).
In one embodiment, wherein the first and second isolated antibody or antigen-binding fragment thereof are combined in a DVD (see examples and Figure 3A), scFv4-Fc or IgG-scFv format. In one embodiment, the format is scFv4-Fc (see examples and Figure 3). Thus, the invention also relates to a DVD, scFv4-Fc and IgG-scFv comprising a first and a second isolated antigen-binding fragment as described above.
Other suitable formats are also included, for example quadromas, mAb2, scFv-Fab IgG, CrossMab, lgG-(scFc)2.
In terms of construction, DVD-lg can be manufactured by fusing the VH domain of antibody A to the heavy chain of antibody B, and the VL domain of antibody A to the light chain of antibody B, via a peptide linker. scFv4-Fc can be manufactured by substituting the original VH and VL domains of an IgG with one scFv for each chain. The resulting antibody would comprise one scFv4 (binding domain A) on the heavy CH1-CH2-CH3 chain, and one scFv4 (binding domain B) on the light chain.
Various suitable formats are reviewed in Wu et al, Experimental Hematology & Oncology volume 10, Article number: 56 (2021).
The biparatopic binding molecule may have an increased overall affinity for the Spike protein relative to the constituent antibodies. Thus, the combination of two competing antibodies may provide an additive or synergistic effect with regard to affinity and/or neutralisation potency. Neutralisation potency can be defined as the capacity to block viral mediated infection on target cells. Neutralisation potency assays can be selected from Pseudovirus infectivity assay with reporter marker gene (Ferrari et al ASM Journals Journal of Virology Vol. 95, No. 19); ACE2- Spike/S1/RBD competition ELISA assays; TCID50 replication competent virus titration assay; Replication competent virus plaque reduction neutralisation assay.
Increase in potency compared the individual constituents may be improved at least 5, 20 or 20 fold. Moreover, the biparatopic binding molecule may have greater resilience to viral mutational drift.
The terms “first” and “second” are used to differentiate between the two antibodies or antigenbinding fragments thereof used in the binding molecules of the invention, but are not understood to designate their orientation in the multivalent molecule with respect to the C and N terminus of the protein. Thus, with reference to the biparatopic molecules specified above, in one embodiment, said antibody or antigen-binding fragment thereof is located N-terminally and said second antibody or antigen-binding fragment thereof is located C-terminally. In one embodiment, said first single antibody or antigen-binding fragment thereof is located C-terminally and said second antibody or antigen-binding fragment thereof is located N-terminally.
Molecules having the sequences shown in Table 4 are all within the scope of the invention. Thus, in one embodiment, a biparatopic construct is one selected from the table below having the sequence shown.
Data for biparatopic molecule is shown in the examples, e.g. tables 9 and 10. The molecules as shown in Tables 9 and 10 are specifically part of the invention. The invention also relates to the use of an antibody or antigen-binding fragment as disclosed herein in a biparatopic binding molecule.
Polynucleotides, vectors and host cells
The present invention further provides an isolated nucleic acid encoding an antibody, antigenbinding fragment thereof or binding molecule of the present invention. The terms “nucleic acid(s)” or polynucleotide as used herein, denotes either DNA or RNA, or molecules which contain both deoxy- and ribonucleotides. Nucleic acid(s) may be naturally occurring or synthetically made, and as such, may denote analogues of naturally occurring polynucleotides in which one or more nucleotides are artificially modified.
Thus, in one aspect, there is provided a polynucleotide encoding an isolated antibody or antigenbinding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said polynucleotide encodes a heavy chain variable region polypeptide that comprises HCDR1 , HCDR2, and HCDR3 sequences as shown in Table 2 or sequences with at least 80%, 90% or 95% sequence identity thereto, and a light chain variable region that encodes a light chain
variable region polypeptide that comprises LCDR1 , LCDR2 and LCDR3 sequences as shown in Table 2 or sequences with at least 80%, 90% or 95% sequence identity thereto.
Also provided is a polynucleotide encoding an isolated antibody or antigen-binding fragment thereof that specifically binds to the SARS-CoV-2 Spike protein RBD region wherein said polynucleotide encodes a VH polypeptide as shown in Table 2 or a polypeptide with at least 80%, 90% or 95% sequence identity thereto and a VL polypeptide as shown in Table 2 or a polypeptide with at least 80%, 90% or 95% sequence identity thereto.
Nucleic acids according to the invention can be selected from the following table
For biparatopic molecules as described herein, nucleic acids as shown in Table 3 can be combined.
The invention also provides kits of nucleic acids where more than two nucleic acids are needed to generate the molecule (this includes full-length antibodies).
The invention also provides nucleic acid constructs that contain two or more nucleic acids (for light and heavy chain respectively), separated by a nucleic acid encoding a sequence that allows co-expression of both nucleic acids, for example an internal ribosome entry site (IRES) or 2A selfcleaving peptide.
Furthermore, the invention relates to a nucleic acid construct comprising at least one nucleic acid as defined herein. The construct may be in the form of a plasmid, vector, transcription or expression cassette.
The invention also relates to an isolated recombinant host cell comprising one or more nucleic acid construct as described above. The host cell may be a bacterial, viral, plant, mammalian or other suitable host cell.
Such host cells are well known in the art and many are available from the American Type Culture Collection (ATCC). These host cells include, inter alia, Chinese hamster ovary (CHO) cells, such as ExpiCHO cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, HEK- 293 cells and a number of other cell lines. Mammalian host cells include human, mouse, rat, dog, monkey, pig, goat, bovine, horse and hamster cells. Other cell lines that may be used are insect cell lines (e.g., Spodoptera frugiperda or Trichoplusia ni), amphibian cells, bacterial cells, plant cells and fungal cells. Fungal cells include yeast and filamentous fungus cells including, for example, Pichia pastoris, Pichia finlandica, Pichia trehalophila, Pichia koclamae, Pichia membranaefaciens, Pichia minuta (Ogataea minuta, Pichia lindneri), Pichia opuntiae, Pichia thermotolerans, Pichia salictaria, Pichia guercuum, Pichia pijperi, Pichia stiptis, Pichia methanolica, Pichia sp., Saccharomyces cerevisiae, Saccharomyces sp., Hansenula polymorpha, Kluyveromyces sp., Kluyveromyces lactis, Candida albicans, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Trichoderma reesei, Chrysosporium lucknowense, Fusarium sp., Fusarium gramineum, Fusarium venenatum, Physcomitrella patens and Neurospora crassa.
Additional moieties
In still other embodiments, the antibodies or antigen-binding fragments thereof of the invention are coupled or conjugated to at least one therapeutic moiety, such as a drug, an enzyme or a toxin, thus forming an immunuconjugate. In one embodiment, the therapeutic moiety is a toxin,
for example a cytotoxic radionuclide, chemical toxin or protein toxin. The terms “conjugation” and “conjugate(d)” refer to chemical linkages, either covalent or non-covalent, which proximally associates one molecule of interest with a second molecule of interest.
As used herein, the term “immunoconjugate” refers to an antigen-binding protein, e.g., an antibody or antigen-binding fragment, which is chemically or biologically linked to a radioactive agent, a cytokine, an interferon, a target or reporter moiety, an enzyme, a peptide or protein or a therapeutic agent. The antigen-binding protein may be linked to the radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, peptide or therapeutic agent at any location along the molecule so long as it is able to bind its target. Examples of immunoconjugates include antibody-drug conjugates and antibody-toxin fusion proteins.
In another embodiment, the second moity is a label, for example a fluorescent molecule, 0- galactosidase, luciferase molecules, chemical dyes, fluorophores or a radioisotope.
In another aspect, the antibodies or antigen-binding fragments thereof of the invention are modified to increase half-life, for example by a chemical modification, especially by PEGylation, or by incorporation in a liposome, or using a serum albumin protein or an antibody or antibody fragment that binds human serum albumin. Increased half-life can also be conferred by conjugating the molecule to an antibody fragment. The term "half-life" as used herein refers to the time taken for the serum concentration of the amino acid sequence, compound or polypeptide to be reduced by 50%, in vivo, for example due to degradation of the sequence or compound and/or clearance or sequestration of the sequence or compound by natural mechanisms.
Half-life may be increased by at least 1 .5 times, preferably at least 2 times, such as at least 5 times, for example at least 10 times or more than 20 times, greater than the half-life of the corresponding antibodies of the invention. For example, increased half-life may be more than 1 hours, preferably more than 2 hours, more preferably more than 6 hours, such as more than 12 hours, or even more than 24, 48 or 72 hours, compared to the antibody of the invention. The in vivo half-life of an amino acid sequence, compound or polypeptide of the invention can be determined in any manner known per se, such as by pharmacokinetic analysis. Suitable techniques will be clear to the person skilled in the art. Half-life can for example be expressed using parameters such as the t1 /2-alpha t1/2-beta and the area under the curve (AUC).
To generate multivalent binding agents and fusion proteins as described above, two or more polypeptides can be connected by a linker, for example a polypeptide linker. Suitable linkers include for example a linkerwith GS residues such as (Gly4Ser)n, where n=from 1 to 10, e.g., 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10. Other linkers are known in the art, for example cysteine linkers for antibody drug conjugates.
Antigen-binding protein e.g. antibody or antigen-binding fragment thereof that competes with an antibody or antigen-binding fragment thereof of the invention
The invention also relates to an antigen-binding protein e.g. an antibody or antigen-binding fragment that competes with an antibody or antigen-binding fragment of the invention. The term “competes” as used herein, refers to an antigen-binding protein e.g., antibody or antigen-binding fragment thereof) that binds to the target antigen (e.g., SARS-CoV-2) and inhibits or blocks the binding of another antigen-binding protein (e.g., antibody or antigen-binding fragment thereof) to the antigen. The term also includes competition between two antigen-binding proteins e.g., antibodies, in both orientations, i.e., a first antibody that binds and blocks binding of second antibody and vice versa. In certain embodiments, the first antigen-binding protein (e.g., antibody) and second antigen-binding protein (e.g., antibody) may bind to the same epitope. Alternatively, the first and second antigen-binding proteins (e.g., antibodies) may bind to different, but, for example, overlapping epitopes, wherein binding of one inhibits or blocks the binding of the second antibody, e.g., via steric hindrance.
Competition between antigen-binding proteins (e.g., antibodies) may be measured by methods known in the art, for example, by a real-time, label-free bio-layer interferometry assay. In an embodiment of the invention, competition between a first and second anti- SARS-CoV-2 antigenbinding protein (e.g., antibody) is determined by measuring the ability of an immobilized first anti- SARS-CoV-2 antigen-binding protein (e.g., antibody) (not initially complexed with SARS-CoV-2 protein) to bind to soluble SARS-CoV-2 protein complexed with a second anti- SARS-CoV-2 antigen-binding protein (e.g., antibody). A reduction in the ability of the first anti- SARS-CoV-2 antigen-binding protein (e.g., antibody) to bind to the complexed SARS-CoV-2 protein, relative to uncomplexed SARS-CoV-2 protein, indicates that the first and second anti- SARS-CoV-2 antigenbinding proteins (e.g., antibodies) compete.
The degree of competition can be expressed as a percentage of the reduction in binding. Such competition can be measured using a real time, label-free bio-layer interferometry assay, e.g., on an Octet RED384 biosensor (Pall ForteBio Corp.), ELISA (enzyme-linked immunosorbent assays) or SPR (surface plasmon resonance), HTRF; flow cytometry; fluorescent microvolume assay technology (FMAT) assay, Mirrorball, high content imaging based fluorescent immunoassays, radioligand binding assays, bio-layer interferometry (BLI), surface plasmon resonance (SPR) and thermal shift assays.
An antibody that binds to the same epitope as a reference antibody, an epitope overlapping with the reference antibody or an epitope that is closely positioned to the epitope of the reference antibody thus eliciting steric hindrance, refers to an antibody that blocks binding of the reference antibody to its binding partner (e.g., an antigen or “target”) in a competition assay by 50% or more, and I or conversely, the reference antibody blocks binding of the antibody to its binding partner in a competition assay by 50% or more. Such antibodies are said to compete for binding to an epitope of interest.
Methods for production
The present disclosure includes an antibody or antigen-binding fragment thereof or binding molecule as described in previous aspects of the invention may be produced in/by murine, mammal or other animal models, by using hybridoma technology or other methods known in the art.
There are several methods by which to produce recombinant antibodies which are known in the art. One of these is production in an E. coli expression system. In this embodiment, nucleic acids encoding the antibody or antigen-binding fragment thereof or binding molecule as described in previous aspects of the invention may be inserted into a plasmid and expressed in a suitable expression system. For example, the present invention includes methods for expressing an antibody or antigen-binding fragment thereof or immunoglobulin chain thereof in a host cell (e.g., bacterial host cell such as E. coli, CHO or other host cell according to the above described aspects fo the invention) comprising expressing T7 RNA polymerase in the cell which also includes a polynucleotide encoding an immunoglobulin chain that is operably linked to a T7 promoter. For example, in an embodiment of the invention, a bacterial host cell, such as an E. coli, includes a polynucleotide encoding the T7 RNA polymerase gene operably linked to a lac promoter and expression of the polymerase and the chain is induced by incubation of the host cell with IPTG (isopropyl-beta-D-thiogalactopyranoside).
Transformation can be by any known method for introducing polynucleotides into a host cell. Methods for introduction of heterologous polynucleotides into mammalian cells are well known in the art and include dextran-mediated transfection, calcium phosphate precipitation, polybrene- mediated transfection, protoplast fusion, electroporation, encapsulation of the polynucleotide(s) in liposomes, biolistic injection and direct microinjection of the DNA into nuclei. In addition, nucleic acid molecules may be introduced into mammalian cells by viral vectors. Methods of transforming cells are well known in the art.
Thus, the present invention also includes recombinant methods for making an antibody or antigen-binding fragment thereof or binding molecule of the present invention comprising (i) introducing one or more polynucleotides (e.g., including the nucleotide sequence disclosed herein) encoding light and/or heavy immunoglobulin domains of the antigen-binding protein, for example, wherein the polynucleotide is in a vector; and/or integrated into a host cell chromosome and/or is operably linked to a promoter; (ii) culturing the host cell (e.g., E. coli, CHO or Pichia or Pichia pastoris) under condition favorable to expression of the polynucleotide and, (iii) optionally, isolating the antigen-binding protein, (e.g., antibody orfragment) or chain from the host cell and/or medium in which the host cell is grown. When making an antigen-binding protein (e.g., antibody or antigen-binding fragment) comprising more than one immunoglobulin chain, e.g., an antibody that comprises two heavy immunoglobulin chains and two light immunoglobulin chains, coexpression of the chains in a single host cell leads to association of the chains, e.g., in the cell or on the cell surface or outside the cell if such chains are secreted, so as to form the antigen-binding protein (e.g., antibody or antigen-binding fragment). The methods include those wherein only a
heavy immunoglobulin chain or only a light immunoglobulin chain (e.g., any of those discussed herein including mature fragments and/or variable domains thereof) is expressed. Such chains are useful, for example, as intermediates in the expression of an antibody or antigen-binding fragment that includes such a chain. Eukaryotic and prokaryotic host cells, including mammalian cells, may be used as hosts for expression of an anti-TMPRSS2 antigen-binding protein. Such host cells are mentioned elsewhere herein,
Pharmaceutical composition and methods of treatment
In one aspect, we provide an isolated antibody or antigen-binding fragment thereof or binding molecule as described herein for use in the treatment of disease. In one embodiment, the disease is a viral infection, i.e. SARS-CoV-2 infection. Methods of treatment are also envisaged.
In another aspect, there is provided a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof or a binding molecule as described herein and optionally a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may comprise one or more antibody or antigen-binding fragment thereof as shown in Table 2 and described herein. All combinations of these antibodies or fragments are envisaged. In one embodiment, the pharmaceutical composition may comprise only one antibody or antigen-binding fragment thereof as shown in Table 2 and described herein. In another embodiment, the pharmaceutical composition may comprise two or more antibodies or antigen-binding fragments thereof as shown in Table 2 and described herein. In another embodiment, the pharmaceutical composition may comprise two or more binding molecules as described herein.
The antibody or antigen-binding fragment thereof or binding molecule as described herein or the pharmaceutical composition of the invention can be administered by any convenient route, including but not limited to oral, topical, parenteral, sublingual, rectal, vaginal, ocular, intranasal, pulmonary, intradermal, intravitreal, intramuscular, intraperitoneal, intravenous, subcutaneous, intracerebral, transdermal, transmucosal, by inhalation, or topical, particularly to the ears, nose, eyes, or skin or by inhalation.
Parenteral administration includes, for example, intravenous, intramuscular, intraarterial, intraperitoneal, intranasal, rectal, intravesical, intradermal, topical or subcutaneous administration.
The pharmaceutically acceptable carrier or vehicle can be particulate, so that the compositions are, for example, in tablet or powder form. The term “carrier” refers to a diluent, adjuvant or excipient, with which an antibody or antigen-binding fragment thereof or binding molecule of the present invention is administered. Such pharmaceutical carriers can be liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. The carriers can be saline, gum acacia, gelatin, starch paste, talc, keratin, colloidal silica, urea, and the like. In addition, auxiliary, stabilizing, thickening, lubricating and coloring agents can be used. In one embodiment, when administered
to an animal, the antibody or antigen-binding fragment thereof or binding molecule of the present invention or compositions and pharmaceutically acceptable carriers are sterile. Water is a preferred carrier when the antibody or antigen-binding fragment thereof or binding molecule of the present invention are administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers also include excipients such as starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The present compositions, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents.
The pharmaceutical composition of the invention can be in the form of a liquid, e.g., a solution, emulsion or suspension. The liquid can be useful for delivery by injection, infusion (e.g., IV infusion) or sub-cutaneously.
When intended for oral administration, the composition is preferably in solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
As a solid composition for oral administration, the composition can be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition typically contains one or more inert diluents. In addition, one or more of the following can be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, corn starch and the like; lubricants such as magnesium stearate; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent. When the composition is in the form of a capsule (e. g. a gelatin capsule), it can contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol, cyclodextrin or a fatty oil.
The composition can be in the form of a liquid, e. g. an elixir, syrup, solution, emulsion or suspension. The liquid can be useful for oral administration or for delivery by injection. When intended for oral administration, a composition can comprise one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition for administration by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent can also be included.
Compositions can take the form of one or more dosage units.
In specific embodiments, it can be desirable to administer the composition locally to the area in need of treatment, or by injection, intravenous injection or infusion. In one embodiment, the
composition is part of a device which includes an injector pen. The composition may be provided as a pre-filled syringe or other self-administration device.
As used herein, the term “effective amount” means an amount of antibody or antigen-binding fragment thereof of the invention, that when administered alone or in combination with an additional therapeutic agent to a cell, tissue, or subject, is effective to achieve the desired therapeutic or prophylactic effect under the conditions of administration. The term “effective amount” of a composition, as used herein, is intended to denote a non-lethal but sufficient amount of the composition to provide the desired effect. For example, in order to elicit a favourable response in a subject when treating a disorder or infection, the effective amount is the one which eliminates or diminishes the symptoms associated with the disorder, e.g. so as to provide control over SARS-Cov-2 infection by eliminating viral particles. An effective amount may be determined by one of ordinary skill in the art, using routine experimentation.
In addition, in vitro or in vivo assays can optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the compositions will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Factors like age, body weight, sex, diet, time of administration, rate of excretion, condition of the host, drug combinations, reaction sensitivities and severity of the disease shall be taken into account.
Typically, the amount is at least about 0.01 % of a the antibody or antigen-binding fragment thereof of the present invention by weight of the composition. When intended for oral administration, this amount can be varied to range from about 0.1 % to about 80% by weight of the composition. Preferred oral compositions can comprise from about 4% to about 50% of the single domain antibody of the present invention by weight of the composition.
Compositions of the present invention can be prepared so that a parenteral dosage unit contains from about 0.01 % to about 2% by weight of the single domain antibody of the present invention.
For administration by injection, the composition can comprise from about typically about 0.1 mg/kg to about 250 mg/kg of the subject’s body weight, forexample, between about 0.1 mg/kg and about 20 mg/kg of the animal's body weight, for example about 1 mg/kg to about 10 mg/kg of the animal's body weight. In one embodiment, the composition is administered at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks.
Depending on the severity of the infection, the frequency and the duration of the treatment can be adjusted. In certain embodiments, the antibody or antigen-binding fragment thereof or binding molecule of the present invention can be administered at an initial dose, followed by one or more secondary doses. In certain embodiments, the initial dose may be followed by administration of a second or a plurality of subsequent doses of antibody or antigen-binding fragment thereof in an amount that can be approximately the same or less than that of the initial dose, wherein the
subsequent doses are separated by at least 1 day to 3 days; at least one week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.
The invention provides methods of treating SARS-CoV-2-mediated diseases or disorders in a mammal, e.g., a human patient or subject, comprising administering an effective amount of an antibody or antigen-binding fragment thereof or binding molecule of the present invention to a mammal in need thereof. In particular, the invention furthermore relates to a method for the prevention and/or treatment of SARS-CoV-2 infection said method comprising administering, to a subject in need thereof, a pharmaceutically active amount of an antibody or antigen-binding fragment thereof or binding molecule of the invention or pharmaceutical composition of the invention.
As used herein, "treat", "treating" or "treatment" means inhibiting or relieving a disease or disorder. For example, treatment can include a postponement of development of the symptoms associated with a disease or disorder, and/or a reduction in the severity of such symptoms that will, or are expected, to develop with said disease. The terms include ameliorating existing symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial result is being conferred on at least some of the mammals, e.g., human patients, being treated. Many medical treatments are effective for some, but not all, patients that undergo the treatment.
The term "subject" or "patient" refers to an animal which is the object of treatment, observation, or experiment. By way of example only, a subject includes, but is not limited to, a mammal, including, but not limited to, a human or a non-human mammal, such as a non-human primate, murine, bovine, equine, canine, ovine, or feline. The subject may have a viral infection, e.g., a SARS-CoV-2 infection, or be predisposed to developing an infection. Subjects predisposed to developing an infection, or subjects who may be at elevated risk for contracting an infection (e.g., of influenza virus), include subjects with compromised immune systems because of autoimmune disease, subjects receiving immunosuppressive therapy (for example, following organ transplant), subjects afflicted with human immunodeficiency virus (HIV) or acquired immune deficiency syndrome (AIDS), subjects with forms of anemia that deplete or destroy white blood cells, subjects receiving radiation or chemotherapy, or subjects afflicted with an inflammatory disorder. Additionally, subjects of old age (e.g., 65 years of age or older) are at increased risk.
The invention also relates to an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region, or pharmaceutical composition of the invention for use in the treatment or prevention of a disease.
In another aspect, the invention relates to an antibody or antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention for use in the treatment or prevention of
a SARS-CoV-2 infection. In another aspect, the invention relates to an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention for use in the manufacture of a medicament for the treatment or prevention of a SARS-CoV-2 infection.
In another aspect, the invention relates to an immunotherapy comprising an antibody or antigenbinding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or a pharmaceutical composition of the invention. This may include the step of administering the antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition to a subject in need thereof.
In another aspect, the invention relates to a method of treating or preventing prevention of a SARS-CoV-2 infection comprising administering an antibody or antigen-binding fragment thereof or binding molecule as described herein that binds to the SARS-CoV-2 Spike protein RBD region or administering a pharmaceutical composition of the invention.
The term “immunotherapy” refers to the treatment of a disease (e.g. of a viral infection) by modulating, directing or supplementing the immune response to an antigen associated with, or produced during, the disease (e.g. an antigen of the infectious agent). In the context of the present disclosure, immunotherapy refers to blocking or diminishing the infection and/or intercellular spreading of the virus in any given subject by administering one or more of the monoclonal antibodies of the invention.
As mentioned elsewhere, the SARS-CoV-2 infection may be caused by a variant, for example as shown in Table 1 . In one embodiment the variant is omicron.
Administration with other agents and combination therapies
The antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention may be administered as the sole active ingredient or in combination with one or more other therapeutic agent. A therapeutic agent is a compound or molecule which is useful in the treatment of a disease. Examples of therapeutic agents include antibodies, antibody fragments, drugs, toxins, nucleases, hormones, immunomodulators, pro-apoptotic agents, anti- angiogenic agents, boron compounds, photoactive agents or dyes and radioisotopes. An antibody molecule includes a full antibody or fragment thereof as mentioned elsewhere herein, e.g., a Fab, F(ab')2, Fv, a single chain Fv fragment (scFv) or a single domain antibody, for example a VH domain, or antibody mimetic protein.
The antibody or antigen-binding fragment thereof or binding molecule may be administered alone or in combination, e.g. one of the antibodies or antibody fragments listed in Table 2 may be administered followed by administration of one, two or three other antibodies or antibody fragments listed in Table 2. Thus, the invention also relates to a combination therapy comprising at least two of the antibodies or antigen-binding fragment thereof listed in Table 2.
In one embodiment, one or more antibody or antigen-binding fragment thereof or binding molecule or pharmaceutical composition as described herein is used in combination with an existing therapy ortherapeutic agent, for example an anti-viral compound, an antibody therapy that targets SARS-CoV-2, a vaccine, an immunomodulator or an anti-inflammatory. Thus, in another aspect, the invention also relates to a combination therapy comprising administration of one or more antibody, or antigen-binding fragment thereof, binding molecule or pharmaceutical composition described herein and an anti-viral therapy.
In one embodiment, the combination therapy may comprise one of more of antibodies or antigenbinding fragments thereof listed in Table 2. In one embodiment, the combination therapy may comprise one antibody or antigen-binding fragment thereof listed in Table 2. In another embodiment, the combination therapy may comprise two or more antibodies or antigen-binding fragments thereof listed in Table 2.
In another embodiment, a further anti-viral therapy may be administered concurrently or sequentially with one or more of antibody or antigen-binding fragment thereof listed in Table 2.
A number of therapies that treat and prevent COVID-19 are known or being developed and the antibody or antibody fragment of the invention and any of these therapies may be used in conjunction with the antibodies of the invention. Without limitation, these therapies include: i) Antivirals, e.g. Remdesivir, Chloroquine/hydroxychloroquine, Lopinavir/ritonavir combination, Favipiravir, Umifenovir, Ribavirin, EIDD-2801 , Niclosamide and Oseltamivir; ii) Immune modulators, e.g. Dexamethasone, Hydrocortisone, Convalescent plasma, Azithromycin, Interferons, Tocilizumab, Sarilumab, Canakinumab, Anakinra, Baricitinib, Ruxolitinib, Acalabrutinib, Brensocatib, Ravulizumab, Gemtuzumab ozogamicin, Namilumab, Infliximab, Adalimumab, Otilimab, Medi3506, Leronlimab, LY-CoV555, LY-CoV016, Risankizumab, Lenzilumab and IMU-838; iii) Other or multiple mechanisms, e.g. Colchicine, Angiotensin-converting-enzyme inhibitors/angiotensin II receptor blockers, Statins, Aspirin, Clopidogrel, Anticoagulants, Bemcentinib, Omeprazole, Famotidine, Zilucoplan, Ascorbic acid/vitamin C, Aviptadil, Opaganib, Tradipitant, AZD1656, Nitric oxide and Razuprotafib or iv) Antibodies that neutralise SARS-CoV-2, e.g. asirivimab and imdevimab. bamlanivimab, etesevimab, casirivimab, imdevimab, sotrovimab, tixagevimab plus cilgavimab: or combinations thereof.
In one embodiment, a viral entry inhibitor or a viral attachment inhibitor is administered.
In one embodiment, administration of the antibody, antigen-binding fragment thereof, binding molecule pharmaceutical composition of the invention with the therapeutic agent; e.g. anti-viral therapy is concurrent or sequential.
In another specific embodiment, the antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention is administered prior or subsequent to administration of the therapeutic agent, e.g. at least an hour, five hours, 12 hours, a day, a week, a month, for example several months (e. g. up to three months), prior or subsequent to administration of composition of the present invention.
Kits
In another aspect, the invention provides a kit for the treatment or prevention of Covid-19 and/or for detecting SARS-CoV-2 for diagnosis, prognosis or monitoring disease comprising an antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention; e.g. one or more antibody or antigen-binding fragment thereof listed in Table 2. Such a kit may contain other components, packaging, instructions, or material to aid in the detection of SARS-CoV-2 protein. The kit may include a labeled antibody, antigen-binding fragment thereof, binding molecule or pharmaceutical composition of the invention and one or more compounds for detecting the label.
The invention in another aspect provides an antibody, antigen-binding fragment thereof, binding molecule or a pharmaceutical composition of the invention packaged in lyophilized form or packaged in an aqueous medium.
Exemplary diagnostic tests and non-therapeutic applications
In another aspect, an antibody, antigen-binding fragment thereof, , e.g. as shown in Table 2, or binding molecule of the invention is used for non-therapeutic purposes, such as diagnostic tests and assays, for example immunoassays for the detection or quantification of SARS-Cov-2 virus. The immunoassays per se are well-known and any of the well-known immunoassays may be employed. That is, classifying the known immunoassays according to the reaction type, known immunoassays include sandwich immunoassays, competition immunoassays, agglutination immunoassays, Western blot and the like. Classifying the known immunoassays according to the label employed, known immunoassays include fluorescence immunoassays, enzyme immunoassays, radio immunoassays, biotin immunoassays and the like. Any of these immunoassays may be employed. Further, diagnosis may be attained by immunohistostaining. In cases where a labeled antibody antigen-binding fragment thereof or binding molecule is used in the immunoassay, the methods per se for labeling an antibody are well-known, and any of the well-known methods may be employed.
Briefly, in sandwich immunoassays, for example, the antibody, antigen-binding fragment thereof or binding molecule of the present invention is immobilized on a solid phase as a first antibody, first antigen-binding fragment thereof or first binding molecule. The first antibody first antigenbinding fragment thereof or first binding molecule is then reacted with a sample, and after washing the solid phase, the resultant is then reacted with a second antibody which reacts with the enzyme of the present invention by antigen-antibody reaction. After washing the solid phase, the second
antibody bound to the solid phase is measured. By labeling the second antibody with an enzyme, fluorescent substance, radioactive substance, biotin or the like, measurement of the second antibody bound to the solid phase may be attained by measuring the label. The above-mentioned measurement is conducted for a plurality of standard samples each containing a known concentration of the enzyme, and the relationship between the concentrations of the enzyme in the standard samples and the measured amounts of the label is plotted to prepare a calibration curve. The enzyme in a test sample may be quantified by applying the measured amount to the calibration curve.
The term "detecting" is used herein in the broadest sense to include both qualitative and quantitative measurements of a target molecule. Detecting includes identifying the mere presence of the target molecule in a sample as well as determining whether the target molecule is present in the sample at detectable levels. Detecting may be direct or indirect.
It should be noted that the above-mentioned first antibody and the above-mentioned second antibody may be exchanged. In agglutination immunoassays, the antibody according to the present invention or an antigen-binding fragment thereof is immobilized on particles such as latex particles, and the particles are reacted with a sample, followed by measurement of the absorbance. The above-mentioned measurement is conducted for a plurality of standard samples each containing a known concentration of the enzyme, and the relationship between the concentrations of the enzyme in the standard samples and the measured absorbance is plotted to prepare a calibration curve. The enzyme in a test sample may be determined by applying the measured absorbance to the calibration curve.
As such, there is provided a method for detecting the presence of SARS-Cov-2 particles or SARS- Cov-2 viral components in a test subject comprising contacting a test sample with an isolated antibody, antigen-binding fragment thereof or binding molecule of the invention.
The method may further comprise i) determining the degree of binding of the antibody, antigenbinding fragment thereof or binding molecule to the test sample (ii) contacting a control sample with an isolated antibody, antigen-binding fragment thereof or binding molecule according to any of claims 1 to x and determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (iii, wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered positive for the presence of SARS-Cov-2.
Alternatively, the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating a healthy value.
Moreover, the method may further comprise the step of obtaining a test sample from a subject.
The test sample may be a healthy subject or a diseased subject, e.g. a subject showing symptoms of CoVID-19 disease. The control sample is from a subject that does not have CoVID-19 disease,
i.e. a healthy subject. In another embodiment, patients may be tested before receiving any treatment.
In another embodiment, patients may be tested following treatment, after a certain period or periodically, to monitor their response to therapy. In another embodiment, the method also includes the additional step of treating the patient with a COVID-19 therapy.
In yet another aspect, there is provided a method for monitoring the progression of COVID -19 disease in a test subject that suffers from infection comprising contacting a test sample with an isolated antibody, antigen-binding fragment thereof or binding molecule of the invention and detecting the presence of SARS-CoV-2 particles or SARS-CoV-2 viral components in a test subject.
The method may further comprise i) determining the degree of binding of the antibody, antigenbinding fragment thereof or binding molecule to the test sample (ii) contacting a control sample with an isolated antibod , antigen-binding fragment thereof or binding molecule as described herein determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (ii), wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered to indicate progression of disease.
Alternatively, the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating a certain stage of disease.
Moreover, the method may further comprise the step of obtaining a test sample from a subject.
The test sample is from a subject which has previously been diagnosed as having COVID-19. In one embodiment, patients may be at an early stage of COVID-19 disease, exhibiting few and mild symptoms. In another embodiment, patients may be at a more advanced stage of COVID-19 disease, exhibiting more severe symptoms.
In another embodiment, patients may be tested before receiving any treatment.
In another embodiment, patients may be tested following treatment, after a certain period or periodically, to monitor their response to therapy.
In another embodiment, the method also includes the additional step of treating the patient with a COVID-19 therapy.
The control sample may be a sample from the same subject taken at an earlier timepoint.
Samples used in the methods above may be used include, but are not limited to, nasal I nasopharyngeal swabs I washes I aspirates, nasal mucosal fluid, oral I oropharyngeal swabs I washes I aspirates, biological fluids such as serum, saliva plasma, whole I peripheral I capillary blood, sputum and cough secretions, isolated / separated cells / cell populations, cultured cells of
any origin and cell extracts, as well as tissue material such as fresh / frozen biopsies and formalin- fixed I paraffin-embedded biopsies.
In yet another aspect, the invention also relates to a method for detecting the presence of SARS- Cov-2 particles or SARS-Cov-2 viral components on solids and in fluids of any type including, but not limited to, surfaces and objects in medical I hospital environments, schools, recreational facilities and households, hotels, drinking I washing I irrigation water supplies, and sewage reservoirs. The method comprises contacting a test solid or fluid sample with an isolated antibody or antigen-binding fragment of the invention and detecting the presence of SARS-Cov-2 particles or SARS-Cov-2 viral components in test solid or fluid sample. Thus, in this method, the test sample is not from a subject.
The method may further comprise i) determining the degree of binding of the antibody or antibody fragment to the test sample (ii) contacting a control sample with an isolated antibody or antigenbinding fragment thereof as described herein determining the degree of binding to the control sample; and (iii) comparing the degree of binding obtained in steps (i) and (ii), wherein, an effective amount obtained in step (i) which is higher than the effective amount obtained in step (ii), is considered to indicate progression of disease.
Alternatively, the degree of binding of the antibody, antigen-binding fragment thereof or binding molecule to the test sample is compared to a pre-determined value indicating test sample free of SARS-Cov-2 particles or SARS-Cov-2 viral components.
Suitable detectable labels which may be conjugated to antigen-binding proteins, such as antibodies are known in the art and include radioisotopes such as iodine-125, iodine-131 , yttrium- 90, indium-1 11 and technetium-99; fluorochromes, such as fluorescein, rhodamine, phycoerythrin, Texas Red and cyanine dye derivatives for example, Cy7, Alexa750 and Alexa Fluor 647; chromogenic dyes, such as diaminobenzidine; latex beads; enzyme labels such as horseradish peroxidase; phospho or laser dyes with spectrally isolated absorption or emission characteristics; electro-chemiluminescent labels, such as SULFO-TAG which may be detected via stimulation with electricity in an appropriate chemical environment; and chemical moieties, such as biotin, which may be detected via binding to a specific cognate detectable moiety, e.g. labelled avidin or streptavidin.
The high sensitivity exhibited by the antibody, antigen-binding fragment thereof or binding molecule of the invention is particularly advantageous in facilitating detection of virus even in low viral titer biological fluids such as might be self-sampled by a consumer relatively non-invasively, e.g., by swabbing mucosal fluids such as nasal fluids or saliva.
For example, by using the antibody, antigen-binding fragment thereof or binding molecule according to the present invention as at least one of the solid phase antibody, antigen-binding fragment thereof or binding molecule and labeled antibody, antigen-binding fragment thereof or binding molecule, a reagent for measuring SARS-Cov-2 virus may be produced. As the solid
phase on which the above-described antibody, antigen-binding fragment thereof or binding molecule is immobilized, various solid phases used in conventional immunoassays may be used.
Examples of such solid phases include various solid phases such as ELISA plates, latices, gelatin particles, magnetic particles, polystyrenes and glasses, insoluble carriers such as beads and matrices through which liquid can be transported and the like. The labeled antibody, antigenbinding fragment thereof or binding molecule may be produced by labeling an antibody, antigenbinding fragment thereof or binding molecule with an enzyme, colloidal metal particle, colored latex particle, luminescent substance, fluorescent substance, radioactive substance or the like. By combining reagents such as these solid phase antibodies, antigen-binding fragment thereof or binding molecule and/or labeled antibodies, antigen-binding fragment thereof or binding molecule, reagents used in enzyme immunoassays, radioimmunoassays, fluoroimmunoassays or the like may be produced. These measurement reagents are the reagents for measuring an antigen of interest present in the test sample by sandwich immunoassay or competitive binding immunoassay. The immunoassay device of the present invention for measuring SARS-Cov-2 virus utilizes the principle of immunochromatography. The device comprises a detection zone having the monoclonal antibody of the present invention immobilized on a matrix through which liquid can be transported, and a labeled reagent zone having a labeled anti- SARS-Cov-2 virus monoclonal antibody of the present invention spotted movably on the above-described matrix.
In a further aspect, the invention relates to a solid support comprising an isolated antibody, antigen-binding fragment thereof or binding molecule according to the invention.
The solid support may be selected from a polystyrene plate, polystyrene beads, nitrocellulose test strip, a nanoparticle or microfluidic chip.
In another aspect, the invention relates to a lateral flow immunoassay for detecting SARS-Cov-2 particles or SARS-Cov-2 viral components in a sample, comprising:
(a) a mobile phase comprising a detection antibody conjugated or otherwise associated with a detectible signal, said detection antibody being capable of binding SARS-Cov-2 particles or SARS-Cov-2 viral components to form a binary complex; and
(b) a stationary phase comprising a substrate comprising immunochromatographic material having immobilized thereon a capture antibody or fragment as described herein, said capture antibody being capable of binding said SARS-Cov-2 of the binary complex to form a ternary complex, whereby a detectible signal generated by said ternary complex is indicative of the presence of SARS-Cov-2 in the sample.
As used herein, the term "lateral flow" refers to capillary flow through a material in a horizontal direction, but will be understood to apply to the flow of a liquid from a point of application of the liquid to another lateral position even if, for example, the device is vertical or on an incline. Lateral flow depends upon properties of the liquid/substrate interaction (surface wetting orwicking action)
and does not require application of outside forces, e.g., vacuum or pressure applications by the user.
In antibody "sandwich-type" LFIA formats, the mobile phase typically comprises the sample, liquid diluents and a detection antibody-signal conjugate, while the immobile phase typically comprises the capture antibody immobilized at the test and control lines, both detection and capture antibodies being specific for the analyte.
In one exemplary test format, the liquid biological sample is absorbed onto the sample pad, and the sample progresses by capillary action into the conjugate pad, where it rehydrates detection antibody particles labelled with a detectable moiety such as a colored label, allowing for the mixing of these particles with the absorbed liquid sample. The labelled antibody interacts with the specific analyte contained in the sample, thereby initiating the intermolecular interactions which are dependent on the affinity and avidity of the reagents. Then the binary complex of the labelled antibody and its specific analyte migrate along the strip toward the capture antibody immobilized in the reaction zone (typically in a line transverse, for example perpendicular, to the sample flow to form a "test line" across the strip), which recognizes and captures the complex, where it becomes immobilized and produces a distinct signal, for example, in the form of a colored line. This technique may be used to obtain quantitative or semi- quantitative results. Excess reagents move past the capture line or lines to an optional control line comprising a positive control that insures that all reagents are functional; and finally, the excess reagents are entrapped in the wick pad, which is designed to draw the biological sample across the membrane by capillary action and thereby maintain a lateral flow along the chromatography strip.
In another exemplary format sometimes referred to as a "dipstick" or "half-strip", solutions or suspensions of labelled antibody and biological sample are combined under conditions to form a binary complex of the labelled antibody with the analyte, prior to application to a test strip. The chromatographic strip is "dipped into" or otherwise contacts the liquid, so that the complex of labelled antibody and target analyte is drawn across the strip as described above, toward the capture antibody at the test line.
In a further aspect, the invention relates to the use of the antibodies, antigen-binding fragment thereof or binding molecule according to the invention as detection agents for SARS-Cov-2 particles or SARS-Cov-2 viral components or therapeutic agents.
The invention relates to the following aspects
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein wherein said isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95%
sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable
region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
2. The isolated antibody or antigen-binding fragment thereof according to aspect 1 comprising i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or viii) a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
3. The isolated antibody or antigen-binding fragment thereof according to aspect 1 or 2 comprising a human heavy chain constant region.
4. The antibody or antigen-binding fragment thereof according to aspect 3, wherein the heavy chain constant region is selected from IgG and IgM.
5. The antibody or antigen-binding fragment thereof according to any a preceding aspect, wherein the antibody or antigen-binding fragment comprises a light chain constant region.
6. The antibody or antigen-binding fragment thereof according to aspect 5 wherein the light chain constant region is a kappa light chain constant region.
7. The antibody or antigen-binding fragment thereof according to aspect 5, wherein the light chain constant region is a lambda light chain constant region.
8. The antibody or antigen-binding fragment thereof according to any preceding aspect, wherein the antibody is a full-length antibody.
9. The antibody or antigen-binding fragment thereof according to any of aspects 1 to 7, wherein the antigen-binding fragment comprises a Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain FV (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, or single domain antibody,.
10. The antibody or antigen-binding fragment thereof according to any preceding aspect, wherein the antibody or antigen-binding fragment neutralizes SARS-CoV-2.
11. The antibody or antigen-binding fragment thereof according to any preceding aspect, wherein the antibody comprises a further moiety.
12. The antibody or antigen-binding fragment thereof according to any preceding aspect, wherein the further moiety is a detectable label, toxin or half-life extending moiety.
13. The antibody or antigen-binding fragment thereof according to any preceding aspect which is linked to a second antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein.
14. The antibody or antigen-binding fragment thereof according to aspect 13 wherein said antibody or antigen-binding fragment binds to a first epitope and the second antibody or antigenbinding fragment binds to a second epitope.
15. The antibody or antigen-binding fragment thereof according to aspect 13 wherein the first and second antibody are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
16. A polynucleotide encoding an antibody or antibody fragment according to any preceding aspect.
17. A vector comprising a polynucleotide according to aspect 16.
18. A host cell comprising a polynucleotide according to aspect 16 or a vector according to aspect 17.
19. A method of making the antibody or antigen-binding fragment according to any one of aspects 1 to 16 comprising (a) culturing a cell according to aspect 18; and (b) isolating the antibody or antigen-binding fragment thereof or the protein from the cultured cell.
20. A binding molecule comprising a) a first antibody or antibody binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antibody fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV-2.
21 . The binding molecule according to aspect 20 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively;
v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
22. The binding molecule according to aspect 20 or 21 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vii) vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or a VH region of SEQ ID NO: 61 thereto or viii) or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
23. The binding molecule according to aspect 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 1 1 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively.
24. The binding molecule according to any of aspects 20 to 23 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
25. The binding molecule according to aspect 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises
HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively.
26. The binding molecule according to any of aspects 20 to 22 or 25 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or a VH region of SEQ ID NO: 61 thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
27. The binding molecule according to aspect 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively
28. The binding molecule according to any of aspects 20 to 22 or 27 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37
or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
29. The binding molecule according to any of aspects 20 to 28 wherein the first and second isolated antibody or antigen-binding fragment thereof are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
30. A combination therapy comprising at least two antibodies or antigen-binding fragments according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 .
31. A pharmaceutical composition comprising one or more isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15 or a binding molecule according to any of aspects 20 to 29.
32. An isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 for use in the treatment of a SARS-CoV-2 infection.
33. A method of treatment of a patient suffering from a SARS-CoV-2 infection comprising administering an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 to said patient.
34. The isolated antibody or antigen-binding fragment thereof, binding molecule or pharmaceutical composition for use according to aspect 32 or the method of aspect 33, wherein the subject is further receiving or has received an anti-viral treatment.
35. The isolated antibody or antigen-binding fragment thereof, binding molecule or method of aspect 34, wherein the anti-viral treatment is selected from remdesivir, supplemental oxygen, ventilation therapy, respiration therapy, dexamethasone, tocilizumab, or any combination thereof.
36. A method for diagnosing a SARS-CoV-2 infection comprising detecting SARS-CoV-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigenbinding fragment thereof according to aspects 1 to 15.
37. A method for monitoring disease progression comprising detecting SARS-Cov-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigen-binding fragment thereof according to aspects 1 to 15.
38. A method for detecting the presence of SARS-CoV-2 particles or SARS-CoV-2 viral components in a test subject comprising contacting a test sample with an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15.
39. A kit comprising an isolated antibody or antigen-binding fragment thereof according to any of aspects 1 to 15, a binding molecule according to any of aspects 20 to 29 or a pharmaceutical composition according to aspect 31 and optionally instructions for use.
Examples
The invention is further described in the following non-limiting examples.
Example 1 Identification of neutralising antibodies
Example 1 - Phage display derived antibodies
Immune phage-display libraries were generated from cDNA derived from PBMCs of two convalescent donors and RNA from 5x106 cells extracted then purified using the I llustra RNAspin Mini kit (GE healthcare, 25-055-71), according to manufacturer’s instructions. cDNA was then amplified from the extracted RNA using oligo dT and the Superscript IV First-Strand Synthesis System (Thermo Fisher) with RiboLock RNase inhibitor (Thermo Fisher), in accordance with manufacturer’s instructions. Heavy chain VDJ and light chain VJ region amplification was performed by PCR on each donor cDNA separately, using KOD Xtreme Hot Start DNA Polymerase Kit (Sigma-Aldrich) to manufacturer’s instructions. Equimolar mixtures of VH /K and VH/VA were joined by overlaping PCR and assembled into pSOS vector using NEBuilder HiFi DNA Assembly (NEB) and electroporated into TG1 Electrocompetent cells (Lucigen) using MicroPulser 165-2089 (BIO-RAD). Libraries were grown and expanded in 2YT media and stored at -80°C in 30% glycerol.
The generated phage display libraries were electroporated in E.coli and subsequently used for the biopanning process. A library size of 108 was determined for both libraries used. Phage particles were obtained by superinfection with helper phage (M13K07, New England Biolabs, N0315). The libraries were initially selected against the full-length Spike protein (Aero biosystems, SPN-C52H9) and a further round of biopanning was carried out against the RBD only domain (Aero biosystems, SPD-C52H3). Briefly, immunotubes were coated at 4°C overnight using the SARS-CoV2 antigens at 5 and 2 pg/ml, respectively, in sterile PBS (Lonza, BE17-513F). After washing the immunotubes twice with PBS 0.1 % Tween20 (PBST) (Sigma-Aldrich, P2287) both the immunotubes and phage particles were blocked for 1 hour with PBST 4% non-fat dry milk (Sigma-Aldrich, 70166). Phage particles were incubated for 90 minutes and then eluted for using a solution of Trypsin-EDTA at 37°C (Sigma-Aldrich, 14849). The recovered phages were used to re-infect E.coli cells for the next round of biopanning. Phage library output was analysed using PacBio Sequel (GENEWIZ) and clones ranked
The variable regions of the identified chains were formatted into full length IgG antibodies, then expressed, purified, and subjected to biophysical and flow cytometry analysis. Antibody clones were assayed for binding against SupT1 cells expressing Spike protein (Wuhan). A total of 24 unique Spike binding clones were identified via phage display approach (Fig. 1A). The
neutralisation capacity of clones capable of binding to Spike protein was evaluated against an engineered replication-deficient lentiviral vector pseudotyped with the Wuhan Spike glycoprotein (76). In an initial screen, Spike-binding clones were each mixed in a 1 :1 ratio with 1x105 IU/ml of pseudotyped lentivirus (PsV), at a fixed concentration of 50 pg/ml. A total of 7 antibodies demonstrated over 85% neutralisation capacity (Fig. 1 B).
Clones D12C1 , D12C3 and D13C1 were analysed via surface plasmon resonance (SPR) for binding kinetics to SARS-CoV-2 S1 domain (Figure 2). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K instrument (Cytiva). HBS-P+ buffer was used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction. For kinetic measurements, a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift. Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case.
Clones D12C1 and D13C1 were screened via SPR for binding kinetics to SARS-CoV-2 S1 domain of variants Wuhan, alpha (B.1.1.7), beta (B.1.351), gamma (P.1), delta (B.1.617.2) and omicron (Figure 3). Similarly, control antibodies LY-CoV555, REGN10933 and REGN10987 were tested on the same variants (Figure 4). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K or Biacore T200 instrument (Cytiva). HBS-P+ buffer was used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction. For kinetic measurements, a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift. Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case.
Table 6. Kinetic affinities of anti-SARs-CoV-2 antibodies to Spike S1 variants
1:1 binding ka
Clone Target kd (1/s) KD (M)
(1/Ms)
Wuhan 1.00E+06 1.54E-03 1.54E-09
REGN 10933
Alpha (B.1.1.7) 8.81E+05 1.40E-03 1.59E-09
Beta (B.1.351) 2.47E+05 8.64E-03 3.49E-08
Gamma (P.1) 1.88E+05 1.97E-03 1.05E-08
Delta (B.1.617.2) 3.26E+05 1.11E-03 3.42E-09
0 micron 5.48E+05 2.80E-03 5.10E-09
Wuhan 1.16E+06 9.36E-03 8.07E-09
Alpha (B.1. 1.7) 5.39E+05 4.51 E-03 8.36E-09
Beta (B.1.351) 3.64E+05 4.25E-03 1.17E-08
REGEN 10987 Gamma (P.1) 3.31 E+05 1.34E-03 4.05E-09
Delta (B.1.617.2) 1.69E+05 7.22E-03 4.27E-08
Omicron N/A N/A N/A
Wuhan 2.64E+05 9.96E-04 3.77E-09
Alpha (B.1. 1.7) 2.22E+05 9.08E-04 4.08E-09
Beta (B.1.351) 1.68E+05 7.60E-03 4.51E-08
LY-COV555 Gamma (P.1) 2.81 E+05 2.23E-03 7.94E-09
Delta (B.1.617.2) N/A N/A N/A
Omicron N/A N/A N/A
Wuhan 8.72E+05 4.68E-03 5.37E-09
Alpha (B. 1.1.7) 1.97E+06 7.03E-03 3.58E-09
Beta (B.1.351) 3.58E+05 3.37E-03 9.42E-09
D12C1
Gamma (P.1) 1.49E+06 4.85E-03 3.25E-09
Delta (B.1.617.2) 1.80E+05 7.13E-03 3.96E-08
Omicron 8.27E+05 1.30E-02 1.57E-08
Wuhan 1.29E+06 4.03E-03 3.12E-09
Alpha (B.1. 1.7) 6.01E+05 1.77E-03 2.95E-09
D13C1
Beta (B.1.351) 5.31 E+05 2.12E-03 4.00E-09
Gamma (P.1) 5.22E+05 1.47E-03 2.81E-09
Delta (B.1.617.2) 3.55E+05 6.57 E-03 1.85E-08
Omicron 2.45E+05 2.97 E-03 1.22E-08
The D12C1 , D12C2, D12C3, D13C1 , D13C27, D13C32 and D13C37 neutralising antibodies were tested in a more stringent neutralisation assay by titrating against 1x106 lU/ml PsV (described above) and compared to the control antibodies REGN10933, REGN10987 and Ly-CoV555 (Figure 5). Clones identified through phage display demonstrated varying levels of neutralisation with four antibodies showing ECso values ranging from 6.5 nM to 0.98 pM and three failing to show appreciable activity.
Clones D12C1 and D13C1 were tested in neutralization assays against SARS-CoV-2 pseudotyped lentiviral vectors carrying the spike protein of Wuhan, Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) variants. Antibodies were tested at a range of concentrations with 4-fold serial dilutions. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x105 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibody-virus mixtures were added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X- 20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. A 1 :1 antibody cocktail of REGN10933 and REGN10987, and the clone LY- CoV555 were used as controls (Figure 6). Clone D13C1 showed sustained neutralisation capacity over all variants tested. Clone D12C1 showed consistent neutralisation against Wuhan, Alpha, Beta and Gamma variants with reduced efficacy against the Delta variant. REGN cocktail showed reduction of potency against Beta variant, while the LY-CoV555 clone showed no efficacy against Beta, Gamma and Delta variants. EC50 values are plotted in Figure 7.
Example 2 - Single B-cell derived antibodies
Activated and memory B cells that bound S1-tetramer were FACS-purified from PBMCs and partitioned into single B cell V(D)J libraries using the 10x genomics platform. The libraries were sequenced, and the native IgA and IgG heavy and light chains identified and paired for each cell using the 10x barcodes. The variable regions of the identified chains from each approach were formatted into full length IgG antibodies, then expressed, purified, and subjected to biophysical and flow cytometry analysis. Antibody clones were assayed for binding against SupT 1 cells expressing Spike protein (Wuhan) (Fig. 8A). A total of 213 unique Spike binding clones were identified, of which 131 demonstrated appreciable binding to the spike protein. The neutralisation capacity of clones capable of binding to Spike protein were evaluated against an engineered replication-deficient lentiviral vector pseudotyped with the Wuhan Spike glycoprotein. In an initial screen, Spike-binding clones were each mixed in a 1 :1 ratio with 1x105 lU/ml of pseudotyped
lentivirus, at a fixed concentration of 50 pg/ml. A total of 24 antibodies demonstrated over 85% neutralisation capacity (Fig. 8B).
Clones showing >85% neutralisation capacity for SARS-CoV-2 pseudotype lentiviral vector were analysed via surface plasmon resonance (SPR) for binding kinetics to SARS-CoV-2 S1 domain (Figure 9). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K instrument (Cytiva). HBS-P+ buffer was used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction. For kinetic measurements, a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift. Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case.
Table 7. Kinetic affinities of anti-SARs-CoV-2 antibodies to Spike S1 variants
1 :1 binding
Clone Target kd (1/s) KD (M) ka (1/Ms)
S4A_16 Wuhan 6.30E+05 5.27E-04 8.37E-10
S4A_18 Wuhan 8.24E+04 2.06E-04 2.50E-09
S4A_54 Wuhan 1.52E+05 2.37E-04 1.56E-09
S4A_60 Wuhan 2.04E+05 4.25E-04 2.08E-09
S4A_79 Wuhan 5.41 E+05 1.96E-04 3.62E-10
S4A_84 Wuhan 3.09E+05 1.63E-04 5.27E-10
S4B_39 Wuhan 8.03E+04 6.82E-04 8.49E-09
S4B_56 Wuhan 1.19E+05 3.24E-04 2.72E-09
S4B_109B Wuhan 9.69E+05 1.12E-04 1.16E-10
S4B_142 Wuhan 7.53E+05 4.55E-04 6.04E-10
S4B_152 Wuhan 2.23E+06 3.44E-04 1.54E-10
S4B_177 Wuhan 1.12E+06 1.24E-04 1.11 E-10
S4B_222 Wuhan 1.09E+06 9.71 E-05 8.91 E-11
S4B_276 Wuhan 1.57e+05 3.67e-03 2.34e-08
Neutralisation of SARS-CoV-2 pseudovirus infection of cell line was tested using 1x106 lU/ml PsV and compared to the control antibodies REGN10933, REGN10987 and Ly-CoV555 (Figure 10). Antibodies were tested at a concentration of 100 pg/ml with 4-fold serial dilutions. Each antibody dilution was mixed 1 :1 with lentiviral vectors to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibody-virus mixtures were added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. Clones demonstrated varying levels of neutralisation with four antibodies showing ECso values ranging from 0.7 nM to 212 nM.
Clones S4A_84 (84), S4B_56 (56), S4B_152 (152) and S4B_222 (222) were screened via SPR for binding kinetics to SARS-CoV-2 S1 domain of variants Wuhan, alpha (B.1 .1 .7), beta (B.1 .351), gamma (P.1), delta (B.1.617.2) and omicron (Figure 11 , Table 3). Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555) to a density of 75 RU, using a Biacore 8K instrument (Cytiva). HBS-P+ buffer was used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction. For kinetic measurements, a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift. Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting in each case. Antibodies tested showed high affinity interactions against the spike variants tested. Clones 84 and 56 showed impaired binding to omicron variant.
Table 8. Kinetic affinities of anti-SARs-CoV-2 antibodies to Spike S1 variants
Analyte 1 1 :1 binding
Clone kd (1/s) KD (M)
Solution ka (1/Ms)
Gamma 1.28e+5 1.23e-5 9.62e-11
Alpha 3.67e+5 8.73e-5 2.38e-10
84 Delta 5.48e+4 3.79e-5 6.92e-10
Beta 1.17e+5 4.59e-6 3.93e-11
Omicron N/A N/A N/A
Gamma 6.08e+4 5.76e-5 9.49e-10
Alpha 8.18e+4 3.60e-7* 4.40e-12*
56 Delta 3.15e+4 1.42e-4 4.52e-9
Beta 6.26e+4 5.58e-5 8.91 e-10
Omicron N/A N/A N/A
Gamma 1.63e+6 3.36e-3 2.06e-9
Alpha 1.47e+6 1.28e-4 8.66e-11
152 Delta 5.05e+5 5.78e-5 1.15e-10
Beta 1.08e+6 2.35e-3 2.18e-9
Omicron 4.90e+6 6.61 e-2 1.35e-8
Gamma 6.84e+5 2.16e-5 3.16e-11
Alpha 7.33e+5 2.48e-7* 3.38e-13*
222 Delta 1.47e+6 2.88e-2 1.96e-8
Beta 6.56e+5 7.00e-5 1.07e-10
Omicron 3.88e+5 1.08e-2 2.79e-8
Clones 84, 56, 152 and 222 were tested at a range of concentrations with 4-fold serial dilutions. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x105 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. SARS-CoV-2 spike variants tested were Wuhan, Beta (1.351) and Delta (B.1.617.2) as these were the ones shoving more challenging conditions among the available Variants of concern. Antibody-virus mixtures were added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. A 1 :1 antibody cocktail of REGN10933 and REGN10987 was used as control (Figure 12). Clone D13C1 showed
sustained neutralisation capacity over all variants tested. All clones showed consistent neutralisation against Wuhan, Beta and delta variants.
Example 3. Biparatopic antibodies
To improve neutralisation efficacy and prevent viral mutational escape, we hypothesised that a biparatopic approach, combining neutralising binders targeting non-overlapping epitopes within the RBD would be beneficial. We performed epitope binning studies using surface plasmon resonance (SPR) to select antibodies for further engineering in the context of a biparatopic molecule. The REGN10933, REGN10987, LY-CoV555 antibodies, as well as ACE2-Fc, were covalently captured to a sensor surface, loaded with recombinant S1 protein, and subsequently challenged by other selected neutralising antibodies. The binding epitope for these binders has already been precisely determined based on their solved co-crystal structures (PDB 6XDG and 7L3N) and would therefore serve as reference for mapping our own candidates. Simultaneous binding of two antibodies to S1 would indicate targeting non-overlapping regions of the S1 protein and would therefore fall into separate bins; while two antibodies binding to the same or overlapping epitopes would show limited secondary binding events and would be grouped into the same bin (Fig. 13A). Mapping the data highlighted a number of antibodies with unique binding epitopes (Fig. 13B).
Antibodies were selected based on ability to co-operatively binding to S1 , as well as showing competition with ACE2-Fc. To LY-CoV555 was assigned the Bin 1 , to REGN10933 the Bin 2, to REGN10987 the Bin 3 and to ACE2-Fc the Bin 4. Bin 1 and Bin 3 are overlapping or in close proximity epitopes and clones LY-CoV555 and REGN10987 do compete with each other. ACE2- Fc bin (bin 4) comprises all 3 bins. Clones D12C3, D13C1 and S4B_177 bound to a distinct epitope not occupied by LY-CoV-555 (Bin 1), REGN10933 (Bin 2) or REGN10987 (Bin 3). However, all competed with ACE2 (Bin 4). Clones S4A_16, S4A_54, S4A_60 and S4A_79 also mapped to a distinct epitope but lied outside of the ACE2 epitope. Clone D12C1 mapped in the Bin 1 and Bin 3. Clones S4A_84 and S4B_56 mapped in Bin 3. Clones S4B_156, S4B_222 and S4B_276 mapped in Bin 1 and Bin 2. Clones D13C27, D13C32, D13C37, S4A_18, S4B_39, S4B109B and S4B_142 mapped on a broad epitope encompassing Bin 1 , 2, 3 and 4 (Figure 13B).
Based on the potential synergistic activity, clones with non-competing profiles were combined in a biparatopic antibody adopting various formats (Figure 14). Tested formats were the Dual Variable Domain (DVD), the scFv4-Fc and the IgG-scFv fusion. Clones D12C1 and D13C1 were first tested in these formats.
Two antibody clones, D12C1 and D13C1 , were clones in the dual variable domain (DVD) architecture (Fig. 14). The DVD construct, alongside the two individual source antibodies and a 1 :1 antibody cocktail, were tested against pseudovirus containing either the Wuhan spike glycoprotein variant, or Spike glycoprotein from the alpha (B.1.17), beta (B.1.351), gamma (P.1)
and delta (B.1.617.2) variants of concern (Fig. 15A). Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x105 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibody-virus mixtures were added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titers were then quantified by eGFP expression in target cells using BD LSRFORTESSA X- 20 cell analyser and infectivity of all fractions was determined as a percentage of viral titres in the PBS only control. As a control, the REGN10933/10987 cocktail and LY-CoV555 were evaluated against the same variants. The D12C1 and D13C1 antibodies were able to neutralise SARS-CoV- 2 (Wuhan), with a dose-response curve demonstrating an EC50 of 4.7 and 7 nM, respectively. A reduction in neutralisation was observed for D12C1 against the beta and delta variants, indicating susceptibility to the current mutational landscape. A similar effect was observed with the REGN10933/10987 antibody cocktail. In contrast, D13C1 proved to be resistant to mutational drift in spike (Fig. 15B). While the D12C1/D13C1 antibody cocktail did not significantly improve the neutralisation capacity of its individual components, the DVD consistently showed better EC50 values across the variants, with a 61- and 21 -fold improvement over D12C1 for the beta and gamma variants, respectively, while maintaining neutralisation capacity against the delta variant.
To maximise flexibility of the molecule and allowing optimal engagement of both RBD epitopes, we cloned D12C1 and D13C1 into two additional biparatopic antibody architectures: IgG-scFv and scFv4-Fc (Fig. 14). The IgG-scFv, and scFv4-Fc constructs showed significantly improved EC50 values, compared to the DVD molecule, ranging between 0.9-5.1 and 0.5-2.7 nM against the Wuhan, alpha, beta and delta variants, respectively. Of note the scFv4-Fc construct showed the highest overall neutralisation, comparable to the REGN10933/10987 cocktail, against the Wuhan, alpha and gamma variants. However, the same construct showed a 5-fold higher neutralisation potency compared to the REGN cocktail against the beta variant (Fig. 15A and 15B). Interestingly, despite the low neutralisation efficiency for the delta variant with the parental D12C1 IgG, scFv4-Fc construct showed a mere 4-fold EC50 reduction compared to the Wuhan variant, further highlighting the considerably increased resistance to mutational drift in spike of our biparatopic antibody.
Binding affinities of the biparatopic constructs were further evaluated to recombinant S1 protein domains of the different variants. Binders were captured on flow cell 2 of a Series S Protein A sensor chip (Cytiva - 29127555), using a Biacore 8K instrument (Cytiva). HBS-P+ bufferwas used as running buffer in all experimental conditions. Recombinant S1 at 250 nM with 2-fold serial dilutions, was used as the ‘analyte’ and injected over the flow channels with 150s contact time and 300s dissociation. All experiments were performed at 25°C with a flow rate of 30 pl/ml. Flow cell 1 was unmodified and used for reference subtraction. For kinetic measurements, a ‘0 concentration’ sensogram of buffer alone was used as a double reference subtraction to factor for drift. Data were fit to a 1 :1 Langmuir binding model using Biacore insight evaluation software (Cytiva). Since a capture system was used, a local Rmax parameter was used for the data fitting
in each case. In line with the neutralisation data, the binding kinetics data indicates that the DVD biparatopic antibody construct was capable of consistently increasing the overall affinity to the Spike protein relative to the constituent antibodies, with a 4.4-fold increase for the delta variant compared to the parental D12C1 antibody, to 6.7 nM (Fig. 16, Table 7). The increased affinity of the biparatopic antibody constructs to the monomeric S1 domain, over the constituent IgGs, confirms the ability of the bispecific format to simultaneously engage two non-overlapping epitopes within the RBD.
The IgG-scFv and the scFv4-Fc formats also showed greatly improved affinities for the SARS- CoV-2 S1 variants compared to the parental D12C1 and D13C1 IgG antibody formats, with up to 6.3-fold affinity increase for the IgG-scFv format and up to 9.7-fold improvement for the scFv4-Fc format (Table 9). Of note, all biparatopic formats (DVD, IgG-scFv and scFv4-Fc) showed a greatly improved affinity profile for the omicron variant.
Table 9. Kinetic affinities of anti-SARs-CoV-2 biparatopic antibodies to Spike S1 variants
1:1 binding ka
Clone Target kd (1/s) KD (M)
(1/Ms)
Wuhan 3.15E+05 7.61 E-04 2.42E-09
Alpha (B.1. 1.7) 3.30E+05 5.99E-04 1.81E-09
Beta (B.1.351) 1.88E+05 8.97E-04 4.76E-09
DVD D12/D13
Gamma (P.1) 1.42E+05 7.01 E-04 4.93E-09
Delta (B.1.617.2) 7.86E+04 5.31E-04 6.75E-09
Omicron 1.67e+5 7.72e-4 4.61E-09
Wuhan 6.37E+05 5.37E-04 8.42E-10
Alpha (B.1. 1.7) 6.93E+05 1.07E-03 1.55E-09
Beta (B.1.351) 5.95E+05 9.89E-04 1.66E-09
IgG-scFv D12/D13
Gamma (P.1) 5.69E+05 7.39E-04 1.30E-09
Delta (B.1.617.2) 1.84E+05 1.53E-03 8.31E-09
Omicron 2.44e+5 1.21e-3 4.96E-09
Wuhan 7.74E+05 5.43 E-04 7.02E-10 scFv4-Fc D12/D13 Alpha (B. 1.1.7) 7.26E+05 4.71 E-04 6.50E-10
Beta (B.1.351) 4.52E+05 5.23E-04 1.16E-09
Gamma (P.1) 4.14E+05 4.27E-04 1.03E-09
Delta (B.1.617.2) 1.47E+05 6.04E-04 4.10E-09
Omicron 3.2e+5 2.06e-3 6.43e-9
ScFv4-Fc biparatopic format of combinations of clone 84 and 152 (84-152 and 152-84 orientations) or 84 and 222 (84-222 and 222-84 orientations) also showed a greatly improved affinities towards Wuhan, alpha, beta gamma and delta S1 variants, with affinity improvements in excess of 10-fold and in the pM range (Figure 17, Table 10). Biparatopic formats also showed nM affinities for the Omicron variant, despite the loss of binding for the parental clone 84, highlighting the resistance to mutational escape (Figure 17 and Table 10).
Table 10. Kinetic affinities of anti-SARs-CoV-2 scFv4-Fc biparatopic antibodies to Spike S1 variants
Wuhan 9.39E+05 5.02E-07* 5.34E-13*
Alpha 1.44E+06 2.75E-06 1.91 E-12
Beta 7.97E+05 4.03E-07* 5.05E-13*
84-152 Gamma 1.01 E+06 8.83E-05 8.73E-11
Delta 5.19E+05 1.27E-05 2.45E-11
Omicron 6.15e+5 4.70e-3 7.64e-9
Wuhan 9.55E+05 3.12E-06 3.27E-12
Alpha 1.47E+06 1.38E-07* 9.35E-14*
Beta 7.61 E+05 8.12E-08* 1.07E-13*
152-84 Gamma 1.01 E+06 2.09E-05 2.08E-11
Delta 5.68E+05 1.07E-05 1.88E-11
Omicron 4.24e+5 3.11 e-3 7.34e-9
Wuhan 5.51 E+05 3.69E-08* 6.70E-14*
84-222
Alpha 8.00E+05 7.33E-08* 9.16E-14*
Beta 5.70E+05 1.28E-07* 2.24E-13*
Gamma 7.30E+05 1.19E-07* 1.64E-13*
Delta 2.53E+05 1.51 E-05 5.98E-11
Omicron 2.89e+5 3.14e-3 1.08e-8
Wuhan 5.92E+05 8.73E-08* 1.47E-13*
Alpha 1.01 E+06 5.61 E-08* 5.58E-14*
Beta 6.47E+05 5.50E-08* 8.51 E-14*
222-84
Gamma 8.63E+05 5.89E-08* 6.82E-14*
Delta 2.68E+05 2.97E-05 1.11 E-10
Neutralisation efficiency of scFv4-Fc 84-152, 152-84, 84-222 and 222-84 against SARS-CoV-2 Wuhan, beta and delta pseudotyped lentiviral vectors was performed as described above. Each antibody dilution was mixed 1 :1 with lentiviral vectors normalised to 1x105 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibody-virus mixtures were added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titres were then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions was determined as a percentage of viral titers in the PBS only control. A 1 :1 antibody cocktail of REGN10933 and REGN10987 was used as control (Figure 18). All biparatopic antibodies showed efficient neutralisation of pseudotyped viral infection with consistent performance across all variants tested. Of note, the scFv4-Fc biparatopic antibodies showed > 5-fold improvement in EC50 compared to the REGN cocktail for the beta variant.
Example 4 -Omicron neutralization
Clones D12C1 , D13C1 , 84, 56, 152, 222 IgG antibodies, D12C1/D13C1 biparatopic antibody (DVD, IgG-Fc and scFv4-Fc) and scFv4-Fc antibodies 84-152, 152-84, 84-222 and 222-84 are tested at a range of concentrations with 4-fold serial dilutions in a SARS-CoV-2 pseudotyped lentiviral vector neutralisation assay against Wuhan and Omicron variants. Each antibody dilution is mixed 1 :1 with lentiviral vectors normalised to 1x105 physical particle of vectors pseudotyped with WT Wuhan glycoprotein, to a final volume of 200 pL and incubated at 37 °C for 1 h. Antibodyvirus mixtures are added to 3x104 HEK-293T (ACE2+, TMPRSS2+) in 48-well plates and incubated for 72 h. Viral titres are then quantified by eGFP expression in target cells using BD LSRFORTESSA X-20 cell analyser and infectivity of all fractions is determined as a percentage
of viral titres in the PBS only control. A 1 :1 antibody cocktail of REGN10933 and REGN10987 and the Ly-CoV555 antibody are used as control.
Example 5 - in vivo study
Study protocol:
8 weeks old hamsters (Syrian golden hamster) in activity-wheel cages from 6 days prior to challenge.
On DPI 0, all hamsters were intranasally inoculated with 100 pl of SARS-CoV-2 prototype strain D614G (SARS-CoV-2/human/NL/Lelystad/2020) at TCIDso 1030, under general anesthesia.
On DP1 1 , 10 hamsters/group were inoculated with test samples, i.p. injections of 1 ml final sample volume.
Groups included:
• Placebo PBS control (buffer only)
• REGN10933/REGN10987 antibody cocktail (1 :1 ratio). Non-commercial source (Ref Ferrari et al. J Virol 2021).
• D12C1/D13C1 antibody cocktail (ratio 1 :1)
• D12/D13 scFV4-Fc biparatopic antibody
Observations from d-5 onwards:
• Daily body weight assessment
• Daily activity wheel measurement
• Blood sampling at day -4, 4 and 10.
• Terminal bleed at d4 (n=6) and d10 (n=4)
• Oropharyngeal swab at day -2, 2-5 and 7-10
• Necropsies at d4 (n=6) and day 10 (n=4) for lungs and conchae
Result:
Body weight measurements (Figure 19)
Significant shift of body weight compared to PBS control group detected at DPI 5-10 for D12C1/D13C1 antibody cocktail, at DPI 6, 7 for REGN antibody cocktail, and at DPI 7 for D12C1/D13C1 scFv4-Fc (Two-way ANOVA with Dunnett’s post-test to PBS control group. * P <0.05, ** P<0.01 , **** P<0.0001). Comparable efficacy for REGN antibody cocktail and D12C1/D13C1 scFv4-Fc. Significantly higher potency for D12C1/D13C1 antibody cocktail over scFv4-Fc biparatopic construct (two-way ANOVA with Tukey’s post test for main effect, # P<0.05, #### P<0.0001).
Activity wheel measurement (rotations/day) (Figure 20)
Significantly higher activity determined for D12C1/D13C1 antibody cocktail over PBS control group at DPI 6-9 (two-way ANOVA with Dunnett’s post-test to PBS control group, * P<0.05, ** P<0.01 , **** P<0.0001). Significantly overall activity difference determined for D12C1/D13C1 antibody cocktail over scFV4-Fc group, and for D12C1/D13C1 scFv4-Fc over PBS control group (Two-way ANOVA with Tukey’s post-test main affect model, # P<0.05).
Macroscopic evaluation (Figure 21)
The total area of consolidated lung tissue was evaluated (dorsal and ventral perspective) with a photograph of the lungs and drawing during necropsy by a veterinary pathologist or trained veterinarian. A second evaluation was performed after the necropsy with the drawing and photos. The score represents mean of both evaluations.
The following macroscopical semi-quantitative scoring scheme was used to evaluate the lungs, focusing on the acute lesions characterized by deep red to brown discoloration:
• 0: no changes
• 1 : focal to multifocal discoloration of lung tissue (<15%)
• 2: multifocal discoloration of lung tissue (15-40%)
• 3: multifocal to coalescing discoloration of lung tissue (40-70%)
• 4: diffuse discoloration of lung tissue (>70%)
In addition, lungs were weighed, and weight was expressed relative to the body weight on the day of necropsy.
Significant difference in macroscopic lung score at DPI 10 detected for D12C1/D13C1 antibody cocktail over PBS (two-way ANOVA with Dunnett’s post test against PBS control, * P<0.05).
Lower general lung weigh at DPI 10 for treatment groups compared to PBS, although without reaching significance (Two-way ANOVA with Dunnett’s post-test against PBS control group).
Extent lung histopathology (Figure 22)
The whole left side (one lobe) was evaluated and the percentage of affected lung tissue of the left lobe was graded (objective 2.5x or 5x in duplicate):
• 0: no changes
• 1 : focal to multifocal (< 15% of tissue)
• 2: multifocal (15-40% of tissue)
• 3: multifocal to coalescing (40-70% of tissue)
• 4: diffuse (>70% of tissue)
Trend in decreased lung surface damage for treatment groups compared to PBC control, without reaching significance (Two-way ANOVA with Dunnett’s post-test against PBS control group).
Table 12 Mean extent of affected lung surface [%] with standard deviation (SD) per group and necropsy day
PCR swabs (Figure 23)
Swabs collected at DPI -4 were all negative for viral RNA.
Following challenge, sub genomic (sg)RNA PCR, was visible at all DPI tested. The D12C1/D13C1 and D12/D13 scFv4-Fc groups trended towards faster RNA clearance. On DPI 5 hamsters from
all groups had undetectable sgRNA levels: 1/4 in group D12C1/D13C1 , 3/4 in group D12/D13 scFv4-Fc, and 1/4 in the Placebo PBS group. On DPI 10, undetectable sgRNA levels were observed in groups D12C1/D13C1 (4/4), D12/D13 scFv4-Fc (3/4), REGN10933/REGN10987 (2/4), and Placebo PBS (2/4). sgRNA levels were significantly lower for D12/D13 scFv4-Fc group compared to PBS at DPI 9 and for D12C1/D13C1 antibody cocktail DP1 10 (two-way ANOVA with Dunnett’s post-test versus PBS group, * P<0.05, ** P<0.01).
PCR tissues (Figure 24)
Organs collected on DPI 4 and 10 were used to determine viral loads by sgRNA PCR.
In lungs, all animals from all groups had detectable levels of total sgRNA. On DPI 4, groups REGN10933/REGN10987, D12C1/D13C1 antibody-cocktail and D12/D13 scFv4-Fc showed significantly lowertotal sgRNA levels compared to Placebo PBS (Two-way ANOVA with Dunnett’s post-test to PBS, ** P< 0.01 , *** P<0.001). On 10, sgRNA levels were undetectable in all animals of all groups.
In conchae, all animals from all groups had detectable levels of sgRNA at DPI 4 but undetectable on DPI 10. No significantly difference compared to PBS control group.
References
1 . P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.- F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 579, 270-273 (2020).
2. M. Voysey, S. A. C. Clemens, S. A. Madhi, L. Y. Weckx, P. M. Folegatti, P. K. Aley, B. Angus, V. L. Baillie, S. L. Barnabas, Q. E. Bhorat, S. Bibi, C. Briner, P. Cicconi, A. M. Collins, R. Colin-Jones, C. L. Cutland, T. C. Darton, K. Dheda, C. J. A. Duncan, K. R. W. Emary, K. J. Ewer, L. Fairlie, S. N. Faust, S. Feng, D. M. Ferreira, A. Finn, A. L. Goodman, C. M. Green, C. A. Green, P. T. Heath, C. Hill, H. Hill, I. Hirsch, S. H. C. Hodgson, A. Izu, S. Jackson, D. Jenkin, C. C. D. Joe, S. Kerridge, A. Koen, G. Kwatra, R. Lazarus, A. M. Lawrie, A. Lelliott, V. Libri, P. J. Lillie, R. Mallory, A. V. A. Mendes, E. P. Milan, A. M. Minassian, A. McGregor, H. Morrison, Y. F. Mujadidi, A. Nana, P. J. O’Reilly, S. D. Padayachee, A. Pittella, E. Plested, K. M. Pollock, M. N. Ramasamy,
S. Rhead, A. V. Schwarzbold, N. Singh, A. Smith, R. Song, M. D. Snape, E. Sprinz, R. K. Sutherland, R. Tarrant, E. C. Thomson, M. E. Torok, M. Toshner, D. P. J. Turner, J. Vekemans,
T. L. Villafana, M. E. E. Watson, C. J. Williams, A. D. Douglas, A. V. S. Hill, T. Lambe, S. C.
Gilbert, A. J. Pollard, Oxford COVID Vaccine Trial Group, Safety and efficacy of the ChAdOxI nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet Lond. Engl. (2020), doi: 10.1016/S0140-6736(20)32661 -1 .
3. L. R. Baden, H. M. El Sahly, B. Essink, K. Kotloff, S. Frey, R. Novak, D. Diemert, S. A. Spector, N. Rouphael, C. B. Creech, J. McGettigan, S. Khetan, N. Segall, J. Solis, A. Brosz, C. Fierro, H. Schwartz, K. Neuzil, L. Corey, P. Gilbert, H. Janes, D. Follmann, M. Marovich, J. Mascola, L. Polakowski, J. Ledgerwood, B. S. Graham, H. Bennett, R. Pajon, C. Knightly, B. Leav, W. Deng, H. Zhou, S. Han, M. Ivarsson, J. Miller, T. Zaks, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403-416 (2021).
4. F. P. Polack, S. J. Thomas, N. Kitchin, J. Absalon, A. Gurtman, S. Lockhart, J. L. Perez, G. Perez Marc, E. D. Moreira, C. Zerbini, R. Bailey, K. A. Swanson, S. Roychoudhury, K. Koury, P. Li, W. V. Kalina, D. Cooper, R. W. Frenck, L. L. Hammitt, O. Tiireci, H. Nell, A. Schaefer, S. Unal, D. B. Tresnan, S. Mather, P. R. Dormitzer, U. §ahin, K. U. Jansen, W. C. Gruber, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N. Engl. J. Med. 383, 2603-2615 (2020).
5. P. C. Taylor, A. C. Adams, M. M. Hufford, I. de la Torre, K. Winthrop, R. L. Gottlieb, Neutralizing monoclonal antibodies for treatment of COVID-19. Nat. Rev. Immunol. 21 , 382-393 (2021).
6. Rambaut, Andrew, Loman, Nick, Pybus, Oliver, Barclay, Wendy, Barnett, Jeff, Carabelli, Alesandro, Connor, Tom, Peacock, Tom, Robertson, David L, Volz, Erik, Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations, (available at https://virological.org/t/preliminary-genomic-characterisation-of-an- emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563).
7. H. Tegally, E. Wilkinson, M. Giovanetti, A. Iranzadeh, V. Fonseca, J. Giandhari, D. Doolabh, S. Pillay, E. J. San, N. Msomi, K. Mlisana, A. von Gottberg, S. Walaza, M. Allam, A. Ismail, T. Mohale, A. J. Glass, S. Engelbrecht, G. Van Zyl, W. Preiser, F. Petruccione, A. Sigal, D. Hardie, G. Marais, M. Hsiao, S. Korsman, M.-A. Davies, L. Tyers, I. Mudau, D. York, C. Maslo, D. Goedhals, S. Abrahams, O. Laguda-Akingba, A. Alisoltani-Dehkordi, A. Godzik, C. K. Wibmer, B. T. Sewell, J. Lourengo, L. C. J. Alcantara, S. L. K. Pond, S. Weaver, D. Martin, R. J. Lessells, J. N. Bhiman, C. Williamson, T. de Oliveira, “Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa” (preprint, Epidemiology, 2020), , doi:10.1101/2020.12.21 .20248640.
8. N. R. Faria, I. M. Clara, D. Candido, Franco, Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings, (available at https://virological.org/tZgenomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus- preliminary-findings/586/1).
9. S. Cherian, V. Potdar, S. Jadhav, P. Yadav, N. Gupta, M. Das, P. Rakshit, S. Singh, P. Abraham, S. Panda, NIC team, “Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681 R, in the second wave of COVID-19 in Maharashtra, India” (preprint, Molecular Biology, 2021), , doi:10.1101/2021 .04.22.440932.
10. Q. Li, J. Wu, J. Nie, L. Zhang, H. Hao, S. Liu, C. Zhao, Q. Zhang, H. Liu, L. Nie, H. Qin, M. Wang, Q. Lu, X. Li, Q. Sun, J. Liu, L. Zhang, X. Li, W. Huang, Y. Wang, The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity. Cell. 182, 1284-1294. e9 (2020).
11. T. Tada, H. Zhou, B. M. Dcosta, M. I. Samanovic, M. J. Mulligan, N. R. Landau, “The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies” (preprint, Immunology, 2021), , doi:10.1101/2021 .05.14.444076.
12. T. N. Starr, A. J. Greaney, A. Addetia, W. W. Hannon, M. C. Choudhary, A. S. Dingens, J. Z. Li, J. D. Bloom, Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science. 371 , 850-854 (2021).
13. M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Kruger, T. Herder, S. Erichsen, T. S. Schiergens, G. Herder, N.-H. Wu, A. Nitsche, M. A. Muller, C. Drosten, S. Pbhlmann, SARS-CoV- 2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 181 , 271 -280. e8 (2020).
14. A. Zoufaly, M. Poglitsch, J. H. Aberle, W. Hoepier, T. Seitz, M. Traugott, A. Grieb, E. Pawelka, H. Laferl, C. Wenisch, S. Neuhold, D. Haider, K. Stiasny, A. Bergthaler, E. Puchhammer-Stoeckl, A. Mirazimi, N. Montserrat, H. Zhang, A. S. Slutsky, J. M. Penninger, Human recombinant soluble ACE2 in severe COVID-19. Lancet Respir. Med. 8, 1154-1 158 (2020).
15. C. Lei, W. Fu, K. Qian, T. Li, S. Zhang, M. Ding, S. Hu, bioRxiv, in press, doi:10.1101/2020.02.01 .929976.
16. M. Ferrari, L. Mekkaoui, F. T. Ilea, Z. Akbar, R. Bughda, K. Lamb, K. Ward, F. Parekh, R. Karattil, C. Allen, P. Wu, V. Baldan, G. Mattiuzzo, E. M. Bentley, Y. Takeuchi, J. Sillibourne, P. Datta, A. Kinna, M. Pule, S. C. Onuoha, “Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants” (preprint, Immunology, 2021), , doi:10.1101/2021 .03.17.435802.
17. A. Miller, A. Leach, J. Thomas, C. McAndrew, E. Bentley, G. Mattiuzzo, L. John, A. Mirazimi, G. Harris, N. Gamage, S. Carr, H. Ali, R. Van Montfort, T. Rabbitts, A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection. Sci. Rep. 11 , 10617 (2021).
18. A. Leach, A. Miller, E. Bentley, G. Mattiuzzo, J. Thomas, C. McAndrew, R. Van Montfort, T. Rabbitts, Implementing a method for engineering multivalency to substantially enhance binding
of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins. Sei. Rep. 11 , 10475 (2021).
Sequence information
Protein and nucleic acid sequences are shown below. CDRs are according to IMGT. CDRs are underlined
>D12C1 heavy chain
HCDR1 SEQ ID NO: 2 GFTFDDYA
HCDR2 SEQ ID NO: 3 TTWNSGTI
HCDR3 SEQ ID NO: 4 AKDLLPDDRMGGGAFDI
VH SEQ ID NO: 5
QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGTTWNSGTIGYA DSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLLPDDRMGGGAFDIWGQGTMVTVS S
HC SEQ ID NO: 154
CAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTGGTGCAGCCCGGAAGAAGCCTGAGGCT GTCTTGTGCCGCTAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGCGGCAGGC CCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCACAACCTGGAACAGCGGCACAATCGGCT
ACGCCGACAGCGTGATGGGCAGATTCACAATCAGCAGAGATAACGCCAAAAACAGCCTGT ATCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACC TGCTGCCTGATGATAGAATGGGCGGCGGTGCTTTTGACATCTGGGGACAGGGCACCATGG
TGACCGTGTCCAGC light chain
LCDR1 SEQ ID NO: 6 NIGSKS
LCDR2 SEQ ID NO: 7 DNT
LCDR3 SEQ ID NO: 8 QVWDSSSDHYV
VL SEQ ID NO: 9
QPVLTQPPSVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVLVVYDNTDRPSGIPERFSG SNSGKTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVLGQP
LC SEQ ID NO: 155
CAGCCTGTGCTGACACAGCCCCCCAGCGTGTCCGTCGCCCCTGGCCAAACAGCCACAATC ACCTGTGGCGGCAACAACATCGGCAGCAAGTCCGTGCACTGGTATCAGCAGAAACCTGGA
CAGGCCCCAGTTCTGGTGGTGTACGACAATACCGATAGACCTTCTGGCATCCCTGAGCGG
TTCAGCGGAAGCAACAGCGGCAAGACCGCCACCCTGACCATCAGCAGAGTGGAAGCCGG
CGACGAGGCTGATTACTACTGCCAGGTGTGGGACAGCTCTAGCGACCACTACGTGTTCGG
CACCGGCACAAAGGTGACCGTGCTGGGCCAGCCT
>D12C3 heavy chain
HCDR1 SEQ ID NO: 26 GFSLSNGRMG
HCDR2 SEQ ID NO: 27 IFSNDEK
HCDR3 SEQ ID NO: 28 ARITDYYDRSGNLLADAFDI
VH SEQ ID NO: 29
QVTLKESGPVLVKPTETLTLTCTVSGFSLSNGRMGVSWIRQPPGKALEWLAHIFSNDEKSYSTS
LKSRLTISKDTSKSQVVLTMTNMDPVDTATYYCARITDYYDRSGNLLADAFDIWGQGTMVTVSS
HC SEQ ID NO: 160
CAAGTGACACTGAAGGAAAGCGGACCTGTGCTGGTGAAGCCTACCGAGACACTGACTCTC
ACCTGTACCGTGTCCGGCTTTAGCCTGAGCAATGGCAGAATGGGCGTGTCCTGGATCCGG
CAGCCTCCAGGCAAGGCCCTGGAATGGCTGGCCCACATCTTCAGCAACGACGAGAAGTCC
TACAGCACCAGCCTGAAAAGCCGGCTGACCATCAGCAAGGATACAAGCAAATCTCAGGTG
GTGCTGACAATGACCAACATGGACCCCGTGGACACCGCCACCTACTATTGCGCCAGAATC
ACAGATTACTACGACAGATCTGGCAACCTGCTGGCTGATGCCTTCGACATCTGGGGACAG
GGCACCATGGTCACCGTGTCTAGC light chain
LCDR1 SEQ ID NO: 30 NIGSKS
LCDR2 SEQ ID NO: 31 DDS
LCDR3 SEQ ID NO: 32 QVWDSSSDHPV
VL SEQ ID NO: 33
QPVLTQPPSVSVAPGQTARITCGGNNIGSKSVHWYQQKPGQAPVLVVYDDSDRPSGIPERFS
GSNSGNTATLTISRVEAGDEADYYCQVWDSSSDHPVFGGGTKVTVLGQP
LC SEQ ID NO: 161
CAACCTGTGCTGACACAGCCTCCAAGCGTGTCCGTCGCCCCTGGACAGACCGCCAGAATC
ACCTGTGGCGGCAACAACATCGGCAGCAAGAGCGTGCACTGGTATCAGCAGAAACCCGG
CCAGGCCCCTGTTCTGGTGGTGTACGACGACAGCGATAGACCTTCTGGCATCCCCGAGCG
GTTCAGCGGCTCCAACAGCGGAAATACAGCTACACTGACCATCAGCAGAGTGGAAGCCGG
CGACGAGGCCGACTACTACTGCCAGGTGTGGGACAGCAGCTCTGATCACCCCGTGTTCG
GCGGAGGCACCAAGGTGACCGTGCTGGGCCAGCCT
D12C2
Heavy chain
HCDR1 SEQ ID NO: 18 GDTFSNYA
HCDR2 SEQ ID NO: 19 IIPIPGIA
HCDR2 SEQ ID NO: 20 ARDYGGNNDAFDI
VH SEQ ID NO: 21
QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSNYAVNWVRQAPGQGLEWMGRIIPIPGIADYAQ
KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYGGNNDAFDIWGQGTMVTVSS
HC SEQ ID NO: 158
CAGGTGCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGACTTCTGGAGACACCTTCAGCAACTATGCTGTCAACTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCCATCCCTGGTATAGCAGACTA
CGCACAGAAATTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGTACAGCCTA
CATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCCGTGTATTACTGTGCGAGAGACTA
CGGTGGTAACAATGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA
Light chain
LCDR1 SEQ ID NO: 22 SSNIGSNY
LCDR2 SEQ ID NO: 23 EYN
LCDR3 SEQ ID NO: 24 GTWDSSLSAGV
VL SEQ ID NO: 25
QSVLTQPPSVSAAPGQKVTISCSGSSSNIGSNYVSWYQQVPGTAPKLLIYEYNKRPSGIPDRFS
GSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL
LC SEQ ID NO: 159
CAGTCTGTGTTGACGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATC
TCCTGCTCTGGTAGCAGCTCCAACATTGGGAGTAATTATGTATCCTGGTACCAGCAGGTCC
CAGGAACAGCCCCCAAACTCCTCATCTATGAATATAATAAGCGACCCTCAGGTATTCCTGA
CCGATTCTCTGGCTCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGAC
TGGGGACGAGGCCGATTATTACTGCGGAACATGGGATAGCAGCCTGAGTGCTGGGGTGTT
CGGCGGAGGGACCAAGCTCACCGTCCTA
>D13C1
Heavy chain
HCDR1 SEQ ID NO: 10 GYSFTSYV
HCDR2 SEQ ID NO: 11 INTGNGNT
HCDR3 SEQ ID NO: 12 ARVPRGYYDRSGYYNAPEYFQH
VH SEQ ID NO: 13
QVQLQQSGAEVKKPGASVKVSCKASGYSFTSYVIHWVRQAPGQRLEWMGWINTGNGNTEYS
QKFQGRVSITRDTSASTAYMDLSSLRSEDTAVYFCARVPRGYYDRSGYYNAPEYFQHWGQGT LVTVSS
HC SEQ ID NO: 156
CAGGTTCAGTTGCAGCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTG
TCCTGCAAGGCTTCCGGCTACTCCTTCACCTCCTACGTGATCCACTGGGTCCGACAGGCT
CCAGGCCAGAGATTGGAATGGATGGGCTGGATCAACACCGGCAACGGCAACACCGAGTA
CTCCCAGAAATTCCAGGGCAGAGTGTCTATCACCCGGGACACCTCTGCCTCCACCGCCTA
TATGGATCTGTCCTCTCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGTGCC
TCGGGGCTACTACGACAGAAGCGGCTACTACAACGCCCCTGAGTACTTCCAGCATTGGGG CCAGGGAACCCTGGTCACAGTCTCTTCT
Light chain
LCDR1 SEQ ID NO: 14 QSISSW
LCDR2 SEQ ID NO: 15 DAS
LCDR3 SEQ ID NO: 16 QQYNSYSRT
VL SEQ ID NO: 17
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG
SGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKR
LC SEQ ID NO: 158
GACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGGGCGACAGAGTGACC
ATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGTATCAGCAGAAGCCTG
GCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAATCCGGCGTGCCCTCTA
GATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCTCCAGCCTGCAGCCTG
ACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCCGGACCTTTGGCCAGG GCACCAAGGTGGAAATCAAGcGT
>S4A_16
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 66 GFSLSTSGVG
HCDR2 SEQ ID NO: 67 IYWDDDQ
HCDR3 SEQ ID NO: 68 AHQRYTSGWYRFDY
VH SEQ ID NO: 69
QITLKESGPTLVKPTQTLTLACTVSGFSLSTSGVGVGWIRQPPGKALEWLALIYWDDDQRYSPS
LRSRLTITKDTSKNQVVLTMTNLDPVDTATYYCAHQRYTSGWYRFDYWGQGAQVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 170
CAGATCACCCTGAAAGAGTCTGGCCCCACACTGGTCAAGCCCACACAGACACTGACACTG
GCCTGTACCGTGTCCGGCTTTAGCCTGTCTACATCTGGCGTCGGCGTCGGCTGGATTAGA
CAGCCTCCTGGAAAAGCCCTGGAATGGCTGGCCCTGATCTACTGGGACGACGACCAGAGA
TACAGCCCCAGCCTGAGAAGCAGACTGACCATCACCAAGGACACCAGCAAGAACCAGGTG
GTGCTGACCATGACAAATCTGGACCCCGTGGACACCGCCACCTACTATTGTGCCCACCAG
AGGTACACCTCCGGCTGGTACAGATTCGACTATTGGGGACAGGGCGCCCAAGTGACCGTT AGCTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 70 QNIGDY
LCDR2 SEQ ID NO: 71 AAS
LCDR3 SEQ ID NO: 72 QQSYSTPYT
VL SEQ ID NO: 73
DIQMTQSPSSLSASVGDRVIITCRASQNIGDYLNWYQLNSGKAPQLLIFAASTLESGVPSRFSG
SGSGTDFTLTISSLQPEDFATYFCQQSYSTPYTFGQGTKLEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 171
GACATCCAGATGACACAGAGCCCTAGCAGCCTGTCTGCCAGCGTGGGAGACAGAGTGATC
ATCACCTGTAGAGCCAGCCAGAACATCGGCGACTACCTGAACTGGTATCAGCTGAACAGC
GGCAAGGCCCCTCAGCTGCTGATCTTTGCCGCCAGCACACTGGAAAGCGGCGTGCCATCT
AGATTTTCCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATATCCAGCCTCCAGCCT
GAGGACTTCGCCACCTACTTTTGCCAGCAGAGCTACAGCACCCCTTACACCTTTGGCCAG GGCACCAAGCTGGAAATCAAG
>S4A_18
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 74 GFSLSTSGMC
HCDR2 SEQ ID NO: 75 IDWDDAK
HCDR3 SEQ ID NO: 76 ARGVGATCDY
VH SEQ ID NO: 77
QVTLRESGPALVKPTQTLTLTCTFSGFSLSTSGMCVNWIRQPPGKALEWLARIDWDDAKYYST
SLETKVTISKDTSKNQVVLTMTNMDPVDTATYYCARGVGATCDYWGQGTLVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 172
CAAGTGACCCTGAGAGAGTCTGGCCCTGCTCTGGTCAAGCCCACACAGACCCTGACACTG
ACCTGCACCTTCAGCGGCTTTAGCCTGAGCACCAGCGGGATGTGCGTGAACTGGATCAGA
CAGCCTCCTGGCAAGGCCCTGGAATGGCTGGCCAGAATCGATTGGGACGACGCCAAGTA
CTACAGCACCAGCCTGGAAACAAAAGTGACCATCAGCAAGGACACCAGCAAGAATCAGGT
GGTGCTGACCATGACCAACATGGACCCTGTGGACACCGCCACCTACTACTGTGCTAGAGG
CGTGGGCGCCACCTGTGATTATTGGGGACAGGGCACACTGGTCACCGTGTCTAGT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 78 QSISSY
LCDR2 SEQ ID NO: 79 AAS
LCDR3 SEQ ID NO: 80 QQSYSTPFS
VL SEQ ID NO: 81
DIQMTQSPSSLSASVGNTVTITCRASQSISSYLNWYQQKPGIAPKLLIYAASRLHSGVPSRFSGS
GSGTDFTLTISSLQPEDFATYYCQQSYSTPFSFGPGTKVDIK
LC SEQ ID NO: 173
Variable Light Chain (DNA)
GACATCCAGATGACACAGAGCCCTAGCAGCCTGTCTGCCAGCGTGGGAAACACCGTGACC
ATCACCTGTAGAGCCAGCCAGAGCATCAGCAGCTACCTGAACTGGTATCAGCAGAAGCCC
GGAATCGCCCCTAAACTGCTGATCTACGCCGCCAGCAGACTGCACTCTGGCGTGCCATCT
AGATTTTCCGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATATCCAGCCTCCAGCCT
GAGGACTTCGCCACCTACTACTGCCAGCAGAGCTACAGCACCCCTTTCAGCTTTGGCCCT
GGCACCAAGGTGGACATCAAG
>S4A_54
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 82 GFTFSDYY
HCDR2 SEQ ID NO: 83 ISGRSTYT
HCDR3 SEQ ID NO: 84 ARAGTNYDPYGGPFDP
VH SEQ ID NO: 85
QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWLSYISGRSTYTNYAD
SVEGRFTISRDNAKNSLFLQMNSLRPEDTAVYYCARAGTNYDPYGGPFDPWGQGTLVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 174
CAGGTGCAGCTGGTTGAATCTGGCGGCGGACTTGTGAAGCCTGGCGGATCTCTGAGACTG
AGCTGTGCCGCCAGCGGCTTCACCTTCAGCGACTACTACATGAGCTGGATCAGACAGGCC
CCTGGCAAAGGCCTGGAATGGCTGAGCTACATCAGCGGCAGAAGCACCTACACCAACTAC
GCCGATAGCGTGGAAGGCCGGTTCACCATCAGCAGAGACAACGCCAAGAACAGCCTGTTC
CTCCAGATGAACTCCCTGCGGCCTGAGGATACCGCCGTGTACTATTGTGCCAGAGCCGGC
ACCAATTACGACCCCTATGGCGGCCCTTTTGACCCTTGGGGACAGGGCACACTGGTCACC GTTTCTTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 86 QSITSY
LCDR2 SEQ ID NO: 87 AAS
LCDR3 SEQ ID NO: 88 QQSYSSPPT
VL SEQ ID NO: 89
DIQMTQSPSSLSASVGDRVTITCRASQSITSYLHWYQQKPGKAPDLLISAASGLQSGVPSRFSG
SGSGTEFTLSISSLQPGDFATYFCQQSYSSPPTFGQGTKVEVK
Variable Light Chain (DNA)
LC SEQ ID NO: 175
GACATCCAGATGACACAGAGCCCTAGCAGCCTGTCTGCCAGCGTGGGAGACAGAGTGAC
CATCACCTGTAGAGCCAGCCAGAGCATCACCAGCTACCTGCACTGGTATCAGCAGAAGCC
TGGCAAGGCCCCTGACCTGCTGATTTCTGCCGCTTCTGGACTCCAGTCTGGCGTGCCAAG
CAGATTTTCTGGCAGCGGCTCTGGCACCGAGTTCACCCTGTCTATCTCTAGCCTCCAGCCT
GGCGACTTCGCCACCTACTTTTGCCAGCAGAGCTACAGCAGCCCTCCTACCTTTGGCCAG GGCACCAAGGTGGAAGTGAAG
>S4A_60
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 90 GSTFGDYA
HCDR2 SEQ ID NO: 91 IRRKGYGGTT
HCDR3 SEQ ID NO: 92 RGELWHYYYYYGMDV
VH SEQ ID NO: 93
EVQLVESGGGSVQPGRSLRLSCTGSGSTFGDYAMSWVRQAPGKGLEWVGLIRRKGYGGTTE YAASVRGRFTISRDDSKNVAYLQMNSLKTEDTAVYYCRGELWHYYYYYGMDVWGQGTTVTV SS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 176
GAGGTGCAGCTGGTTGAATCTGGCGGAGGATCTGTGCAGCCTGGCAGAAGCCTGAGACT
GAGCTGTACAGGCAGCGGCAGCACCTTTGGCGATTACGCCATGAGCTGGGTCCGACAGG
CTCCTGGCAAAGGCCTTGAATGGGTCGGACTGATCCGGCGGAAAGGCTATGGCGGCACA
ACAGAGTATGCCGCCAGCGTGCGAGGCAGATTCACCATCAGCAGAGATGACAGCAAGAAC
GTGGCCTACCTCCAGATGAACAGCCTGAAAACCGAGGACACCGCCGTGTACTACTGTAGA GGCGAGCTGTGGCACTACTACTATTACTACGGCATGGACGTGTGGGGCCAGGGCACCACA GTGACAGTTTCTTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 94 SSNIGNNH
LCDR2 SEQ ID NO: 95 END
LCDR3 SEQ ID NO: 96 GTWDNSLSAGV
VL SEQ ID NO: 97
QSVLTQPPSVSAAPGQKVTISCSGSSSNIGNNHVSWYQQLPGTAPKVLIYENDKRPSGIPDRFS ASKSGTSATLGITGLQTGDEADYYCGTWDNSLSAGVFGGGTKLTVL
Variable Light Chain (DNA)
LC SEQ ID NO: 177
CAGTCTGTGCTGACACAGCCTCCATCCGTGTCTGCTGCCCCTGGCCAGAAAGTGACCATC AGCTGTAGCGGCAGCAGCAGCAACATCGGCAACAACCACGTGTCCTGGTATCAGCAGCTG CCTGGCACAGCCCCTAAGGTGCTGATCTACGAGAACGACAAGCGGCCCAGCGGCATCCC
CGATAGATTTTCTGCCAGCAAGAGCGGCACCAGCGCCACACTGGGAATTACAGGACTGCA
AACAGGCGACGAGGCCGACTACTACTGTGGCACCTGGGACAATTCTCTGTCTGCCGGCGT TTTCGGCGGAGGCACAAAACTGACAGTGCTG
>S4A_79
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 98 GFTFSHYG
HCDR2 SEQ ID NO: 99 ILYDGSEK
HCDR3 SEQ ID NO: 100 AKAGAPYCSGGNCYVAYFDY
VH SEQ ID NO: 101
QVQLVESGGGVVQPGRSLRLSCAVSGFTFSHYGMHWVRQAPGKGLEWVAVILYDGSEKYYA DSVKDRFTISRDNSKNTLYVQMNSLRAEDTAVYYCAKAGAPYCSGGNCYVAYFDYWGQGTLV
TVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 178
CAGGTGCAGCTGGTTGAATCTGGTGGCGGAGTTGTGCAGCCTGGCAGAAGCCTGAGACT
GAGCTGTGCCGTGTCCGGCTTCACCTTTAGCCACTACGGCATGCACTGGGTCCGACAGGC
ACCTGGCAAAGGCCTTGAATGGGTTGCCGTGATCCTGTACGACGGCAGCGAGAAGTACTA
CGCCGACAGCGTGAAGGACAGATTCACCATCAGCCGGGACAACAGCAAGAACACCCTGTA
CGTGCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTATTGTGCCAAAGCCG
GCGCTCCTTACTGCTCCGGCGGAAATTGCTACGTGGCCTACTTCGACTATTGGGGCCAGG
GCACACTGGTCACCGTTAGCTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 102 QDINHY
LCDR2 SEQ ID NO: 103 DAS
LCDR3 SEQ ID NO: 104 QQYGSLPLT
VL SEQ ID NO: 105
DIQMTQSPSSRSASVGDRVTITCQASQDINHYLNWYQQKAGKAPKLLIYDASNLETGVPSRFS GSGSGTDFTFTISSLQPEDIATYYCQQYGSLPLTFGGGTKVEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 179
GACATCCAGATGACACAGAGCCCCAGCTCTAGAAGCGCCAGCGTGGGAGACAGAGTGAC
CATTACCTGTCAGGCCAGCCAGGACATCAACCACTACCTGAACTGGTATCAGCAGAAGGC
CGGCAAGGCCCCTAAGCTGCTGATCTACGATGCCAGCAACCTGGAAACCGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCTGGCACCGACTTCACCTTCACAATATCCAGCCTCCAGCC
TGAGGATATCGCCACCTACTACTGCCAGCAGTACGGCAGCCTGCCTCTGACATTTGGCGG
CGGAACAAAGGTGGAAATCAAG
>S4A_84
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 34 GFTFSNYA
HCDR2 SEQ ID NO: 35 ISGNGGAI
HCDR3 SEQ ID NO: 36 AKGYYYDDGGYSGREDAFDI
VH SEQ ID NO: 37
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWLSFISGNGGAIYHAD
SVKGRFTVSRDNFKNALYLQMNSLKAEDTAVYYCAKGYYYDDGGYSGREDAFDIWGQGTMV TVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 162
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAACTACGCCATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGACTGGAATGGCTGAGCTTCATCAGCGGCAATGGCGGAGCCATCTACCA
CGCCGATTCTGTGAAGGGCAGATTCACCGTGTCCAGGGACAACTTCAAGAACGCCCTGTA
CCTCCAGATGAACAGCCTGAAGGCCGAGGACACCGCCGTGTACTATTGTGCCAAGGGCTA
CTACTACGACGATGGCGGCTACAGCGGAAGAGAGGACGCCTTTGATATCTGGGGCCAGG
GCACAATGGTCACAGTGTCTAGT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 38 QGISNF
LCDR2 SEQ ID NO: 39 AAN
LCDR3 SEQ ID NO: 40 LQHSSHPYT
VL SEQ ID NO: 41
DIQMTQSPSAMSASVGDRVTITCRASQGISNFLAWFQQKPGKVPKRLIYAANSLQSGVPSRFS GSGYGTEFTLTISSLQPEDFATYYCLQHSSHPYTFGPGTKVEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 163
GACATCCAGATGACACAGAGCCCTAGCGCCATGTCTGCCAGCGTGGGAGACAGAGTGAC
CATCACCTGTAGAGCCAGCCAGGGCATCAGCAACTTTCTGGCCTGGTTCCAGCAGAAACC
CGGCAAGGTGCCCAAGAGACTGATCTACGCCGCCAACTCTCTCCAGAGCGGAGTGCCTAG
CAGATTTTCCGGCAGCGGCTACGGCACCGAGTTCACCCTGACAATATCCAGCCTCCAGCC
TGAGGACTTCGCCACCTACTACTGTCTCCAGCACAGCTCTCACCCCTACACATTTGGCCCT GGCACCAAGGTGGAAATCAAG
>S4B_39
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 106 GITVSSNY
HCDR2 SEQ ID NO: 107 IYSGGST
HCDR3 SEQ ID NO: 108 ARDLIVYGMDV
VH SEQ ID NO: 109
EVQLVESGGGLVQPGGSLRLSCAASGITVSSNYMNWVRQAPGKGLEWVSVIYSGGSTYYADS
VKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDLIVYGMDVWGQGTTVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 180
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCTCTGGCATCACCGTGTCCAGCAACTACATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGCCTTGAATGGGTGTCCGTGATCTACAGCGGCGGCAGCACCTACTACGC
CGATTCTGTGAAGGGCAGATTCACCATCAGCCGGGACAACAGCAAGAACACCCTGTACCT
CCAGATGAACAGCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAGAGATCTGAT
CGTGTACGGCATGGACGTGTGGGGCCAGGGAACAACCGTGACAGTCTCTTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 110 QSVSSSS
LCDR2 SEQ ID NO: 111 GAS
LCDR3 SEQ ID NO: 112 QQYGSSLLT
VL SEQ ID NO: 113
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSSLAWYQQKPGQAPRLLIYGASSRATGIPDRFS
GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSLLTFGGGTKVEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 181
GAGATCGTGCTGACACAGAGCCCTGGCACACTGTCACTGTCTCCAGGCGAAAGAGCCACA
CTGAGCTGTAGAGCCAGCCAGAGCGTGTCCTCTTCTAGCCTGGCTTGGTATCAGCAGAAG
CCCGGACAGGCTCCCAGACTGCTGATCTATGGCGCCTCTAGCAGAGCCACAGGCATCCCC
GATAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCAGACTGGAA
CCCGAGGACTTCGCCGTGTACTACTGTCAGCAGTACGGCAGCAGCCTGCTGACATTTGGC
GGCGGAACAAAGGTGGAAATCAAG
>S4B_56
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 42 GVTFSTYT
HCDR2 SEQ ID NO: 43 IIPIFGAA
HCDR3 SEQ ID NO: 44 ATRSQWELLDY
VH SEQ ID NO: 45
QVQLVQSGADVRKPGSSVKVFCKASGVTFSTYTINWVRQAPGQGLEWMGGIIPIFGAAHSAQ RFHGRLTITADESTSTAYMELSSLTSDDTAVYYCATRSQWELLDYWGQGTLVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 164
CAGGTTCAGCTGGTTCAGTCTGGTGCCGATGTGCGGAAGCCTGGCAGCTCTGTGAAGGTG
TTCTGTAAAGCCAGCGGCGTGACCTTCAGCACCTACACCATCAACTGGGTCCGACAGGCC
CCTGGACAAGGCTTGGAATGGATGGGCGGCATCATCCCCATCTTTGGCGCCGCTCATAGC
GCCCAGAGATTCCACGGCAGACTGACCATCACAGCCGACGAGAGCACAAGCACCGCCTA
CATGGAACTGAGCAGCCTGACCTCCGATGACACCGCCGTGTACTACTGCGCCACCAGATC
TCAGTGGGAGCTGCTGGATTATTGGGGCCAGGGCACACTGGTCACCGTGTCATCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 46 QSVSSSY
LCDR2 SEQ ID NO: 47 DAV
LCDR3 SEQ ID NO: 48 QHYGTSPPQLT
VL SEQ ID NO: 49
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLTWYQQKPGQAPRLLIYDAVGRATGIPDRFS
GSGSGTDFTLTISRLEPEDSAVYYCQHYGTSPPQLTFGGGTRVEIK
Variable Light Chain (DNA)
HC SEQ ID NO: 165
GAGATCGTGCTGACACAGAGCCCTGGCACACTGTCACTGTCTCCAGGCGAAAGAGCCACA
CTGAGCTGTAGAGCCAGCCAGAGCGTGTCCAGCAGCTACCTGACATGGTATCAGCAGAAG
CCCGGACAGGCCCCTAGACTGCTGATCTATGATGCCGTGGGCAGAGCCACAGGCATCCC
CGATAGATTTTCTGGCAGCGGCTCCGGCACCGACTTCACCCTGACAATCAGCAGACTGGA
ACCCGAGGACAGCGCCGTGTACTACTGTCAGCACTACGGCACAAGCCCTCCACAGCTGAC
ATTTGGCGGCGGAACCAGAGTGGAAATCAAG
>S4B_109B
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 114 GYTVTSHY
HCDR2 SEQ ID NO: 115 INPSDGST
HCDR3 SEQ ID NO: 116 ASSSGSASRGYLFDY
VH SEQ ID NO: 117
QVQLVQSGAEVKKPGASVKVSCMASGYTVTSHYIHWVRQAPGQGLAWMGIINPSDGSTDFAQ
DFQGRVALTRDTSANIVYMELSSLRSEDTAIYFCASSSGSASRGYLFDYWGQGSQITVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 182
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTG
TCCTGTATGGCCAGCGGCTACACCGTGACCAGCCACTATATCCACTGGGTCCGACAGGCC
CCTGGACAAGGACTTGCCTGGATGGGCATCATCAACCCTTCCGACGGCAGCACCGATTTC
GCCCAGGATTTTCAGGGCAGAGTGGCCCTGACCAGAGACACCTCTGCCAACATCGTGTAC
ATGGAACTGAGCAGCCTGCGGAGCGAGGACACCGCCATCTACTTTTGTGCCAGCAGCAGC
GGCTCTGCCAGCAGAGGCTACCTGTTTGATTATTGGGGCCAGGGCAGCCAGATCACCGTG
TCATCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 118 SNNVGTYA
LCDR2 SEQ ID NO: 119 GNS
LCDR3 SEQ ID NO: 120 STWDNRLSTRV
VL SEQ ID NO: 121
QSVLTQEASVSGTVGQKVTLSCTGNSNNVGTYAVGWYQQISHGAPKTVMFGNSLASGIPDRF
SGSKSGTTASLTISALQPEDEADYYCSTWDNRLSTRVFGGGTRLTVL
Variable Light Chain (DNA)
LC SEQ ID NO: 183
CAGAGCGTGCTGACACAAGAGGCTTCCGTGTCTGGCACCGTGGGCCAGAAAGTGACCCT
GAGCTGTACCGGCAACAGCAACAACGTGGGCACATATGCCGTCGGCTGGTATCAGCAGAT
CAGCCACGGCGCTCCTAAGACCGTGATGTTCGGCAATTCTCTGGCCAGCGGCATCCCCGA
TAGATTCAGCGGCTCTAAGAGCGGCACAACCGCCAGCCTGACAATCTCTGCTCTCCAGCC
TGAGGACGAGGCCGACTACTACTGTAGCACCTGGGACAACCGGCTGAGCACCAGAGTTTT
TGGCGGCGGAACCAGACTGACCGTGCTT
>S4B_142
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 122 GGTFGSYA
HCDR2 SEQ ID NO: 123 IIPVLGIP
HCDR3 SEQ ID NO: 124 AGCGGDCYSWVYAFDI
VH SEQ ID NO: 125
QVQLVQSGAEVKKPGSSVKVSCKASGGTFGSYAISWVRQAPGQGLEWMGRIIPVLGIPNYAQ
KFQGRVTITADTSTTTAYMELSSLRSEDTAVYYCAGCGGDCYSWVYAFDIWGQGTMVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 184
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGT
GTCCTGCAAAGCTAGCGGCGGCACCTTTGGCAGCTACGCCATCTCTTGGGTTCGACAGGC
TCCTGGACAGGGCCTCGAATGGATGGGCAGAATCATCCCTGTGCTGGGCATCCCCAACTA
CGCCCAGAAATTCCAGGGCAGAGTGACCATCACCGCCGACACCTCTACCACCACCGCCTA
CATGGAACTGAGCAGCCTGAGAAGCGAGGACACCGCCGTGTATTACTGTGCCGGATGTGG
CGGCGATTGCTACTCTTGGGTGTACGCCTTCGACATCTGGGGCCAGGGCACAATGGTCAC CGTTAGCTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 126 QSVSSSF
LCDR2 SEQ ID NO: 127 GAS
LCDR3 SEQ ID NO: 128 QQYGSSQT
VL SEQ ID NO: 129
EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYGASSRATGIPDRFS GSGSGTDFTLTISRLEPEDFAVYYCQQYGSSQTFGQGTKVEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 185
GAGATCGTGCTGACACAGAGCCCTGGCACACTGTCACTGTCTCCAGGCGAAAGAGCCACA
CTGAGCTGTAGAGCCAGCCAGAGCGTGTCCAGCTCTTTCCTGGCTTGGTATCAGCAGAAG
CCCGGACAGGCTCCCAGACTGCTGATCTATGGCGCCTCTTCTAGAGCCACAGGCATCCCC
GATAGATTCAGCGGCTCTGGCAGCGGCACCGATTTCACCCTGACAATCAGCAGACTGGAA
CCCGAGGACTTCGCCGTGTACTACTGTCAGCAGTACGGCAGCAGCCAGACCTTTGGCCAG
GGCACCAAGGTGGAAATCAAG
>S4B_152
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 50 GGTFSRYV
HCDR2 SEQ ID NO: 51 IIPIIGTA
HCDR3 SEQ ID NO: 52 ARSSDPIDTADWYFNL
VH SEQ ID NO: 53
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYVISWVRQAPGQGLELMGGIIPIIGTANYAQKF
QGRVTITTDESTSTVYMELSSLRPEDTAVYYCARSSDPIDTADWYFNLWGRGTLVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 166
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGT
GTCCTGCAAAGCTAGCGGCGGCACCTTCAGCAGATACGTGATCAGCTGGGTCCGACAGG
CCCCTGGACAAGGACTGGAACTGATGGGCGGCATCATCCCCATCATCGGCACAGCCAATT
ACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACCAGCACCGTGT
ACATGGAACTGAGCAGCCTGAGGCCTGAGGACACCGCCGTGTACTACTGTGCCAGAAGCA
GCGACCCTATCGATACCGCCGACTGGTACTTCAACCTGTGGGGCAGAGGCACCCTGGTCA CAGTCTCTTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 54 QSVLYSSNNKNF
LCDR2 SEQ ID NO: 55 WAS
LCDR3 SEQ ID NO: 56 QQYYSIPL
VL SEQ ID NO: 57
DIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNFLAWYQQKPGQPPKLLIYWASTRESG
VPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPLFGGGTKVEIT
Variable Light Chain (DNA)
LC SEQ ID NO: 167
GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACC
ATCAACTGCAAGAGCAGCCAGAGCGTGCTGTACTCCAGCAACAACAAGAACTTCCTGGCC
TGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGA
GAAAGCGGCGTGCCCGATAGATTTTCTGGCAGCGGCTCTGGCACCGACTTCACCCTGACA
ATTAGCAGCCTCCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGTACTACAGCATC CCTCTGTTCGGCGGAGGCACCAAGGTGGAAATCACA
>S4B_177
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 138 GFTFSSYD
HCDR2 SEQ ID NO: 139 ISSSGSTI
HCDR3 SEQ ID NO: 140 ARDSRFWSGYFPSFFDN
VH SEQ ID NO: 141
EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYDMNWVRQAPGKGLEWVSYISSSGSTIYYTD SVKGRFTMSRDNAKNSLYLQMNSLRAEDTAVYYCARDSRFWSGYFPSFFDNWGQGTLVTVS S
Variable Heavy Chain (DNA)
HC SEQ ID NO: 188
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAGCTACGACATGAACTGGGTCCGACAGGC CCCTGGCAAAGGCCTTGAATGGGTGTCCTACATCAGCAGCAGCGGCAGCACCATCTACTA
CACCGACAGCGTGAAGGGCAGATTCACCATGAGCCGGGACAACGCCAAGAACAGCCTGT
ACCTCCAGATGAACTCCCTGAGAGCCGAGGACACCGCCGTGTACTACTGTGCCAGAGACA GCAGATTTTGGAGCGGCTACTTCCCCAGCTTCTTCGACAATTGGGGCCAGGGCACACTGG TCACCGTTAGCTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 142 QDISNY
LCDR2 SEQ ID NO: 143 DAS
LCDR3 SEQ ID NO: 144 QQYENLLPLT
VL SEQ ID NO: 145
DIQMTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASSLETGVPSRFSG SGSGTDFTFTISSLQPEDFATYYCQQYENLLPLTFGGGTKVEIK
Variable Light Chain (DNA)
LC SEQ ID NO: 189
GACATCCAGATGACACAGAGCCCTAGCAGCCTGTCTGCCAGCGTGGGAGACAGAGTGAC CATTACCTGTCAGGCCAGCCAGGACATCAGCAACTACCTGAACTGGTATCAGCAGAAGCC
CGGCAAGGCCCCTAAGCTGCTGATCTACGATGCCAGCAGCCTGGAAACAGGCGTGCCCA
GCAGATTTTCTGGCAGCGGCTCTGGCACCGACTTCACCTTCACAATATCCAGCCTCCAGCC
TGAGGACTTCGCCACCTACTACTGCCAGCAGTACGAGAACCTGCTGCCTCTGACATTTGG
CGGAGGCACCAAGGTGGAAATCAAG
>S4B_222
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 58 GDTFSSFA
HCDR2 SEQ ID NO: 59 VIPIFGTA
HCDR3 SEQ ID NO: 60 ARCPKLSPTVYNYEYYMDV
VH SEQ ID NO: 61
QVQLVQSGAEVKKPGSSLKVSCRASGDTFSSFAISWVRQAPGQGLEWMGGVIPIFGTANYAQ
KFQGRVTITTDESTSTAYMELSSLTSEDTAVYYCARCPKLSPTVYNYEYYMDVWGKGTTVSVS S
Variable Heavy Chain (DNA)
HC SEQ ID NO: 168
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAGCCTGGCAGCTCTCTGAAGGTG
TCCTGTAGAGCCAGCGGCGACACCTTTAGCAGCTTCGCCATCAGCTGGGTCCGACAGGCT
CCTGGACAAGGCTTGGAATGGATGGGCGGCGTGATCCCTATCTTCGGCACAGCCAATTAC
GCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACAAGCACCGCCTAC
ATGGAACTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTACTGTGCCAGATGTCCC
AAGCTGAGCCCCACCGTGTACAACTACGAGTACTACATGGACGTGTGGGGCAAGGGCACC
ACCGTGTCTGTTTCTTCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 62 SSDIGTYNY
LCDR2 SEQ ID NO: 63 DVS
LCDR3 SEQ ID NO: 64 SSYISSNTWYV
VL SEQ ID NO: 65
QSALTQPASVSGSPGQSITISCTGTSSDIGTYNYVSWYQQLPGKAPKLMIYDVSNRPSGVSNR
FSGSKSGNTASLTISGLQAEDEADYYCSSYISSNTWYVFGTGTKVTVL
Variable Light Chain (DNA)
LC SEQ ID NO: 169
CAGTCTGCTCTGACACAGCCTGCCTCTGTGTCTGGCTCTCCTGGCCAGAGCATCACCATC
AGCTGTACCGGCACCAGCAGCGACATCGGCACCTACAATTACGTGTCCTGGTATCAGCAG
CTGCCCGGCAAGGCCCCTAAGCTGATGATCTACGACGTGTCCAACAGACCCAGCGGCGT
GTCCAATAGATTCTCCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATTTCTGGACT
GCAAGCCGAGGACGAGGCCGACTACTACTGCTCCAGCTACATCAGCAGCAACACTTGGTA
CGTGTTCGGCACCGGCACAAAAGTGACCGTGCTT
>S4B_276
Variable Heavy Chain (Protein)
HCDR1 SEQ ID NO: 146 GGIIRRTGYY
HCDR2 SEQ ID NO: 147 MYYSGST
HCDR3 SEQ ID NO: 148 ARGTIWFGELLGNTFDV
VH SEQ ID NO: 149
QLQLQESGPGLEKPSETLSLTCSVSGGIIRRTGYYWGWIRQPPGKGLEWIASMYYSGSTYYSP
SLQSRVTISVDTSKNQLSLKLSSVTVADTAIYYCARGTIWFGELLGNTFDVWGRGTMVTVSS
Variable Heavy Chain (DNA)
HC SEQ ID NO: 190
CAGCTCCAGCTGCAAGAGTCTGGACCTGGCCTGGAAAAGCCCAGCGAGACACTGAGCCT
GACCTGTTCTGTGTCCGGCGGCATCATCAGACGGACCGGCTATTACTGGGGCTGGATCAG
ACAGCCTCCTGGCAAAGGCCTGGAATGGATCGCCAGCATGTACTACAGCGGCAGCACCTA
CTACAGCCCCAGCCTCCAGAGCAGAGTGACCATCTCTGTGGACACCAGCAAGAACCAGCT
GTCCCTGAAGCTGAGCAGCGTGACCGTGGCCGATACCGCCATCTACTATTGTGCCAGAGG
CACCATTTGGTTCGGCGAGCTGCTGGGCAACACCTTCGATGTGTGGGGCAGAGGCACAAT
GGTCACCGTGTCATCT
Variable Light Chain (Protein)
LCDR1 SEQ ID NO: 150 SSDVGGHNY
LCDR2 SEQ ID NO: 151 DVT
LCDR3 SEQ ID NO: 152 SSYTDSSAYV
VL SEQ ID NO: 153
QSALTQPASVSGSPGQSITISCTGTSSDVGGHNYVSWYQQYPGKAPKLIIYDVTHRPSGVSNR
FSGSKSGNTASLTISGLQTEDESDYYCSSYTDSSAYVFGTGTKVTVL
Variable Light Chain (DNA)
LC SEQ ID NO: 191
CAGTCTGCTCTGACACAGCCTGCCTCTGTGTCTGGCTCTCCTGGCCAGAGCATCACCATC
AGCTGTACCGGCACCAGCTCTGATGTCGGCGGCCACAATTACGTGTCCTGGTATCAGCAG
TACCCCGGCAAGGCCCCTAAGCTGATCATCTACGACGTGACCCACAGACCTAGCGGCGTG
TCCAATAGATTCAGCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATCTCTGGACTC
CAGACCGAGGACGAGAGCGACTACTACTGCTCCAGCTACACCGACAGCAGCGCCTACGTT
TTCGGCACCGGCACAAAAGTGACCGTGCTG
Biparatopic constructs
DVD format
SEQ ID NO 192
>D12C1-D13C1 DVD heavy chain
D12C1 VH - LINKER - D13C1 VH - Constant domain (CH1-Hinge-CH2-CH3)
QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGTTWNSGTIGYA
DSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLLPDDRMGGGAFDIWGQGTMVTVS
SASTKGPSVFPLAPQVQLQQSGAEVKKPGASVKVSCKASGYSFTSYVIHWVRQAPGQRLEW
MGWINTGNGNTEYSQKFQGRVSITRDTSASTAYMDLSSLRSEDTAVYFCARVPRGYYDRSGY
YNAPEYFQHWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWN
SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKT
HTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHN
AKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVY
TLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVD
KSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO 193 nucleic acid
CAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTGGTGCAGCCCGGAAGAAGCCTGAGGCT
GTCTTGTGCCGCTAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGCGGCAGGC
CCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCACAACCTGGAACAGCGGCACAATCGGCT
ACGCCGACAGCGTGATGGGCAGATTCACAATCAGCAGAGATAACGCCAAAAACAGCCTGT
ATCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACC
TGCTGCCTGATGATAGAATGGGCGGCGGTGCTTTTGACATCTGGGGACAGGGCACCATGG
TGACCGTGTCCAGCGCCAGCACCAAGGGCCCCTCTGTCTTTCCTCTGGCCCCTCAGGTTC
AGTTGCAGCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTGTCCTGCA
AGGCTTCCGGCTACTCCTTCACCTCCTACGTGATCCACTGGGTCCGACAGGCTCCAGGCC
AGAGATTGGAATGGATGGGCTGGATCAACACCGGCAACGGCAACACCGAGTACTCCCAGA
AATTCCAGGGCAGAGTGTCTATCACCCGGGACACCTCTGCCTCCACCGCCTATATGGATCT
GTCCTCTCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGTGCCTCGGGGCTA
CTACGACAGAAGCGGCTACTACAACGCCCCTGAGTACTTCCAGCATTGGGGCCAGGGAAC
CCTGGTCACAGTCTCTTCTgcgTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCC
TCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCC
CGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCC
CGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCA
GCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGG
TGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGC
ACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCT
CATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACC
CTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGC
CGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCAC
CAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCC
CCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACC
CTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAA
GGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAA
CTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCT
CACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGA
GGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO 194 light chain
D12C1 VL - LINKER - D13C1 VL - C kappa
QPVLTQPPSVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVLVVYDNTDRPSGIPERFSG
SNSGKTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVLGQPKAAPSVTLFPPDIQM
TQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSGSGS
GTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKR
TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS
TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 195 nucleic acid
CAGCCTGTGCTGACACAGCCCCCCAGCGTGTCCGTCGCCCCTGGCCAAACAGCCACAATC
ACCTGTGGCGGCAACAACATCGGCAGCAAGTCCGTGCACTGGTATCAGCAGAAACCTGGA
CAGGCCCCAGTTCTGGTGGTGTACGACAATACCGATAGACCTTCTGGCATCCCTGAGCGG
TTCAGCGGAAGCAACAGCGGCAAGACCGCCACCCTGACCATCAGCAGAGTGGAAGCCGG
CGACGAGGCTGATTACTACTGCCAGGTGTGGGACAGCTCTAGCGACCACTACGTGTTCGG
CACCGGCACAAAGGTGACCGTGCTGGGCCAGCCTAAGGCCGCCCCTAGCGTGACCCTGT
TCCCCCCCGACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGGGCGACA
GAGTGACCATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGTATCAGCA
GAAGCCTGGCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAATCCGGCGT
GCCCTCTAGATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCTCCAGCCTG
CAGCCTGACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCCGGACCTTT
GGCCAGGGCACCAAGGTGGAAATCAAGcGTACGGTGGCTGCACCATCTGTCTTCATCTTC
CCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACT
TCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACT
CCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACC
CTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCAT
CAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
SEQ ID NO 196
>D13C1-D12C1 DVD heavy chain
D13C1 VH - LINKER - D12C1 VH - Constant domain (CH1-Hinge-CH2-CH3)
QVQLQQSGAEVKKPGASVKVSCKASGYSFTSYVIHWVRQAPGQRLEWMGWINTGNGNTEYS
QKFQGRVSITRDTSASTAYMDLSSLRSEDTAVYFCARVPRGYYDRSGYYNAPEYFQHWGQGT
LVTVSSASTKGPSVFPLAPQVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPG
KGLEWVSGTTWNSGTIGYADSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLLPDDR
MGGGAFDIWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNS
GALTSGVHTFPAVLQSSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH
TCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNA
KTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTL
PPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDK
SRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ ID NO 197 nucleic acid
CAGGTTCAGTTGCAGCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTG
TCCTGCAAGGCTTCCGGCTACTCCTTCACCTCCTACGTGATCCACTGGGTCCGACAGGCT
CCAGGCCAGAGATTGGAATGGATGGGCTGGATCAACACCGGCAACGGCAACACCGAGTA
CTCCCAGAAATTCCAGGGCAGAGTGTCTATCACCCGGGACACCTCTGCCTCCACCGCCTA
TATGGATCTGTCCTCTCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGTGCC
TCGGGGCTACTACGACAGAAGCGGCTACTACAACGCCCCTGAGTACTTCCAGCATTGGGG
CCAGGGAACCCTGGTCACAGTCTCTTCTgcgTCGACCAAGGGCCCATCGGTCTTCCCCCTG
GCACCCCAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTGGTGCAGCCCGGAAGAAGCCT
GAGGCTGTCTTGTGCCGCTAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGCG
GCAGGCCCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCACAACCTGGAACAGCGGCACAA
TCGGCTACGCCGACAGCGTGATGGGCAGATTCACAATCAGCAGAGATAACGCCAAAAACA
GCCTGTATCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCCCTGTACTACTGCGCCA
AGGACCTGCTGCCTGATGATAGAATGGGCGGCGGTGCTTTTGACATCTGGGGACAGGGCA
CCATGGTGACCGTGTCCAGCGCCTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCT
CCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTC
CCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTT
CCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTC
CAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAA
GGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCC
AGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACAC
CCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGA
CCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAA
GCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGC
ACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAG
CCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACA
CCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCA
AAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAAC
AACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAG
CTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCAT
GAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
SEQ ID NO 198 light chain
D13C1 VL - LINKER - D12C1 VL - C lambda
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG
SGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKRTVAAPSVFIFPPQPVLTQPP
SVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVLWYDNTDRPSGIPERFSGSNSGKTAT
LTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVLGQPKAAPSVTLFPPSSEELQANKATL
VCLISDFYPGAVTVAWKADSSPVKAGVETTTPSKQSNNKYAASSYLSLTPEQWKSHRSYSCQV
THEGSTVEKTVAPTECS
SEQ ID NO 199 nucleic acid
GACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGGGCGACAGAGTGACC
ATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGTATCAGCAGAAGCCTG
GCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAATCCGGCGTGCCCTCTA
GATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCTCCAGCCTGCAGCCTG
ACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCCGGACCTTTGGCCAGG
GCACCAAGGTGGAAATCAAGcGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCACA
GCCTGTGCTGACACAGCCCCCCAGCGTGTCCGTCGCCCCTGGCCAAACAGCCACAATCAC
CTGTGGCGGCAACAACATCGGCAGCAAGTCCGTGCACTGGTATCAGCAGAAACCTGGACA
GGCCCCAGTTCTGGTGGTGTACGACAATACCGATAGACCTTCTGGCATCCCTGAGCGGTT
CAGCGGAAGCAACAGCGGCAAGACCGCCACCCTGACCATCAGCAGAGTGGAAGCCGGCG
ACGAGGCTGATTACTACTGCCAGGTGTGGGACAGCTCTAGCGACCACTACGTGTTCGGCA
CCGGCACAAAGGTGACCGTGCTGGGCCAGCCTAAGGCCGCCCCTAGCGTGACCCTGTTC
CCCCCCAGCAGCGAGGAACTGCAGGCCAACAAGGCCACACTGGTGTGCCTGATCAGCGA
CTTCTACCCCGGCGCCGTGACCGTGGCCTGGAAGGCAGATAGCAGCCCTGTGAAGGCCG
GAGTTGAGACAACCACACCTAGCAAGCAGAGCAACAACAAGTACGCCGCTTCTTCTTACCT
GAGCCTGACCCCTGAGCAGTGGAAAAGCCACAGAAGCTACAGCTGCCAGGTGACACACG
AGGGCAGCACCGTGGAAAAGACCGTGGCCCCTACCGAGTGCAGC
ScFv4-Fc format
SEQ ID NO 200
>D12C1-D13C1 scFv4-Fc
Heavy chain
D12C1 VH - LINKER - D12C1 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGTTWNSGTIGYA
DSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLLPDDRMGGGAFDIWGQGTMVTVS
SGGGGSGGGGSGGGGSQPVLTQPPSVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVL
WYDNTDRPSGIPERFSGSNSGKTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL
GSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGK
SEQ ID NO 201 nucleic acid
CAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTGGTGCAGCCCGGAAGAAGCCTGAGGCT
GTCTTGTGCCGCTAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGCGGCAGGC
CCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCACAACCTGGAACAGCGGCACAATCGGCT
ACGCCGACAGCGTGATGGGCAGATTCACAATCAGCAGAGATAACGCCAAAAACAGCCTGT
ATCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACC
TGCTGCCTGATGATAGAATGGGCGGCGGTGCTTTTGACATCTGGGGACAGGGCACCATGG
TGACCGTGTCCAGCGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGGATC
TCAGCCTGTGCTGACACAGCCCCCCAGCGTGTCCGTCGCCCCTGGCCAAACAGCCACAAT
CACCTGTGGCGGCAACAACATCGGCAGCAAGTCCGTGCACTGGTATCAGCAGAAACCTGG
ACAGGCCCCAGTTCTGGTGGTGTACGACAATACCGATAGACCTTCTGGCATCCCTGAGCG
GTTCAGCGGAAGCAACAGCGGCAAGACCGCCACCCTGACCATCAGCAGAGTGGAAGCCG
GCGACGAGGCTGATTACTACTGCCAGGTGTGGGACAGCTCTAGCGACCACTACGTGTTCG
GCACCGGCACAAAGGTGACCGTGCTGGGCTCTTCTgcgTCGACCAAGGGCCCATCGGTCT
TCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTG
GTCAAGGACTACTTCCCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGACCAGC
GGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTG
GTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAG
CCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACAT
GCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAA
AACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACG
TGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATA
ATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTC
CTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAAC
AAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAA
CCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTG
ACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTC
CTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG GGTAAA
SEQ ID NO 202
Light chain
D13C1 VH - LINKER - D13C1 VL - light constant
QVQLQQSGAEVKKPGASVKVSCKASGYSFTSYVIHWVRQAPGQRLEWMGWINTGNGNTEYS
QKFQGRVSITRDTSASTAYMDLSSLRSEDTAVYFCARVPRGYYDRSGYYNAPEYFQHWGQGT
LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKP
GKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKV
EIKRTVAAPSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQD
SKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 203 nucleic acid
CAGGTTCAGTTGCAGCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTG
TCCTGCAAGGCTTCCGGCTACTCCTTCACCTCCTACGTGATCCACTGGGTCCGACAGGCT
CCAGGCCAGAGATTGGAATGGATGGGCTGGATCAACACCGGCAACGGCAACACCGAGTA
CTCCCAGAAATTCCAGGGCAGAGTGTCTATCACCCGGGACACCTCTGCCTCCACCGCCTA
TATGGATCTGTCCTCTCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGTGCC
TCGGGGCTACTACGACAGAAGCGGCTACTACAACGCCCCTGAGTACTTCCAGCATTGGGG
CCAGGGAACCCTGGTCACAGTCTCTTCTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTG
GTGGTGGTGGATCTGACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGG
GCGACAGAGTGACCATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGT
ATCAGCAGAAGCCTGGCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAAT
CCGGCGTGCCCTCTAGATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCT
CCAGCCTGCAGCCTGACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCC
GGACCTTTGGCCAGGGCACCAAGGTGGAAATCAAGcGTACGGTGGCTGCACCATCTGTCT
TCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCT
GAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATC
GGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCA GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAG TCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
SEQ ID NO 204
>D13C1-D12C1 scFv4-Fc
Heavy chain
D13C1 VH - LINKER - D13C1 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
QVQLQQSGAEVKKPGASVKVSCKASGYSFTSYVIHWVRQAPGQRLEWMGWINTGNGNTEYS
QKFQGRVSITRDTSASTAYMDLSSLRSEDTAVYFCARVPRGYYDRSGYYNAPEYFQHWGQGT LVTVSSGGGGSGGGGSGGGGSDIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKP GKAPKLLIYDASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKV
EIKSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQS SGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPS VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV
VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLT CLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVM HEALHNHYTQKSLSLSPGK
SEQ ID NO 205 nucleic acid
CAGGTTCAGTTGCAGCAGTCTGGCGCCGAAGTGAAGAAACCTGGCGCCTCTGTGAAGGTG
TCCTGCAAGGCTTCCGGCTACTCCTTCACCTCCTACGTGATCCACTGGGTCCGACAGGCT
CCAGGCCAGAGATTGGAATGGATGGGCTGGATCAACACCGGCAACGGCAACACCGAGTA
CTCCCAGAAATTCCAGGGCAGAGTGTCTATCACCCGGGACACCTCTGCCTCCACCGCCTA
TATGGATCTGTCCTCTCTGCGGAGCGAGGATACCGCCGTGTACTTCTGTGCCAGAGTGCC
TCGGGGCTACTACGACAGAAGCGGCTACTACAACGCCCCTGAGTACTTCCAGCATTGGGG CCAGGGAACCCTGGTCACAGTCTCTTCTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTG GTGGTGGTGGATCTGACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGG
GCGACAGAGTGACCATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGT
ATCAGCAGAAGCCTGGCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAAT
CCGGCGTGCCCTCTAGATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCT
CCAGCCTGCAGCCTGACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCC
GGACCTTTGGCCAGGGCACCAAGGTGGAAATCAAGTCTTCTgcgTCGACCAAGGGCCCATC
GGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCT
GCCTGGTCAAGGACTACTTCCCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGA
CCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCA
GCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATC
ACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCA
CACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCC
CCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGT
GGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGG
TGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCA
GCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCT
CCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCC
GAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCA
GCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCA
ATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCC
TTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTC
TCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTG
TCTCCGGGTAAA
SEQ ID NO 206
Light chain
D12C1 VH - LINKER - D12C1 VL - light constant
QVQLVESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGTTWNSGTIGYA
DSVMGRFTISRDNAKNSLYLQMNSLRAEDTALYYCAKDLLPDDRMGGGAFDIWGQGTMVTVS
SGGGGSGGGGSGGGGSQPVLTQPPSVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVL
VVYDNTDRPSGIPERFSGSNSGKTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVL
GTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 207 nucleic acid
CAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTGGTGCAGCCCGGAAGAAGCCTGAGGCT
GTCTTGTGCCGCTAGCGGCTTCACCTTCGACGACTACGCCATGCACTGGGTGCGGCAGGC
CCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCACAACCTGGAACAGCGGCACAATCGGCT
ACGCCGACAGCGTGATGGGCAGATTCACAATCAGCAGAGATAACGCCAAAAACAGCCTGT
ATCTGCAGATGAACTCCCTGCGGGCCGAGGACACCGCCCTGTACTACTGCGCCAAGGACC
TGCTGCCTGATGATAGAATGGGCGGCGGTGCTTTTGACATCTGGGGACAGGGCACCATGG
TGACCGTGTCCAGCGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGGATC
TCAGCCTGTGCTGACACAGCCCCCCAGCGTGTCCGTCGCCCCTGGCCAAACAGCCACAAT
CACCTGTGGCGGCAACAACATCGGCAGCAAGTCCGTGCACTGGTATCAGCAGAAACCTGG
ACAGGCCCCAGTTCTGGTGGTGTACGACAATACCGATAGACCTTCTGGCATCCCTGAGCG
GTTCAGCGGAAGCAACAGCGGCAAGACCGCCACCCTGACCATCAGCAGAGTGGAAGCCG
GCGACGAGGCTGATTACTACTGCCAGGTGTGGGACAGCTCTAGCGACCACTACGTGTTCG
GCACCGGCACAAAGGTGACCGTGCTGGGCACGGTGGCTGCACCATCTGTCTTCATCTTCC
CGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTT
CTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTC
CCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC
TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATC
AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
SEQ ID NO 208
>S4A_84-S4B_152 scFv4-Fc
Heavy chain
S4A_84 VH - LINKER - S4A_84 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWLSFISGNGGAIYHAD
SVKGRFTVSRDNFKNALYLQMNSLKAEDTAVYYCAKGYYYDDGGYSGREDAFDIWGQGTMV
TVSSGGGGSGGGGSGGGGSDIQMTQSPSAMSASVGDRVTITCRASQGISNFLAWFQQKPGK
VPKRLIYAANSLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYYCLQHSSHPYTFGPGTKVEIK
RSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE
ALHNHYTQKSLSLSPGK
SEQ ID NO 209
Light chain
S4B_152 VH - LINKER - S4B_152 VL - light constant domain
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYVISWVRQAPGQGLELMGGIIPIIGTANYAQKF
QGRVTITTDESTSTVYMELSSLRPEDTAVYYCARSSDPIDTADWYFNLWGRGTLVTVSSGGGG
SGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNFLAWYQQKPGQPPK
LLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPLFGGGTKVEITRTVA
APSVFIFPPSDEQLKSGTASWCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 210
>S4A_84-S4B_152 scFv4-Fc
Heavy chain
S4B_152 VH - LINKER - S4B_152 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
QVQLVQSGAEVKKPGSSVKVSCKASGGTFSRYVISWVRQAPGQGLELMGGIIPIIGTANYAQKF QGRVTITTDESTSTVYMELSSLRPEDTAVYYCARSSDPIDTADWYFNLWGRGTLVTVSSGGGG SGGGGSGGGGSDIVMTQSPDSLAVSLGERATINCKSSQSVLYSSNNKNFLAWYQQKPGQPPK LLIYWASTRESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQYYSIPLFGGGTKVEITRSSA STKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYS
LSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPP KPKDTLMISRTPEVTCWVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWSVLTV LHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGF YPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN
HYTQKSLSLSPGK
SEQ ID NO 211
Light chain
S4A_84 VH - LINKER - S4A_84 VL - light constant domain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWLSFISGNGGAIYHAD SVKGRFTVSRDNFKNALYLQMNSLKAEDTAVYYCAKGYYYDDGGYSGREDAFDIWGQGTMV TVSSGGGGSGGGGSGGGGSDIQMTQSPSAMSASVGDRVTITCRASQGISNFLAWFQQKPGK VPKRLIYAANSLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYYCLQHSSHPYTFGPGTKVEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 212
>S4A_84-S4B_222 scFv4-Fc
Heavy chain
S4A_84 VH - LINKER - S4A_84 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWLSFISGNGGAIYHAD SVKGRFTVSRDNFKNALYLQMNSLKAEDTAVYYCAKGYYYDDGGYSGREDAFDIWGQGTMV TVSSGGGGSGGGGSGGGGSDIQMTQSPSAMSASVGDRVTITCRASQGISNFLAWFQQKPGK VPKRLIYAANSLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYYCLQHSSHPYTFGPGTKVEIK
RSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
GLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVF
LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCL
VKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHE ALHNHYTQKSLSLSPGK
SEQ ID NO 213
Light chain
S4B_222 VH - LINKER - S4B_222 VL - light constant domain
QVQLVQSGAEVKKPGSSLKVSCRASGDTFSSFAISWVRQAPGQGLEWMGGVIPIFGTANYAQ
KFQGRVTITTDESTSTAYMELSSLTSEDTAVYYCARCPKLSPTVYNYEYYMDVWGKGTTVSVS
SGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDIGTYNYVSWYQQLPGKA
PKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYISSNTWYVFGTGTKVT
VLGTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 214
>S4B_222-S4A_84 scFv4-Fc
Heavy chain
S4B_222 VH - LINKER - S4B_222 VL - Heavy constant domain (CH1-Hinge-CH2-CH3)
QVQLVQSGAEVKKPGSSLKVSCRASGDTFSSFAISWVRQAPGQGLEWMGGVIPIFGTANYAQ
KFQGRVTITTDESTSTAYMELSSLTSEDTAVYYCARCPKLSPTVYNYEYYMDVWGKGTTVSVS
SGGGGSGGGGSGGGGSQSALTQPASVSGSPGQSITISCTGTSSDIGTYNYVSWYQQLPGKA
PKLMIYDVSNRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYCSSYISSNTWYVFGTGTKVT
VLGSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQ
SSGLYSLSSWTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGP
SVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
WSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSL
TCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGK
SEQ ID NO 215
Light chain
S4A_84 VH - LINKER - S4A_84 VL - light constant domain
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYAMNWVRQAPGKGLEWLSFISGNGGAIYHAD
SVKGRFTVSRDNFKNALYLQMNSLKAEDTAVYYCAKGYYYDDGGYSGREDAFDIWGQGTMV
TVSSGGGGSGGGGSGGGGSDIQMTQSPSAMSASVGDRVTITCRASQGISNFLAWFQQKPGK
VPKRLIYAANSLQSGVPSRFSGSGYGTEFTLTISSLQPEDFATYYCLQHSSHPYTFGPGTKVEIK
RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
IqG-scFv format
SEQ ID NO 216
>D13C1-D12C1 IgG-scFv
Heavy chain
D13C1 VH - Constant heavy - LINKER - D12C1 VH - LINKER - D12C1 VL
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG
SGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGECGGGGSGGGGSGGGGSQVQLVESGGGLVQPGRSLRLSC
AASGFTFDDYAMHWVRQAPGKGLEWVSGTTWNSGTIGYADSVMGRFTISRDNAKNSLYLQM
NSLRAEDTALYYCAKDLLPDDRMGGGAFDIWGQGTMVTVSSGGGGSGGGGSGGGGSQPVL
TQPPSVSVAPGQTATITCGGNNIGSKSVHWYQQKPGQAPVLVVYDNTDRPSGIPERFSGSNS GKTATLTISRVEAGDEADYYCQVWDSSSDHYVFGTGTKVTVLG
SEQ ID NO 217 nucleic acid
GACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGGGCGACAGAGTGACC
ATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGTATCAGCAGAAGCCTG
GCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAATCCGGCGTGCCCTCTA
GATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCTCCAGCCTGCAGCCTG
ACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCCGGACCTTTGGCCAGG
GCACCAAGGTGGAAATCAAGcGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATC
TGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAG
AGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCT
GAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT
GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGTGGCGGCGGAGGAAGCGGAG
GCGGAGGTTCTGGTGGTGGTGGATCTCAAGTGCAGCTGGTGGAAAGCGGCGGCGGACTG
GTGCAGCCCGGAAGAAGCCTGAGGCTGTCTTGTGCCGCTAGCGGCTTCACCTTCGACGAC
TACGCCATGCACTGGGTGCGGCAGGCCCCTGGCAAGGGCCTCGAGTGGGTCAGCGGCAC
AACCTGGAACAGCGGCACAATCGGCTACGCCGACAGCGTGATGGGCAGATTCACAATCAG
CAGAGATAACGCCAAAAACAGCCTGTATCTGCAGATGAACTCCCTGCGGGCCGAGGACAC
CGCCCTGTACTACTGCGCCAAGGACCTGCTGCCTGATGATAGAATGGGCGGCGGTGCTTT
TGACATCTGGGGACAGGGCACCATGGTGACCGTGTCCAGCGGCGGCGGAGGAAGCGGA
GGCGGAGGTTCTGGTGGTGGTGGATCTCAGCCTGTGCTGACACAGCCCCCCAGCGTGTC
CGTCGCCCCTGGCCAAACAGCCACAATCACCTGTGGCGGCAACAACATCGGCAGCAAGTC
CGTGCACTGGTATCAGCAGAAACCTGGACAGGCCCCAGTTCTGGTGGTGTACGACAATAC
CGATAGACCTTCTGGCATCCCTGAGCGGTTCAGCGGAAGCAACAGCGGCAAGACCGCCA
CCCTGACCATCAGCAGAGTGGAAGCCGGCGACGAGGCTGATTACTACTGCCAGGTGTGG
GACAGCTCTAGCGACCACTACGTGTTCGGCACCGGCACAAAGGTGACCGTGCTGGGC
SEQ ID NO 218
Light chain
D13C1 VL - Constant light
DIQMTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYDASSLESGVPSRFSG
SGSGTEFTLTISSLQPDDFATYYCQQYNSYSRTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSG
TASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKV
YACEVTHQGLSSPVTKSFNRGEC
SEQ ID NO 219
GACATCCAGATGACCCAGTCTCCATCCACACTGTCCGCCTCTGTGGGCGACAGAGTGACC
ATCACCTGTCGGGCCTCTCAGTCCATCTCTTCTTGGCTGGCCTGGTATCAGCAGAAGCCTG
GCAAGGCTCCCAAGCTGCTGATCTACGATGCCTCCTCTCTGGAATCCGGCGTGCCCTCTA
GATTCTCCGGCTCTGGATCTGGCACCGAGTTTACCCTGACAATCTCCAGCCTGCAGCCTG
ACGACTTCGCCACCTACTACTGCCAGCAGTACAACTCCTACAGCCGGACCTTTGGCCAGG
GCACCAAGGTGGAAATCAAGcGTACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATC
TGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCC
AGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAG
AGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCCTGACGCT
GAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCT
GAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
S4A_84-S4B_152 scFv4-Fc HC SEQ ID NO. 220
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAACTACGCCATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGACTGGAATGGCTGAGCTTCATCAGCGGCAATGGCGGAGCCATCTACCA
CGCCGATTCTGTGAAGGGCAGATTCACCGTGTCCAGGGACAACTTCAAGAACGCCCTGTA
CCTCCAGATGAACAGCCTGAAGGCCGAGGACACCGCCGTGTACTATTGTGCCAAGGGCTA
CTACTACGACGATGGCGGCTACAGCGGAAGAGAGGACGCCTTTGATATCTGGGGCCAGG
GCACAATGGTCACAGTGTCTAGT
GGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGGATCT
GACATCCAGATGACACAGAGCCCTAGCGCCATGTCTGCCAGCGTGGGAGACAGAGTGAC
CATCACCTGTAGAGCCAGCCAGGGCATCAGCAACTTTCTGGCCTGGTTCCAGCAGAAACC
CGGCAAGGTGCCCAAGAGACTGATCTACGCCGCCAACTCTCTCCAGAGCGGAGTGCCTAG
CAGATTTTCCGGCAGCGGCTACGGCACCGAGTTCACCCTGACAATATCCAGCCTCCAGCC
TGAGGACTTCGCCACCTACTACTGTCTCCAGCACAGCTCTCACCCCTACACATTTGGCCCT
GGCACCAAGGTGGAAATCAAG
TCTTCTgcgTCGACCAAGGGCCCATCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCT
CTGGGGGCACAGCGGCCCTGGGCTGCCTGGTCAAGGACTACTTCCCCGAACCTGTGACG
GTCTCGTGGAACTCAGGCGCCCTGACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACA
GTCCTCAGGACTCTACTCCCTCAGCAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCAC
CCAGACCTACATCTGCAACGTGAATCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGT
TGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCAGCACCTGAACTCCTG
GGGGGACCGTCAGTCTTCCTCTTCCCCCCAAAACCCAAGGACACCCTCATGATCTCCCGG
ACCCCTGAGGTCACATGCGTGGTGGTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTC
AACTGGTACGTGGACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCA
GTACAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAA
TGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAAC
CATCTCCAAAGCCAAAGGGCAGCCCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCG
GGATGAGCTGACCAAGAACCAGGTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAG
CGACATCGCCGTGGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACTACAAGACCACGC
CTCCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGA
GCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACC
ACTACACGCAGAAGAGCCTCTCCCTGTCTCCGGGTAAA
S4A_84-S4B_152 scFv4-Fc LC SEQ ID NO. 221
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGT
GTCCTGCAAAGCTAGCGGCGGCACCTTCAGCAGATACGTGATCAGCTGGGTCCGACAGG
CCCCTGGACAAGGACTGGAACTGATGGGCGGCATCATCCCCATCATCGGCACAGCCAATT
ACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACCAGCACCGTGT
ACATGGAACTGAGCAGCCTGAGGCCTGAGGACACCGCCGTGTACTACTGTGCCAGAAGCA
GCGACCCTATCGATACCGCCGACTGGTACTTCAACCTGTGGGGCAGAGGCACCCTGGTCA CAGTCTCTTCT
GGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGGATCT
GACATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACC
ATCAACTGCAAGAGCAGCCAGAGCGTGCTGTACTCCAGCAACAACAAGAACTTCCTGGCC
TGGTATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGA
GAAAGCGGCGTGCCCGATAGATTTTCTGGCAGCGGCTCTGGCACCGACTTCACCCTGACA
ATTAGCAGCCTCCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGTACTACAGCATC
CCTCTGTTCGGCGGAGGCACCAAGGTGGAAATCACA
ACGGTGGCTGCACCATCTGTCTTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAA
CTGCCTCTGTTGTGTGCCTGCTGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAA
GGTGGATAACGCCCTCCAATCGGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAA
GGACAGCACCTACAGCCTCAGCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACA
CAAAGTCTACGCCTGCGAAGTCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTT CAACAGGGGAGAGTGT
S4B_152-S4A_84 scFv4-Fc HC SEQ ID NO. 222
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAACCTGGCAGCAGCGTGAAGGT
GTCCTGCAAAGCTAGCGGCGGCACCTTCAGCAGATACGTGATCAGCTGGGTCCGACAGG
CCCCTGGACAAGGACTGGAACTGATGGGCGGCATCATCCCCATCATCGGCACAGCCAATT
ACGCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACCAGCACCGTGT
ACATGGAACTGAGCAGCCTGAGGCCTGAGGACACCGCCGTGTACTACTGTGCCAGAAGCA
GCGACCCTATCGATACCGCCGACTGGTACTTCAACCTGTGGGGCAGAGGCACCCTGGTCA
CAGTCTCTTCTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGGATCTGAC
ATCGTGATGACACAGAGCCCTGATAGCCTGGCCGTGTCTCTGGGAGAGAGAGCCACCATC
AACTGCAAGAGCAGCCAGAGCGTGCTGTACTCCAGCAACAACAAGAACTTCCTGGCCTGG
TATCAGCAGAAGCCCGGCCAGCCTCCTAAGCTGCTGATCTACTGGGCCAGCACCAGAGAA
AGCGGCGTGCCCGATAGATTTTCTGGCAGCGGCTCTGGCACCGACTTCACCCTGACAATT
AGCAGCCTCCAGGCCGAGGATGTGGCCGTGTACTACTGCCAGCAGTACTACAGCATCCCT
CTGTTCGGCGGAGGCACCAAGGTGGAAATCACATCTTCTgcgTCGACCAAGGGCCCATCGG
TCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGC
CTGGTCAAGGACTACTTCCCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGACC
AGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGC
GTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCAC
AAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACA
CATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCC
CAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGG
ACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTG
CATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGC
GTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCC
AACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGA
GAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGC
CTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAAT
GGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTT
CTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTC
ATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTC TCCGGGTAAA
S4B_152-S4A_84 scFv4-Fc LC SEQ ID NO. 223
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAACTACGCCATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGACTGGAATGGCTGAGCTTCATCAGCGGCAATGGCGGAGCCATCTACCA
CGCCGATTCTGTGAAGGGCAGATTCACCGTGTCCAGGGACAACTTCAAGAACGCCCTGTA
CCTCCAGATGAACAGCCTGAAGGCCGAGGACACCGCCGTGTACTATTGTGCCAAGGGCTA
CTACTACGACGATGGCGGCTACAGCGGAAGAGAGGACGCCTTTGATATCTGGGGCCAGG
GCACAATGGTCACAGTGTCTAGTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGT
GGTGGATCTGACATCCAGATGACACAGAGCCCTAGCGCCATGTCTGCCAGCGTGGGAGAC
AGAGTGACCATCACCTGTAGAGCCAGCCAGGGCATCAGCAACTTTCTGGCCTGGTTCCAG
CAGAAACCCGGCAAGGTGCCCAAGAGACTGATCTACGCCGCCAACTCTCTCCAGAGCGGA
GTGCCTAGCAGATTTTCCGGCAGCGGCTACGGCACCGAGTTCACCCTGACAATATCCAGC
CTCCAGCCTGAGGACTTCGCCACCTACTACTGTCTCCAGCACAGCTCTCACCCCTACACAT
TTGGCCCTGGCACCAAGGTGGAAATCAAGACGGTGGCTGCACCATCTGTCTTCATCTTCC
CGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTT
CTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTC
CCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC
TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATC AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
S4A_84-S4B_222 scFv4-Fc HC SEQ ID NO. 224
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAACTACGCCATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGACTGGAATGGCTGAGCTTCATCAGCGGCAATGGCGGAGCCATCTACCA
CGCCGATTCTGTGAAGGGCAGATTCACCGTGTCCAGGGACAACTTCAAGAACGCCCTGTA
CCTCCAGATGAACAGCCTGAAGGCCGAGGACACCGCCGTGTACTATTGTGCCAAGGGCTA
CTACTACGACGATGGCGGCTACAGCGGAAGAGAGGACGCCTTTGATATCTGGGGCCAGG
GCACAATGGTCACAGTGTCTAGTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGT
GGTGGATCTGACATCCAGATGACACAGAGCCCTAGCGCCATGTCTGCCAGCGTGGGAGAC
AGAGTGACCATCACCTGTAGAGCCAGCCAGGGCATCAGCAACTTTCTGGCCTGGTTCCAG
CAGAAACCCGGCAAGGTGCCCAAGAGACTGATCTACGCCGCCAACTCTCTCCAGAGCGGA
GTGCCTAGCAGATTTTCCGGCAGCGGCTACGGCACCGAGTTCACCCTGACAATATCCAGC
CTCCAGCCTGAGGACTTCGCCACCTACTACTGTCTCCAGCACAGCTCTCACCCCTACACAT
TTGGCCCTGGCACCAAGGTGGAAATCAAGTCTTCTgcgTCGACCAAGGGCCCATCGGTCTT
CCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGGCTGCCTGG
TCAAGGACTACTTCCCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCTGACCAGCG
GCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAGCAGCGTGG
TGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAATCACAAGC
CCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACTCACACATG
CCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTCCCCCCAAA
ACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTGGTGGACGT
GAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGAGGTGCATAA
TGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGGTCAGCGTCC
TCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACA
AAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAGGTCAGCCTGA
CCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAGAGCAATGGG
CAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGGCTCCTTCTTC
CTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGC
TCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCG GGTAAA
S4A_84-S4B_222 scFv4-Fc LC SEQ ID NO. 225
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAGCCTGGCAGCTCTCTGAAGGTG
TCCTGTAGAGCCAGCGGCGACACCTTTAGCAGCTTCGCCATCAGCTGGGTCCGACAGGCT
CCTGGACAAGGCTTGGAATGGATGGGCGGCGTGATCCCTATCTTCGGCACAGCCAATTAC
GCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACAAGCACCGCCTAC
ATGGAACTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTACTGTGCCAGATGTCCC
AAGCTGAGCCCCACCGTGTACAACTACGAGTACTACATGGACGTGTGGGGCAAGGGCACC
ACCGTGTCTGTTTCTTCTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGG
ATCTCAGTCTGCTCTGACACAGCCTGCCTCTGTGTCTGGCTCTCCTGGCCAGAGCATCACC
ATCAGCTGTACCGGCACCAGCAGCGACATCGGCACCTACAATTACGTGTCCTGGTATCAG
CAGCTGCCCGGCAAGGCCCCTAAGCTGATGATCTACGACGTGTCCAACAGACCCAGCGG
CGTGTCCAATAGATTCTCCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATTTCTGG
ACTGCAAGCCGAGGACGAGGCCGACTACTACTGCTCCAGCTACATCAGCAGCAACACTTG
GTACGTGTTCGGCACCGGCACAAAAGTGACCGTGCTTggcACGGTGGCTGCACCATCTGTC
TTCATCTTCCCGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGC
TGAATAACTTCTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATC
GGGTAACTCCCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCA
GCAGCACCCTGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAG TCACCCATCAGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
S4B_222-S4A_84 scFv4-Fc HC SEQ ID NO. 226
CAGGTTCAGCTGGTTCAGTCTGGCGCCGAAGTGAAGAAGCCTGGCAGCTCTCTGAAGGTG
TCCTGTAGAGCCAGCGGCGACACCTTTAGCAGCTTCGCCATCAGCTGGGTCCGACAGGCT
CCTGGACAAGGCTTGGAATGGATGGGCGGCGTGATCCCTATCTTCGGCACAGCCAATTAC
GCCCAGAAATTCCAGGGCAGAGTGACCATCACCACCGACGAGAGCACAAGCACCGCCTAC
ATGGAACTGAGCAGCCTGACCAGCGAGGACACCGCCGTGTACTACTGTGCCAGATGTCCC
AAGCTGAGCCCCACCGTGTACAACTACGAGTACTACATGGACGTGTGGGGCAAGGGCACC
ACCGTGTCTGTTTCTTCTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGTGGTGG ATCTCAGTCTGCTCTGACACAGCCTGCCTCTGTGTCTGGCTCTCCTGGCCAGAGCATCACC ATCAGCTGTACCGGCACCAGCAGCGACATCGGCACCTACAATTACGTGTCCTGGTATCAG
CAGCTGCCCGGCAAGGCCCCTAAGCTGATGATCTACGACGTGTCCAACAGACCCAGCGG
CGTGTCCAATAGATTCTCCGGCAGCAAGAGCGGCAACACCGCCAGCCTGACAATTTCTGG
ACTGCAAGCCGAGGACGAGGCCGACTACTACTGCTCCAGCTACATCAGCAGCAACACTTG
GTACGTGTTCGGCACCGGCACAAAAGTGACCGTGCTTTCTTCTgcgTCGACCAAGGGCCCA TCGGTCTTCCCCCTGGCACCCTCCTCCAAGAGCACCTCTGGGGGCACAGCGGCCCTGGG CTGCCTGGTCAAGGACTACTTCCCCGAACCTGTGACGGTCTCGTGGAACTCAGGCGCCCT
GACCAGCGGCGTGCACACCTTCCCGGCTGTCCTACAGTCCTCAGGACTCTACTCCCTCAG
CAGCGTGGTGACCGTGCCCTCCAGCAGCTTGGGCACCCAGACCTACATCTGCAACGTGAA
TCACAAGCCCAGCAACACCAAGGTGGACAAGAAAGTTGAGCCCAAATCTTGTGACAAAACT
CACACATGCCCACCGTGCCCAGCACCTGAACTCCTGGGGGGACCGTCAGTCTTCCTCTTC
CCCCCAAAACCCAAGGACACCCTCATGATCTCCCGGACCCCTGAGGTCACATGCGTGGTG
GTGGACGTGAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGGACGGCGTGGA
GGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTACAACAGCACGTACCGTGTGG TCAGCGTCCTCACCGTCCTGCACCAGGACTGGCTGAATGGCAAGGAGTACAAGTGCAAGG TCTCCAACAAAGCCCTCCCAGCCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGC
CCCGAGAACCACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCCAGCGACATCGCCGTGGAGTGGGAG
AGCAATGGGCAGCCGGAGAACAACTACAAGACCACGCCTCCCGTGCTGGACTCCGACGG
CTCCTTCTTCCTCTACAGCAAGCTCACCGTGGACAAGAGCAGGTGGCAGCAGGGGAACGT CTTCTCATGCTCCGTGATGCATGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCC CTGTCTCCGGGTAAA
S4B_222-S4A_84 scFv4-Fc LC SEQ ID NO. 227
GAGGTGCAGCTGGTTGAATCTGGCGGAGGACTGGTTCAGCCTGGCGGATCTCTGAGACT
GTCTTGTGCCGCCAGCGGCTTCACCTTCAGCAACTACGCCATGAACTGGGTCCGACAGGC
CCCTGGCAAAGGACTGGAATGGCTGAGCTTCATCAGCGGCAATGGCGGAGCCATCTACCA
CGCCGATTCTGTGAAGGGCAGATTCACCGTGTCCAGGGACAACTTCAAGAACGCCCTGTA
CCTCCAGATGAACAGCCTGAAGGCCGAGGACACCGCCGTGTACTATTGTGCCAAGGGCTA
CTACTACGACGATGGCGGCTACAGCGGAAGAGAGGACGCCTTTGATATCTGGGGCCAGG GCACAATGGTCACAGTGTCTAGTGGCGGCGGAGGAAGCGGAGGCGGAGGTTCTGGTGGT
GGTGGATCTGACATCCAGATGACACAGAGCCCTAGCGCCATGTCTGCCAGCGTGGGAGAC
AGAGTGACCATCACCTGTAGAGCCAGCCAGGGCATCAGCAACTTTCTGGCCTGGTTCCAG
CAGAAACCCGGCAAGGTGCCCAAGAGACTGATCTACGCCGCCAACTCTCTCCAGAGCGGA
GTGCCTAGCAGATTTTCCGGCAGCGGCTACGGCACCGAGTTCACCCTGACAATATCCAGC
CTCCAGCCTGAGGACTTCGCCACCTACTACTGTCTCCAGCACAGCTCTCACCCCTACACAT
TTGGCCCTGGCACCAAGGTGGAAATCAAGACGGTGGCTGCACCATCTGTCTTCATCTTCC
CGCCATCTGATGAGCAGTTGAAATCTGGAACTGCCTCTGTTGTGTGCCTGCTGAATAACTT
CTATCCCAGAGAGGCCAAAGTACAGTGGAAGGTGGATAACGCCCTCCAATCGGGTAACTC
CCAGGAGAGTGTCACAGAGCAGGACAGCAAGGACAGCACCTACAGCCTCAGCAGCACCC
TGACGCTGAGCAAAGCAGACTACGAGAAACACAAAGTCTACGCCTGCGAAGTCACCCATC
AGGGCCTGAGCTCGCCCGTCACAAAGAGCTTCAACAGGGGAGAGTGT
D12C2 scFv SEQ ID NO. 228
QVQLVQSGAEVKKPGSSVKVSCKTSGDTFSNYAVNWVRQAPGQGLEWMGRIIPIPGIADYAQ
KFQGRVTITADKSTSTAYMELSSLRSEDTAVYYCARDYGGNNDAFDIWGQGTMVTVSSGGGG
SGGGGSGGGGSQSVLTQPPSVSAAPGQKVTISCSGSSSNIGSNYVSWYQQVPGTAPKLLIYE
YNKRPSGIPDRFSGSKSGTSATLGITGLQTGDEADYYCGTWDSSLSAGVFGGGTKLTVL
D12C2 scFv SEQ ID NO. 229 nucleic acid
CAGGTGCAGCTGGTGCAATCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGT
CTCCTGCAAGACTTCTGGAGACACCTTCAGCAACTATGCTGTCAACTGGGTGCGACAGGC
CCCTGGACAAGGGCTTGAGTGGATGGGAAGGATCATCCCCATCCCTGGTATAGCAGACTA
CGCACAGAAATTCCAGGGCAGAGTCACGATTACCGCGGACAAATCCACGAGTACAGCCTA
CATGGAGCTGAGCAGCCTGAGATCTGAAGACACGGCCGTGTATTACTGTGCGAGAGACTA
CGGTGGTAACAATGATGCTTTTGATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA
GGTGGCGGTGGCAGCGGCGGCGGCGGAAGCGGAGGTGGTGGCAGCCAGTCTGTGTTGA
CGCAGCCGCCCTCAGTGTCTGCGGCCCCAGGACAGAAGGTCACCATCTCCTGCTCTGGTA
GCAGCTCCAACATTGGGAGTAATTATGTATCCTGGTACCAGCAGGTCCCAGGAACAGCCC
CCAAACTCCTCATCTATGAATATAATAAGCGACCCTCAGGTATTCCTGACCGATTCTCTGGC
TCCAAGTCTGGCACGTCAGCCACCCTGGGCATCACCGGACTCCAGACTGGGGACGAGGC
CGATTATTACTGCGGAACATGGGATAGCAGCCTGAGTGCTGGGGTGTTCGGCGGAGGGA
CCAAGCTCACCGTCCTA
Claims
1. An isolated antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein wherein said isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively; iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or
95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
2. The isolated antibody or antigen-binding fragment thereof according to claim 1 comprising i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto; ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or viii) a VH region of SEQ ID NO: 61 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
3. The isolated antibody or antigen-binding fragment thereof according to claim 1 or 2 comprising a human heavy chain constant region.
4. The antibody or antigen-binding fragment thereof according to claim 3, wherein the heavy chain constant region is selected from IgG and IgM.
5. The antibody or antigen-binding fragment thereof according to any a preceding claim, wherein the antibody or antigen-binding fragment comprises a light chain constant region.
6. The antibody or antigen-binding fragment thereof according to claim 5 wherein the light chain constant region is a kappa light chain constant region.
7. The antibody or antigen-binding fragment thereof according to claim 5, wherein the light chain constant region is a lambda light chain constant region.
8. The antibody or antigen-binding fragment thereof according to any preceding claim, wherein the antibody is a full-length antibody.
9. The antibody or antigen-binding fragment thereof according to any of claims 1 to 7, wherein the antigen-binding fragment comprises a Fab, Fab', F(ab')2, F(ab')3, Fabc, Fd, single chain FV (scFv), (scFv)2, Fv, scFv-Fc, heavy chain only antibody, diabody, tetrabody, triabody, minibody, or single domain antibody.
10. The antibody or antigen-binding fragment thereof according to any preceding claim, wherein the antibody or antigen-binding fragment neutralizes SARS-CoV-2.
11. The antibody or antigen-binding fragment thereof according to any preceding claim, wherein the antibody comprises a further moiety.
12. The antibody or antigen-binding fragment thereof according to any preceding claim, wherein the further moiety is a detectable label, toxin or half-life extending moiety.
13. The antibody or antigen-binding fragment thereof according to any preceding claim which is linked to a second antibody or antigen-binding fragment thereof that specifically binds to the receptor binding domain (RBD) region of the SARS-CoV-2 Spike (S) protein.
14. The antibody or antigen-binding fragment thereof according to claim 13 wherein said antibody or antigen-binding fragment binds to a first epitope and the second antibody or antigenbinding fragment binds to a second epitope.
15. The antibody or antigen-binding fragment thereof according to claim 13 wherein the first and second antibody are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
16. A polynucleotide encoding an antibody or antigen-binding fragment thereof according to any preceding claim.
17. A vector comprising a polynucleotide according to claim 16.
18. A host cell comprising a polynucleotide according to claim 16 or a vector according to claim 17.
19. A method of making the antibody or antigen-binding fragment according to any one of claims 1 to 16 comprising (a) culturing a cell according to claim 18; and (b) isolating the antibody or antigen-binding fragment thereof or the protein from the cultured cell.
20. A binding molecule comprising a) a first antibody or antibody binding fragment thereof directed against a first epitope located in the RBD region of the Spike protein of SARS-CoV-2 and b) a second antibody or antibody fragment thereof directed against a second epitope located in the RBD region of the Spike protein of SARS-CoV-2.
21 . The binding molecule according to claim 20 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; ii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 1 1 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 11 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively; iii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 18, 19 and 20, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 18, 19 and 20, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 22, 23 and 24, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 22, 23 and 24 respectively;
iv) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 26, 27 and 28, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 26, 27 and 28, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 30, 31 and 32, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 30, 31 and 32 respectively; v) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively; vi) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 42, 43 and 44, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 42, 43 and 44, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 46, 47 and 48, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 46, 47 and 48 respectively; vii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively; or viii) a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively.
22. The binding molecule according to claim 20 or 21 wherein said first and/or said second isolated antibody or antigen-binding fragment thereof comprises i) a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
ii) a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iii) a VH region of SEQ ID NO: 21 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 25 or a sequence with at least 80%, 90% or 95% sequence identity thereto; iv) a VH region of SEQ ID NO: 29 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 33 or a sequence with at least 80%, 90% or 95% sequence identity thereto; v) a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vi) a VH region of SEQ ID NO: 45 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 49 or a sequence with at least 80%, 90% or 95% sequence identity thereto; vii) vii) a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or a VH region of SEQ ID NO: 61 thereto or viii) or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
23. The binding molecule according to claim 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 2, 3 and 4, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 2, 3 and 4 respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 6, 7 and 8, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 6, 7 and 8 respectively; and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 10, 11 and 12, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 10, 1 1 and 12, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 14, 15 and 16, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 14, 15 and 16 respectively.
24. The binding molecule according to any of claims 20 to 23 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 5 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID
NO: 9 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 13 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 17 or a sequence with at least 80%, 90% or 95% sequence identity thereto;
25. The binding molecule according to claim 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 50, 51 and 52, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 50, 51 and 52, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 54, 55 and 56, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 54, 55 and 56 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively.
26. The binding molecule according to any of claims 20 to 22 or 25 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 53 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 57 or a sequence with at least 80%, 90% or 95% sequence identity thereto; or a VH region of SEQ ID NO: 61 thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
27. The binding molecule according to claim 20 or 21 wherein said first isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 58, 59 and 60, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 58, 59 and 60, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 62, 63 and 64, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 62, 63 and 64 respectively and said second isolated antibody or antigen-binding fragment thereof comprises a heavy chain variable region that comprises HCDR1 , HCDR2, and HCDR3 comprising the amino acid sequences of SEQ ID NOs: 34, 35 and 36, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 34, 35 and 36, respectively, and a light chain variable region that comprises LCDR1 , LCDR2 and LCDR3 comprising the amino acid sequences of SEQ ID NOs: 38, 39 and 40, or a sequence with at least 80%, 90% or 95% sequence identity to SEQ ID NOs: 38, 39 and 40 respectively
28. The binding molecule according to any of claims 20 to 22 or 27 wherein said first isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 61 a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 65 or a sequence with at least 80%, 90% or 95% sequence identity thereto and said second isolated antibody or antigen-binding fragment thereof comprises a VH region of SEQ ID NO: 37 or a sequence with at least 80%, 90% or 95% sequence identity thereto and a VL region of SEQ ID NO: 41 or a sequence with at least 80%, 90% or 95% sequence identity thereto.
29. The binding molecule according to any of claims 20 to 28 wherein the first and second isolated antibody or antigen-binding fragment thereof are combined in a dual variable domain (DVD), scFv4-Fc or IgG-scFv format.
30. A combination therapy comprising at least two antibodies or antigen-binding fragments thereof according to any of claims 1 to 15, a binding molecule according to any of claims 20 to 29 or a pharmaceutical composition according to claim 31 .
31 . A pharmaceutical composition comprising one or more isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15 or a binding molecule according to any of claims 20 to 29.
32. An isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15, a binding molecule according to any of claims 20 to 29 or a pharmaceutical composition according to claim 31 for use as a medicament.
33. An isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15, a binding molecule according to any of claims 20 to 29 or a pharmaceutical composition according to claim 31 for use in the treatment of a SARS-CoV-2 infection.
34. A method of treatment of a patient suffering from a SARS-CoV-2 infection comprising administering an isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15, a binding molecule according to any of claims 20 to 29 or a pharmaceutical composition according to claim 31 to said patient.
35. The isolated antibody or antigen-binding fragment thereof, binding molecule or pharmaceutical composition for use according to claim 32 or the method of claim 34, wherein the subject is further receiving or has received an anti-viral treatment.
36. The isolated antibody or antigen-binding fragment thereof, binding molecule or method of claim 35, wherein the anti-viral treatment is selected from remdesivir, supplemental oxygen, ventilation therapy, respiration therapy, dexamethasone, tocilizumab, or any combination thereof.
37. A method for diagnosing a SARS-CoV-2 infection comprising detecting SARS-CoV-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigenbinding fragment thereof according to claims 1 to 15.
38. A method for monitoring disease progression comprising detecting SARS-Cov-2 particles or SARS-CoV-2 viral components in a sample using an isolated antibody or antigen-binding fragment thereof according to claims 1 to 15.
39. A method for detecting the presence of SARS-CoV-2 particles or SARS-CoV-2 viral components in a test subject comprising contacting a test sample with an isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15.
40. A kit comprising an isolated antibody or antigen-binding fragment thereof according to any of claims 1 to 15, a binding molecule according to any of claims 20 to 29 or a pharmaceutical composition according to claim 31 and optionally instructions for use.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2210573.8 | 2022-07-19 | ||
GBGB2210573.8A GB202210573D0 (en) | 2022-07-19 | 2022-07-19 | Antibodies against SARS-CoV-2 and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024018205A1 true WO2024018205A1 (en) | 2024-01-25 |
Family
ID=84540120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2023/051898 WO2024018205A1 (en) | 2022-07-19 | 2023-07-19 | Antibodies against sars-cov-2 and uses thereof |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB202210573D0 (en) |
WO (1) | WO2024018205A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021205184A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Polypeptide |
WO2022122788A1 (en) * | 2020-12-09 | 2022-06-16 | Institute For Research In Biomedicine | Multispecific antibodies against severe acute respiratory syndrome coronavirus 2 |
WO2022136685A1 (en) * | 2020-12-23 | 2022-06-30 | Vib Vzw | Antibody compositions for treatment of corona virus infection |
-
2022
- 2022-07-19 GB GBGB2210573.8A patent/GB202210573D0/en active Pending
-
2023
- 2023-07-19 WO PCT/GB2023/051898 patent/WO2024018205A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021205184A1 (en) * | 2020-04-09 | 2021-10-14 | Autolus Limited | Polypeptide |
WO2022122788A1 (en) * | 2020-12-09 | 2022-06-16 | Institute For Research In Biomedicine | Multispecific antibodies against severe acute respiratory syndrome coronavirus 2 |
WO2022136685A1 (en) * | 2020-12-23 | 2022-06-30 | Vib Vzw | Antibody compositions for treatment of corona virus infection |
Non-Patent Citations (36)
Title |
---|
"Antibody Engineering", vol. 1,2, 2010, SPRINGER-VERLAG |
"Therapeutic Monoclonal Antibodies: From Bench to Clinic", 2009, WILEY |
A. LEACHA. MILLERE. BENTLEYG. MATTIUZZOJ. THOMASC. MCANDREWR. VAN MONTFORTT. RABBITTS: "Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins", SCI. REP., vol. 11, 2021, pages 10475 |
A. MILLERA. LEACHJ. THOMASC. MCANDREWE. BENTLEYG. MATTIUZZOL. JOHNA. MIRAZIMIG. HARRISN. GAMAGE: "A super-potent tetramerized ACE2 protein displays enhanced neutralization of SARS-CoV-2 virus infection", SCI. REP., vol. 11, 2021, pages 10617 |
A. ZOUFALYM. POGLITSCHJ. H. ABERLEW. HOEPLERT. SEITZM. TRAUGOTTA. GRIEBE. PAWELKAH. LAFERLC. WENISCH: "Human recombinant soluble ACE2 in severe COVID-19", LANCET RESPIR. MED., vol. 8, 2020, pages 1154 - 1158 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 405 - 410 |
ALTSCHUL ET AL., NUCL. ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BAUM ALINA ET AL: "REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters", SCIENCE, vol. 370, no. 6520, 27 November 2020 (2020-11-27), US, pages 1110 - 1115, XP055848621, ISSN: 0036-8075, DOI: 10.1126/science.abe2402 * |
C. LEIW. FUK. QIANT. LIS. ZHANGM. DINGS. HU, BIORXIV |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
D. B. TRESNANS. MATHERP. R. DORMITZERU. SAHINK. U. JANSENW. C. GRUBE: "Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine", N. ENGL. J. MED., vol. 383, 2020, pages 2603 - 2615 |
DE GASPARO RAOUL ET AL: "Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice", CLEO: APPLICATIONS AND TECHNOLOGY 2019 SAN JOSE, CALIFORNIA UNITED STATES 5-10 MAY 2019, OPTICA, vol. 593, no. 7859, 25 March 2021 (2021-03-25), pages 424 - 428, XP037528403, DOI: 10.1038/S41586-021-03461-Y * |
EDGA, NUCLEIC ACIDS RES, vol. 32, 2004, pages 1792 - 7 |
EDGAR, BMC BIOINFORMATICS, vol. 5, 2004, pages 113 |
FERRARI ET AL., ASM JOURNALS JOURNAL OF VIROLOGY, vol. 95, no. 19 |
FERRARI ET AL., J VIROL, 2021 |
GILBERTA. J. POLLARD: "Oxford COVID Vaccine Trial Group, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK", LANCET LOND. ENGL., 2020 |
J. N. BHIMANC. WILLIAMSONT. DE OLIVEIRA: "Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa", EPIDEMIOLOGY, 2020 |
KABAT ET AL., ANN. NY ACAD. SCI., vol. 190, 1971, pages 382 - 391 |
KABAT ET AL.: "U.S. Department of Health and Human Services", 1991, NIH PUBLICATION, article "Sequences of Proteins of Immunological Interest, Fifth Edition" |
KONTERMANN, MABS, vol. 4, no. 2, 2012, pages 182 - 97 |
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203 |
M. FERRARIL. MEKKAOUIF. T. ILCAZ. AKBARR. BUGHDAK. LAMBK. WARDF. PAREKHR. KARATTILC. ALLEN: "Characterisation of a novel ACE2-based therapeutic with enhanced rather than reduced activity against SARS-CoV2 variants", IMMUNOLOGY, 2021 |
M. HOFFMANNH. KLEINE-WEBERS. SCHROEDERN. KRUGERT. HERRLERS. ERICHSENT. S. SCHIERGENSG. HERRLERN.-H. WUA. NITSCHE: "SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor", CELL., vol. 181, 2020, pages 271 - 280 |
MIERSCH SHANE ET AL: "Ultrapotent and broad neutralization of SARS-CoV-2 variants by modular, tetravalent, bi-paratopic antibodies", CELL REPORTS, vol. 39, no. 9, 31 May 2022 (2022-05-31), US, pages 110905, XP093091984, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2022.110905 * |
P. C. TAYLORA. C. ADAMSM. M. HUFFORDDE LA TORREK. WINTHROPR. L. GOTTLIEB: "Neutralizing monoclonal antibodies for treatment of COVID-19", NAT. REV. IMMUNOL., vol. 21, pages 382 - 393, XP037470979, DOI: 10.1038/s41577-021-00542-x |
P. ZHOUX.-L. YANGX.-G. WANGB. HUL. ZHANGW. ZHANGH.-R. SIY. ZHUB. LIC.-L. HUANG: "A pneumonia outbreak associated with a new coronavirus of probable bat origin", NATURE., vol. 579, 2020, pages 270 - 273 |
PEARSONLIPMAN, PNAS USA, vol. 85, 1988, pages 2444 - 2448 |
Q. LIJ. WUJ. NIEL. ZHANGH. HAOS. LIUC. ZHAOQ. ZHANGH. LIUL. NIE: "The Impact of Mutations in SARS-CoV-2 Spike on Viral Infectivity and Antigenicity", CELL, vol. 182, 2020, pages 1284 - 1294 |
S. CHERIANV. POTDARS. JADHAVP. YADAVN. GUPTAM. DAS, P. RAKSHITS. SINGHP. ABRAHAMS. PANDA: "NIC team, ''Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681 R, in the second wave of COVID-19 in Maharashtra, India", MOLECULAR BIOLOGY, 2021 |
SMITHWATERMAN, J. MOL BIOL., vol. 147, 1981, pages 195 - 197 |
SPIESS, MOL IMMUNOL, vol. 67, 2015, pages 95 - 106 |
T. TADAH. ZHOUB. M. DCOSTAM. I. SAMANOVICM. J. MULLIGANN. R. LANDAU: "The Spike Proteins of SARS-CoV-2 B.1.617 and B.1.618 Variants Identified in India Provide Partial Resistance to Vaccine-elicited and Therapeutic Monoclonal Antibodies", IMMUNOLOGY, 2021 |
W. DENGH. ZHOUS. HANM. IVARSSONJ. MILLET. ZAKS: "Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine", N. ENGL. J. MED., vol. 384, 2021, pages 403 - 416 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
Z. LIJ. D. BLOOM: "Prospective mapping of viral mutations that escape antibodies used to treat COVID-19", SCIENCE., vol. 371, 2021, pages 850 - 854, XP055981531, DOI: 10.1126/science.abf9302 |
Also Published As
Publication number | Publication date |
---|---|
GB202210573D0 (en) | 2022-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3889177B1 (en) | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments | |
WO2021196268A1 (en) | Antibody having neutralizing activity against coronavirus, and use thereof | |
CN106687479B (en) | anti-CTLA 4 monoclonal antibody or antigen binding fragment thereof, pharmaceutical composition and application | |
AU2017237543B2 (en) | Antibody that binds to envelope glycoprotein of severe fever with thrombocytopenia syndrome virus, and use for same | |
WO2021244089A1 (en) | Sars-cov-2 spike protein binding molecule and application thereof | |
JP2024506315A (en) | Antibodies that target the coronavirus spike protein | |
CN113480641B (en) | Antibodies for the treatment of hepatitis B infections and related diseases | |
JP2022516848A (en) | BTN3A binding protein and its use | |
WO2021189160A1 (en) | Anti-sars-cov-2 antibodies and uses thereof | |
CN113583116A (en) | Antibodies against SARS-CoV-1 or SARS-CoV-2 and uses thereof | |
EP4206224A1 (en) | Human antibody or antigen-binding fragment thereof against coronavirus spike protein | |
EP4093762A1 (en) | Epstein-barr virus monoclonal antibodies and uses thereof | |
CN110914298A (en) | Humanized CXCR3 antibodies with reduced activity and methods of use thereof | |
WO2024018205A1 (en) | Antibodies against sars-cov-2 and uses thereof | |
WO2023208182A1 (en) | Anti-ccr8 antibody and use thereof | |
WO2021065846A1 (en) | ANTIBODY BINDING TO ANTI-HIV-1 V3 ANTIBODY 1C10(0.5γ), ANTIGEN-BINDING FRAGMENT THEREOF AND APPLICATION OF SAME | |
KR20230117183A (en) | Development of new tumor engager therapeutic drugs and their uses | |
EP4157876B1 (en) | Anti-pd-1 antibodies | |
JP7372638B2 (en) | Anti-hepatitis B virus antibody and its use | |
JP7392200B2 (en) | Antibody that specifically binds to glycosylated CEACAM5 | |
CN113549146B (en) | Monoclonal antibody against coxsackievirus B1 and application thereof | |
EP4183800A1 (en) | Novel sars-cov-2 neutralizing antibodies | |
GR20200100703A (en) | Monoclonal antibodies against sars-cov-2 and uses thereof | |
WO2022187626A1 (en) | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments | |
AU2021373318A1 (en) | Antigen binding domain with reduced clipping rate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23751058 Country of ref document: EP Kind code of ref document: A1 |